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The Role of Cocrystals in Solid-State Synthesis of Imides and the Development of
Novel Crystalline Forms of Active Pharmaceutical Ingredients
Miranda L. Cheney
ABSTRACT

With a greater understanding of the fundamentals of crystal engineering lays the
potential for the development of a vast array of novel materials for a plethora of
applications. Addressed herein is the latent potential of the current knowledge base with
an emphasis upon cocrystallization and the desire for scientific exploration that will lead
to the development of a future generation of novel cocrystals. The focus of this
dissertation is to expand the cocrystallization knowledge base in two directions with the
utilization of cocrystals in the novel synthetic technique of cocrystal controlled solid-state
synthesis and in the development of active pharmaceutical ingredients.
Cocrystal controlled solid-state synthesis uses a cocrystal to align the reactive
moieties in such a way that the reaction occurs more quickly and in higher yield than the
typical solution methodology. The focus herein is upon cocrystal controlled solid-state
synthesis of imides where an anhydride and primary amine were the reactive moieties.
Forty-nine reactions were attempted and thirty-two resulted in successful imide
formation. In addition, the cocrystal was isolated as part of the reaction pathway in three
cases and is described in detail.

xix

The impact of cocrystals upon active pharmaceutical ingredients is also addressed
with a focus upon generating novel crystal forms of lamotrigine and meloxicam.
Cocrystallization attempts of lamotrigine resulted in ten novel crystal forms including
three cocrystals, one cocrystal solvate, three salts, one solvated salt, a methanol solvate,
and an ethanol hydrate. Additionally, cocrystallization attempts of meloxicam afforded
seven novel cocrystals. Solubility and pharmacokinetic studies were conducted for a
selected set of lamotrigine and meloxicam crystal forms to determine the crystal form
with the most desirable properties. Properties between crystal form and cocrystal former
were also examined.

xx

Chapter 1- Introduction

1.1. Introduction
1.2. Supramolecular chemistry
Supramolecular chemistry,1, 2 or the chemistry of the intermolecular bond,3 has
been defined by Jean Marie Lehn as “chemistry beyond the molecule”.4 Supramolecular
chemistry is therefore inherently reliant upon the understanding of molecules at the
molecular level, i.e. the chemistry of covalent interactions that hold atoms together, to
facilitate the study of the intermolecular interactions between neighboring molecules.
Initial studies of complexes once called “Übermolecüles” 5 or “supermolecules” were
examined to gain insight into the intermolecular interactions that afforded such
conglomerations. The basic concepts that developed were premised upon the reliability
of molecular recognition events between two different but complementary molecules
initially described as the receptor and the substrate. Investigations into substrate-receptor
binding was first examined in the context of biological processes which led to the
development of the “lock and key” model described by Emil Fischer.6 The realization of
Nature’s success with molecular recognition led to the deliberate design of complexes
founded upon molecular recognition events such as crown ethers,7 cavitands,8 and
cryptands9 designed for ion selection.10-12 Further exploration into molecular recognition

1

devices produced functional supramolecular receptors for applications such as catalysis13,
14

and carrier-mediated membrane transport.15, 16

1.3. Self Assembly and Intermolecular Interactions
Supramolecular chemistry is reliant upon molecular recognition and self assembly
of target molecules via weak non covalent intermolecular interactions such as hydrogen
bonds, metal coordination bonds, CH-π, π-π, van der Waals forces, and electrostatic
interactions.2 A summary of the bond energies of a select set of intermolecular
interactions with a relevant example is provided in Table 1.1.17

Table 1.1. Summary of intermolecular interactions commonly exhibited in supramolecular
chemistry with the covalent bond included for comparison
Interaction

Strength
(kJ/mol)
150-450

O-O to C-C bond

Non Covalent

2-300

Dispersion to ion-ion

Hydrogen Bond

4-120

CH π to HF

Dipole-Dipole

5-50

Acetone

π-π Stacking

<50

Benzene

van der Waals

<5

Inert gas

Covalent

Example

The hydrogen bond is of particular importance in supramolecular chemistry
because of its relative strength and directionality.18 A definition of a hydrogen bond has
been suggested by many authors with the earliest examples being the most restrictive
(electronegative atom interacting with another electronegative atom with a hydrogen in
2

between).19-23 However, more recent definitions include weaker interactions such as
CHO as hydrogen bonds.24 For the purpose of this dissertation a hydrogen bond will
include interactions between two electronegative atoms, typically separated by a distance
less than the sum of the van der Waals radii, where one atom can be defined as the
hydrogen bond donor and the other atom acts as the acceptor, where hydrogen is located
between the two atoms and is directional in nature. Table 1.2 summarizes strong,
moderate, and weak hydrogen bonds and their characteristic bond strengths, lengths,
angles, interaction type, and the position of the hydrogen (closer to the donor (D) or
acceptor (A)) relative to the strength of the bond.18

Table 1.2. Summary of hydrogen bonds and their characteristics (D = donor, A = acceptor)
Strong

Moderate

Weak

Hydrogen bond energy (kcal/mol)

15-40

4-15

Less than 4

DA distance (Å)

2.2-2.5

2.5-3.2

Less than 3.2

D-H vs. HA

X-H ≡ HA

X-H > HA

X-H >> HA

Bond angles (º)

170-180

>130

>90

Hydrogen bond interaction type

covalent

electrostatic

electrostatic or
dispersion

Hydrogen bonding is also of great importance in biological systems. DNA, for
example, is a molecular complex comprised of two strands of long chains of base pairs
held together by hydrogen bonds. The replication of DNA relies upon the reversibility of
hydrogen bonding as the process breaks then makes new hydrogen bonds facilitating data
transcription and eventually cell replication.25 Without the occurrence of hydrogen bonds
base pairs would not interact, DNA could not replicate, and life could not exist.
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Hydrogen bonding is a key element throughout this dissertation and it will be the
main intermolecular interaction focused upon for crystal structure analysis. Π system
overlap resulting in charge-transfer complexes will also be highlighted.

1.4. The Design of Supramolecular Solids – Crystal Engineering
Supramolecular chemistry was initially focused upon the study of supermolecules
in solution. However, the field has since split into two directions: the study of
supermolecules in solution and the study of supermolecules in the solid-state. The
explorations into solid-state supramolecular chemistry led to the development of crystal
engineering. The term crystal engineering was introduced by Pepinsky26, 27 in 1955 and
was first practiced by Schmidt who utilized trans-cinnamic acids to design organic solidstate photochemical reactions.26, 28 The term “molecular engineering” was also
introduced and used by Hippel to describe the building of materials and devices to
order.29 Crystal engineering was later defined in 1989 by Desiraju as “the understanding
of intermolecular interactions in the context of crystal packing and the utilization of such
understanding in the design of new solids with desired physical and chemical
properties”.30 Thus, Desiraju’s definition portrays the potential of crystal engineering to
result in the development of novel materials. Further exploration of organic
supramolecular assemblies via crystal engineering by Etter,31-33 Desiraju, 30, 34-37 Wuest,3841

Aoyama,42, 43 Whitesides,44-48 Stoddart,49-51 and many others has since realized this

potential, affording a plethora of materials that are sustained by various molecular
recognition events, including supramolecular synthons.34, 37
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1.4.1. Supramolecular Synthons
Supramolecular synthons have been defined as non-covalent bonding between at
least two complementary functional groups.34 The study of supramolecular synthons
began with the carboxylic acid dimer formation with acetic acid in solution52 and has
since progressed into two distinct types: the supramolecular homosynthon and the
supramolecular heterosynthon.53 The supramolecular homosynthon is generated by a
non-covalent interaction between two of the same moieties. A supramolecular
heterosynthon also incorporates a non-covalent interaction however the interaction is
between two different but complementary moieties.
Supramolecular synthons are typically sustained via hydrogen bonds formed
between two electronegative atoms where one atom is also covalently bound to a
hydrogen atom. Additionally, other weaker interactions such as π-π stacking54 can also
be considered a supramolecular synthon. Commonly employed supramolecular
heterosynthons sustained via hydrogen bonding include carboxylic acid-amide,55-68
carboxylic acid-aromatic nitrogen,69-81 carboxylate-aromatic nitrogen,71, 82-84 alcoholaromatic nitrogen,85-92 and alcohol-amine.93-96 Typical distance ranges for these common
supramolecular heterosynthons are ca. 2.5-2.8 Å, 2.4-2.8 Å, 2.5-3.0 Å, and 2.5-3.1 Å,
respectively. Supramolecular homosynthons can also exist with any self complementary
moiety such as a carboxylic acid or a primary amide. An example of an amide-amide
supramolecular homosynthon and a carboxylic acid-amide supramolecular heterosynthon
are shown in Figure 1.1. (a) and (b), respectively.
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(a)

(b)

Figure 1.1. (a) Supramolecular homosynthon exemplified by an amide-amide dimer (b)
Supramolecular heterosynthon exemplified by an acid-amide dimer

A commonly employed supramolecular heterosynthon is the carboxylic acidaromatic nitrogen supramolecular heterosynthon, most likely due to its strength and
reliability.55, 64, 69-81, 97-107 Additionally, the aromatic nitrogen-alcohol supramolecular
heterosynthon has also been researched to examine its dependability.85-92 A pictorial
representation of the two supramolecular heterosynthons is provided in Figure 1.2.

(a)

(b)
Figure 1.2. (a) Alcohol-aromatic nitrogen supramolecular heterosynthon
(b) Carboxylic acid-aromatic nitrogen supramolecular heterosynthon

The ability to manipulate supramolecular synthon formation to generate a desired
supramolecular synthon has been explored by many. The work of Margret Etter is
particularly noteworthy as, based upon her experimental data, she developed a set of rules
to determine the potential for supramolecular synthon formation given various donoracceptor systems.31, 33 Her studies concluded with the development of three general
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rules: (1) all good proton donors and acceptors are used (2) six membered ring
intramolecular hydrogen bonds will form in preference to intermolecular hydrogen bonds
and (3) the best proton donors and acceptors remaining after intramolecular hydrogen
bonding will form intermolecular hydrogen bonds with each other.33 She also developed
a plethora of more specific rules that applied only to certain functionalities. For further
knowledge one is directed to her Accounts of Chemical Research article entitled
“Encoding and Decoding Hydrogen-Bond Patterns of Organic Compounds”. Etter was
also influential in the development of graph set analysis of supramolecular synthons.32
Although the use of graph set notation to describe a supramolecular synthon can be
beneficial, the complexity that arises from larger supramolecular synthons has limited the
use of the terminology.

1.5. Cocrystals – A History
The history of cocrystals began in 1844 with Friedrich Wöhler’s synthesis of
quinhydrone from hydroquinone and quinone.108 The material, however, was not called a
cocrystal. In fact, many early cocrystals were hidden under the guise of other names such
as addition compounds,109 molecular complexes,110 organic molecular compounds,111 and
solid-state complexes.112 The term “co-crystal” was not used until 1967 to describe the
hydrogen bonded complex formed between 9-methyladenine and 1-methylthymine.113
The term was then later popularized by Margret Etter in the 1990’s.
The debate over the term cocrystal began in 2003 with a controversial letter from
Desiraju where he asks: “what is co- to what?”.114 Desiraju continues to explain that he
would prefer to call a multiple component system that is held together by non-covalent
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interactions a “molecular complex”. Dunitz replies to Desiraju’s letter in agreement that
the term is inaccurate and inelegant; however, he argues that the term molecular complex
is too vague and could be interpreted to include solvates, inclusion compounds or
amorphous solids. Dunitz also insists that the hyphen remain as it is used to signify a
“togetherness” of two components.115 Aakeröy later defined cocrystals with a strict
definition where three criteria must be satisfied: the components must be neutral, the
solid must be made from components that are solids under ambient conditions, and it
must consist of homogenous crystalline material where the components are present in
stoichiometric ratios.116 However, Andrew Bond did not agree with the restrictions
placed by Aakeröy (specifically that all components must be solids) as he calls the
distinction “contrived and inappropriate”. He suggests that the term “multiplecomponent molecular crystals” be employed to describe a crystalline material containing
components that are either liquid or solid under ambient conditions.117 Currently a
ubiquitous definition for the term cocrystal does not exist. For the purpose of this
dissertation, however, a cocrystal is defined as a stoichiometric multiple component
crystal that is formed between two crystalline materials that are solids under ambient
conditions. At least one of the components is molecular and forms a supramolecular
synthon with the remaining component.118, 119
Cocrystals are typically comprised of two or more molecules that contain multiple
functional groups and are sustained by various supramolecular synthons. In general
supramolecular heterosynthons are used in the formation of cocrystals; however, there are
a few select examples where cocrystals are sustained via supramolecular mixed
homosynthons, i.e. the carboxylic acid dimer formed by two chemically distinct
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carboxylic acids.120 Due to the frequent use of supramolecular synthons to sustain
cocrystals, cocrystals have played an integral part in furthering the understanding of
supramolecular synthons and their hierarchy. The seminal works of Aakeroy,116
Shattock,121 and Bis85 are particularly noteworthy as they employ cocrystallization to
delineate supramolecular synthon formation in the presence of carboxylic acids, amides,
aromatic nitrogens, alcohols, and cyanos.
Aakeröy and co-workers tested Etter’s rules to determine if the strongest
acid/base from their dataset would form a supramolecular synthon with the next strongest
acid/base.19, 116, 122-124 Specifically, Aakeröy targeted ternary cocrystal formation60, 116, 125,
126

by using three molecules that contained carboxylic acid, amide, and aromatic nitrogen

moieties to determine which of the many possible supramolecular synthons would persist,
however, this resulted in ternary cocrystals that were sustained by carboxylic acidaromatic nitrogen and carboxylic acid-amide supramolecular synthons.58 An additional
study for the generation of ternary cocrystals involved two carboxylic acid containing
molecules (one stronger acid, one weaker acid) and one molecule with two aromatic
nitrogen moieties of different basicities. The results confirmed one of Etter’s rules as the
ternary cocrystals were sustained by the stronger acid forming a supramolecular synthon
with the stronger base while the weaker acid formed a supramolecular synthon with the
weaker base.116, 125 The ternary cocrystal is shown in Figure 1.3. with the stronger acid
(3,5-dinitrobenzoic acid (left)) paired with the imidazole nitrogen (1-((3pyridyl)methyl)benzimidazole) and the weaker acid (3-(dimethylamino)benzoic acid
(right)) paired with the aromatic nitrogen.
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Figure 1.3. Ternary cocrystal developed by establishing a synthon hierarchy

Shattock121, 127 and Bis85, 128 have taken a different approach to delineating the
hierarchy of supramolecular synthons with the utilization of cocrystallization. Their
studies involved three functional groups and three combinations of molecules. Each
experiment was comprised of two molecules, one with two moieties present on the same
molecule and another molecule that only contained one moiety. All permutations of
molecular combinations were attempted. The experiments were designed in such a way
that if a supramolecular synthon hierarchy existed then two out of the three experimental
arms would succeed in cocrystal formation while the third would not form cocrystals.
The experimental work was divided into two separate competitive studies. Bis’ work
tested the supramolecular synthon formation between alcohols, aromatic nitrogens, and
cyanos128 while Shattock’s studies employed carboxylic acids, aromatic nitrogens, and
alcohols.127 From the first set of moieties it was determined that the alcohol preferred to
form a supramolecular synthon with the aromatic nitrogen, not the cyano moiety. The
second set of moieties was more complex as the number of donor molecules increased to
two with still only one acceptor. An additional unforeseen problem occurred due to the
selection of molecules with more than one carboxylic acid or aromatic nitrogen moiety.
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Thus in some cocrystals both the carboxylic acid-aromatic nitrogen and aromatic
nitrogen-alcohol supramolecular heterosynthons were visualized. However, the study
concluded that the carboxylic acid-aromatic nitrogen supramolecular heterosynthon was
stronger than the alcohol-aromatic nitrogen due to the absence of cocrystal formation
when a molecule containing both a carboxylic acid and aromatic nitrogen moiety was
paired with an alcohol. Schematic representations of the potential supramolecular
heterosynthons from both studies are shown in Figure 1.4. The reliable supramolecular
heterosynthons (a, c, d) are shown with a green check mark while supramolecular
heterosynthons with low percentage of occurrences (b, e) are indicated by a red X.
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Figure 1.4. Possible supramolecular synthons from supramolecular heterosynthon
competitive studies. Green check marks indicate common supramolecular synthons.
Red X’s indicate supramolecular synthons with a low percentage of occurrences

The previously described crystal engineering studies employ cocrystal formation
to determine the reliability of supramolecular synthon formation in a competitive
situation. The success of these studies has provided valuable insight into the
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supramolecular synthon hierarchy that can be applied to future cocrystallization attempts
with molecules containing more than one moiety.
That cocrystals are an expanding field that continues to gain interest from both
academia and the pharmaceutical industry is made evident from a search of SciFinder
Scholar for references in the chemical abstracts that contain the term “cocrystal”.129 The
search provided a list of 1,523 references. Analyzing those references by year elucidates
their growing popularity. A pictorial representation is highlighted in Figure 1.5. The
rapid increase can be attributed to their variety of applications such as non-linear optics
for polar molecules,130-132 Polaroid film development,133 decrease tendency for
hydration,134-138 improve thermal stability,139-141 chiral separation,142 improve
compressibility and tabletting,143 increase % yield for solid-state synthesis,144 and alter
solubility139, 145-154 which can lead to improved bioavailability for active pharmaceutical
ingredients.
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Figure 1.5. Analysis of SciFinder Scholar references by year for the term “cocrystal”
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1.5.1. Cocrystal Synthesis
Cocrystals can be synthesized by various techniques including dry grinding or
neat grinding,155, 156 solvent-drop grinding (also called liquid-assisted grinding),119, 155, 157167

mixing, milling,168 reaction crystallization,169 slurring,158, 170-172 sonic slurring,161 and

solution crystallization techniques designed to grow single crystals119 including slow
evaporation from solution, vapor diffusion, and layering for liquid diffusion. The oldest
cocrystallization technique is perhaps dry grinding as it was performed as early as the
1800’s.108 It was only since 2002 that solvent-drop grinding has been implemented for
the synthesis of cocrystals.164 Grinding and milling are beneficial over traditional
solution techniques as they are a “greener” approach requiring much less solvent and
cocrystal formation tends to occur at a faster rate with higher yields.155 Solvent-drop
grinding with multiple solvents has also proven to be a reliable method to generate
polymorphs of a particular cocrystal.173 Recently the ability to interconvert between
cocrystals of different stoichiometries via solvent-drop grinding has also been highlighted
by Jones et.al.163 Additionally, the slurry methodology, widely used as a screening
technique in the pharmaceutical industry, can be advantageous when gram-level amounts
of cocrystal are required.
Attempts to illuminate cocrystal formation conditions were initiated by studies of
the two components interacting in solution. Rodríguez-Hornedo pioneered the area with
her studies of the carbamazepine nicotinamide cocrystal in solution by measuring the
amount of cocrystal formed with variable concentrations of either carbamazepine or
nicotinamide present in solution.174 Her studies showed that the greater the concentration
of nicotinamide in solution, the greater the reduction in solubility of the cocrystal.175
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This is most likely due to the solid phase that is present in equilibrium with the liquid
phase shifting from cocrystal to nicotinamide.176 Additional studies to investigate the
equilibrium between solid and liquid phases of two molecules in solution have been
conducted by the determination of ternary phase diagrams.177 The ternary phase diagram
plotted by Chiarella et al. for trans-cinnamic acid and nicotinamide was generated to
assist in the understanding of why solvent-drop grinding can be such a successful
cocrystallization technique in lieu of traditional solution crystallization methods.178
Chiarella179 concluded that in a solvent system where the two components are of similar
solubility then a 1:1 stoichiometric ratio solvent-drop grind will produce the cocrystal due
to the correct balance of cocrystal formers and solvent. However, if cocrystal formation
is attempted in a solvent in which the two components are of varying solubility then the
region where the cocrystal formation occurs will be skewed to one side of the ternary
diagram. Thus if a slow evaporation experiment was attempted, which inherently
progresses down the center of the phase diagram as it looses solvent, the likelihood of
cocrystal formation is decreased.

1.6. The Cambridge Structural Database and the Supramolecular Synthon
Approach
With the vast improvements in X-ray crystallographic equipment within the past
decade the amount of crystallographic data has grown exponentially as structural data can
be collected and crystallographic details resolved more quickly than ever before. The
increase in crystal data is reflected in the Cambridge Structural Database (CSD) which
currently contains ca. 481,000 crystal structures.180 The CSD is a structural visualization
14

and analysis software developed by the Cambridge Crystallographic Data Centre. The
contents of the CSD can be readily searched by multiple methods including chemical
structures, names, authors, etc. The ability to search the CSD for a desired
functionality181 can be useful in the design of cocrystals, moreover, the ability to search
for specified supramolecular homosynthons and heterosynthons make the CSD an
invaluable tool for crystal engineering of supramolecular solids including cocrystals.182186

The first step in a cocrystallization experiment is to conduct a search of the CSD
for the moiety present on the target molecule. The resulting entries are then cross
referenced with the presence of a plethora of additional complementary moieties. The
next step is to determine if the supramolecular homosynthon or heterosynthon is the
dominant interaction between the moieties in question. If the supramolecular
heterosynthon has a greater percentage of occurrences then a cocrystal can most likely be
made, however, if the supramolecular homosynthon is dominant then the likelihood of
cocrystal formation is reduced. This type of statistical analysis of the CSD has been
coined the “supramolecular synthon approach”.85, 119, 121 The statistics that can be
procured from the CSD is beneficial for cocrystal synthesis and has proven to be fairly
reliable for simple systems were there are only one or two functional groups such as
carboxylic acid-aromatic nitrogen, alcohol-aromatic nitrogen, or carboxylic acid-amide.
The major weakness of the CSD is that even with its ca. 481,000 entries there is still not
enough data to address some competitive supramolecular synthon situations. This lack of
data spawned the works of Shattock127 and Bis128 which has since provided partial
guidance in the design of cocrystals in the presence of multiple functional groups.
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1.7. Solid-State Synthesis is Green Chemistry
The emergence of green chemistry187 in the early 1990’s has lead to an increased
interest in the development of many solid-state synthetic methodologies.
Photodimerization,188 for example, is a widely accepted solid-state reaction technique
first practiced in the early 1900’s, and incorporates the principles of topochemistry189-191
into solid-state organic synthesis. Schmidt’s192 exploration of topochemical reactions via
photodimerizations193, 194 led him to further develop the field of topochemistry towards
the development of the topochemical postulate, first proposed by Kohlschutter in 1919.195
The postulate states that a “reaction in the solid state occurs with a minimum amount of
atomic or molecular movement”.189 The postulate therefore implies that the reactivity of
a complex is controlled by the distances and orientations established by the molecular
packing within the crystal structure. Schmidt’s studies involving the [2+2]
photodimerizations of α- and β-cinnamic acids to their corresponding truxillic acids led
him to the conclusion that typically, if the reacting moieties are at a distance less than
4.2Å apart in the solid-state, the photodimerization will occur.196 From these findings
Schmidt was able to develop a variety of principles which served to guide others in the
field including the requirement for π electron system overlap for photodimerization to
occur. With these imposing restrictions, solid-state reactions tend to be more selective
than those in solution, however, if the reaction does occur it is typically with higher
yields and greater stereospecificity.197-199
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hv

Figure 1.6. [2+2] Photodimerization of cinnamic acid to truxillic acid

More recently, the field of solid-state synthesis has been explored by many
scientists including Fumio Toda,197, 200, 201 Reiko Kuroda,202-204 and Gerd Kaupp.205-209
Interestingly, through the use of a multiple of reaction types, Kaupp has shown that solidstate reactions can and do often result in 100% yield.208 Kaupp employs multiple solidstate synthetic techniques such as grinding, heating, and photoirradiation and monitors
the reactions with atomic force microscopy and scanning electron microscopy.210 With
these powerful tools, he has found that molecular movement can occur across distances
of greater than 4.2Å therefore questioning the guidelines imposed by Schmidt. In
particular, anthracene can undergo photodimerization when the distance between
anthracene molecules is 6.038Ǻ, as was proven by atomic force microscopy. After
analysis of a group of solid-state reactions that occur where the reactants are at a distance
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greater than 4.2Å apart he concludes that “we found no fundamental differences between
topochemically allowed and forbidden reactions”.211

1.7.1. Cocrystals and Solid-State Synthesis
The influence of the principles of crystal engineering upon cocrystallization in
solid-state synthesis has afforded an effective synthetic reaction design strategy. As was
previously discussed, a cocrystal can be designed by utilizing the supramolecular synthon
approach and the crystallographic information in the Cambridge Structural Database.
The target molecule and cocrystal former are chosen such that complementary moieties
are present, allowing for robust and reliable supramolecular heterosynthon formation.
The cocrystal is then subjected to conditions under which the reaction can occur. [2+2]
photodimerization212-217 and nucleophilic substitution reactions218 have thus far been
successful in the utilization of cocrystals for solid-state chemistry. It is believed that the
presence of the cocrystal prior to the reaction allows for the proper orientation of the
molecules in the solid-state (less than 4.2Å for the reacting synthons) such that the
reaction will occur faster and with a higher yield than if the cocrystal was not formed.
Primary interactions commonly employed to sustain cocrystals are strong hydrogen
bonds; however, cocrystals are also supported by other weaker interactions such as
CHπ and π-π stacking.
Leonard MacGillivray has pioneered the area of template directed solid-state
synthesis via cocrystallization.212-215 A protypal cocrystal for MacGillivray is comprised
of an aromatic dialcohol such as resorcinol and an olefin containing two aromatic
nitrogens. The cocrystal is sustained via alcohol-aromatic nitrogen interactions, which
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forces a geometrical alignment of the alkene segments such that the cocrystal facilitates
the [2+2] photodimerization reaction. A prototypal example is shown in Figure 1.7.
where the cocrystal is formed between resorcinol and trans-1,2-bis(4-pyridyl)ethylene.
The cocrystal allows for the appropriate alignment of the molecules such that when the
solid is photoirradiated the [2+2] photodimerizations occurs resulting in rctt-tetrakis(4pyridyl)cyclobutane.87 The cocrystal is considered by MacGillivray to be a reaction
template because without the formation of the cocrystal, the olefins would not be in the
proper orientation in the solid for the reaction to occur. MacGillivrays recent work has
implemented his cocrystal template photodimerization reactions for the development of
novel ligands for the synthesis of metal-organic frameworks.219

hv

Figure 1.7. MacGillivray’s [2+2] photodimeraztion utilizing a cocrystal template

An additional example of a cocrystal incorporated in organic synthesis was
conducted by Etter who performed a nucleophilic substitution reaction employing a
cocrystal as a reagent.218 The cocrystal, generated from solvent-drop grinding of 419

chloro-3,5-dinitrobenzoic acid and 4-aminobenzoic acid, was sustained by a carboxylic
acid dimer and, in the solid state, the chlorine and the primary amine were in close
proximity (less than 4.2Å) allowing for the SN2 nucleophilic substitution reaction to
occur upon heating of the cocrystal at 180°C.
Cocrystallization is also particularly amenable to condensation reactions in the
solid-state. The condensation of a primary amine and a carboxylic acid anhydride to
generate an imide provides an exemplary case as the supramolecular synthon formation
can be envisioned between the amine and anhydride moieties and the loss of water
molecules can be accomplished by simple heating of solids. The focus of the second
chapter of this dissertation addresses the use of cocrystals as reactive intermediates with
an emphasis upon the cocrystals ability to align the reactive moieties and bring them into
close proximity to encourage the minimal amount of molecular movement required to
conduct the synthetic reaction in the solid-state.

1.8.

The Impact of Crystal Form
A crystal has been suggested by Dunitz to be a “supermolecule par excellence” 220

as it involves a complicated array of molecular recognition and periodic arrangement to
result in long range order. The molecular recognition events and desire for energy
minimizations drive the arrangement of the molecules in the crystal lattice.221
Additionally the particular arrangement determines the physical properties of the crystal,
including polarizability,222 magnetic susceptibility, piezoelectricity,223 melting point, and
solubility. The development of a crystal form is also of great importance in the
pharmaceutical industry as crystalline forms tend to be more stable than amorphous
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forms.224 Some drugs, however, are still marketed as amorphous forms due to the
improved solubility in comparison to the crystalline competitor.225
The propensity for an alternate crystal form of an active pharmaceutical
ingredient (API) to posses different physical and pharmacokinetic properties from the
original API is of great value to the pharmaceutical industry especially as many (ca. 60%)
of the new APIs being developed are of low solubility.226 The increased occurrence of
low solubility drugs can be attributed in part to the modeling methods used in the design
of some new drugs. For example, the API zanamivir227 was synthesized after molecular
modeling provided insight into the binding sites of the influenza virus. The drug was
then designed to bind to the virus with the intent of virus inhibition.228 This drug design
plan does not consider the physicochemical properties of the resulting API.

1.8.1. Crystal Form Types
There are a plethora of crystal form types that can be isolated for an API. The
synthesis and investigation of physical properties of various crystal forms is the subject
of many review articles.229-243 The diversity of moieties and torsional flexibility of many
APIs predisposes the formation of multiple crystal forms including, pharmaceutical salts,
cocrystals, solvates, hydrates, cocrystals of salts, and polymorphs of all of the above.
Some API’s, however, may not possess an ionizable group thus limiting its ability to
form salts. In such a situation the API can then be targeted for cocrystal formation.
Additional crystal forms such as solvates and hydrates that may not be intentionally
created are not uncommon in the pharmaceutical industry. Polymorphs may also be
formed for all crystal forms and are prevalent in ca. 50% of all drug substances.244
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All of the crystal forms highlighted above can alter the physicochemical
properties of the API. The earliest crystal forms intentionally studied for their unique
properties were pharmaceutical salts. Due to the well established history of
pharmaceutical salts and their ability to alter physicochemical and pharmacokinetic
properties, only one example will be provided herein. Pharmaceutical cocrystals,118 first
developed in 2003, will be addressed in much greater detail as there are only a few
published reports providing solubility or pharmacokinetic data of pharmaceutical
cocrystals.
Pharmaceutical salts are materials formed by an ionic API and a suitable,
pharmaceutically acceptable counterion.245 They have been a part of crystal form
selection for decades as they offer diversity of composition and can therefore exhibit a
wide range of physicochemical properties.246 The most commonly used anion and cation
in the generation of pharmaceutical salts is chloride and sodium, respectively.
Pharmaceutical salts have been used to enhance the solubility of poorly soluble APIs
which represent approximately 40% of the drugs on the market247 and as many as 60% of
APIs in development.248 Improving the solubility or dissolution rate of a
Biopharmaceutics Classification System (BCS)249, 250 Class II API is possible via
pharmaceutical salt formation.246 For example, in the late 1950’s Juncher and
Raaschou251 developed three novel salt forms of penicillin V that exhibited superior
dissolution profiles in comparison to the original API. When conducting a
pharmacokinetic study, it was observed that the salt form enabling the highest in vivo
exposure of penicillin V was the same form that possessed the most rapid dissolution
rate.
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The BCS scheme was developed as a method of classifying drugs based upon
their solubility and permeability. A BCS type I drug is high solubility and high
permeability, type II shows low solubility but high permeability, type III is high
solubility and low permeability, and type IV exhibits low solubility and low permeability.
The definition of high solubility for the BCS system is determined by the ability of the
largest dose size of the drug to dissolve in less than 250 mL of water over the pH range of
1-7.5. If the API does not fit these criteria then it is classified as low solubility. BCS
defines high permeability as the ability for greater than 90% of the dose of the API to be
absorbed. If the absorption is less than 90% then it is classified as low permeability. The
initial intention of the BCS was to correlate the solubility and permeability of a drug such
that an estimation of absorption could be made. Currently the federal drug administration
implements the BCS as guidance for qualification for a biowaiver, i.e. a waiver for the in
vivo bioavailability and bioequivalence studies. To obtain a biowaiver from the federal
drug administration there are many restrictions including that the drug must be BCS class
I (high solubility, high permeability) and must be an immediate release drug that is
administered as a solid dosage form.252
The importance of hydrates and solvates in pharmaceutical development has also
been recognized.253, 254 Various examples have demonstrated that the formation of
hydrates and solvates can significantly alter the physicochemical properties of APIs, such
as chemical stability, solubility, and dissolution rate.255-258
A more recently applied technique for crystal form development is
pharmaceutical cocrystallization.118 Pharmaceutical cocrystals can be defined as multiple
component crystals in which at least one component is molecular and a solid at room
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temperature (the cocrystal former) and forms a supramolecular synthon with a molecular
or ionic API.118 The cocrystal former must also be a pharmaceutically acceptable
compound.119, 121 Pharmaceutical cocrystals have demonstrated that they can profoundly
modify the physicochemical properties of the parent API molecule136, 139-141, 145-147, 149-154,
259-268

and at least 90 APIs have been studied in the context of cocrystallization. Often

APIs that are targeted for pharmaceutical cocrystallization experience undesirable
solubility and/or stability and possess multiple hydrogen bonding sites.269 The following
sections summarize a set of existing pharmaceutical cocrystals were their solubility and
animal pharmacokinetic behavior is known.

1.8.2. Pharmaceutical Cocrystals with Solubility Data
Solubility can be defined as the concentration at which the solution phase is in
equilibrium with the solid phase at a given temperature and pressure.270 The solubility of
a pharmaceutical cocrystal is of great importance as it can be the limiting factor in the
absorption of a drug.271 Solubilities of pharmaceutical cocrystals have been measured in
water, pH 1 HCl solutions, fasted and fed simulated gastric fluid, and fasted and fed
simulated intestinal fluid. Variability amongst the conditions is attributed to the desire to
mimic specific regions along the gastrointestinal tract to gain a better understanding of
the drugs behavior after it is administered orally. Furthermore a solubility study can
indicate whether the cocrystal disassociates back to its original components in solution by
testing the solid post solubility study.
The first dissolution profile for a pharmaceutical cocrystal was published by
Almarsson et.al.154 The target API was itraconazole, an antifungal drug with poor
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aqueous solubility. The resulting pharmaceutical cocrystals include a fumaric acid,
succinic acid, L-malic acid, L-tartaric acid, D-tartaric acid, and DL-tartaric acid cocrystal.
The crystal structure of the itraconazole succinic acid cocrystal is shown in Figure 1.8.
The solubility of the succinic acid, L-malic acid, and L-tartaric acid cocrystals was
measured in 0.1 N HCl and compared to an amorphous formulation of itraconazole
coated on Sporanox® beads and a crystalline form of itraconazole. The study showed
that the L-malic acid cocrystal was as soluble as the on the market Sporonox® bead form
of itraconazole thus proving that a cocrystal can be just as soluble as an amorphous form.

Figure 1.8. Hydrogen bonding of itraconazole succinic acid cocrystal
with succinic acid molecule in green

During an attempt to generate pharmaceutical cocrystals of fluoxetine HCl a
unique supramolecular synthon was discovered in 2004 by Childs et.al.153 The
supramolecular synthon involved a secondary amine and a carboxylic acid hydrogen
bonded together with a chloride anion positioned in between. Childs’ JACS article
published in 2004 highlighted three pharmaceutical cocrystals with the commonly
prescribed antidepressant that were all sustained via the novel supramolecular synthon.
Fluoxetine HCl fumaric acid, fluoxetine HCl succinic acid, fluoxetine HCl benzoic acid
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cocrystals were synthesized from crystallization of the HCl salt of fluoxetine with the
respective cocrystal formers. The supramolecular synthon is exemplified in the
fluoxetine HCl succinic acid cocrystal shown in Figure 1.9. The dissolution profiles were
conducted both on free flowing powdered cocrystal and on compressed tablets of
cocrystal. Both methods were conducted to elucidate the solubility of the cocrystals
before forty minutes. The dissolution profiles from the free flowing powder study
showed that the benzoic acid cocrystal was the least soluble cocrystal. The fumaric acid
cocrystal achieved a 30% improvement in solubility in comparison to fluoxetine HCl and
the succinic acid cocrystal doubled the concentration of fluoxetine HCl. Interestingly, the
succinic acid cocrystal concentration begins to decline after twenty minutes into a profile
that is now commonly referred to as a spring and parachute profile.272 This behavior is
attributed to the cocrystal initially enhancing the solubility of the API but then
disassociating into the original components in solution.

Figure 1.9. Fluoxetine HCl succinic acid cocrystal supramolecular synthons
were the Cl is shown in dark green
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The next solubility study published chronologically incorporated both salts and
cocrystals of saccharin with various APIs.152 When saccharin was complexed with
quinine, hapoperidol, mirtazapine, pseudoephedrine, lamivudine, risperidone, sertraline,
venlafaxine, zolepidem, and amlodipine the result was a pharmaceutical salt. Attempts to
complex saccharin to piroxicam led to the only cocrystal reported in the study. The
solubilites of the various saccharin salts previously mentioned will not be covered in
detail, however, it is noteworthy to mention that eight out of the ten saccharin salts
showed appreciably higher solubility than the pure API. The piroxicam saccharin
cocrystal, shown in Figure 1.10., obtained a solubility level similar to that of pure
piroxicam. Thus the conclusions of this study imply that salts can be more soluble than
cocrystals.

Figure 1.10. Intermolecular and intramolecular interactions found
in the piroxicam saccharin cocrystal

Norfloxacin, a potent antibacterial agent, was targeted for salt and cocrystal
formation due to its low aqueous solubility.151 When complexed with acidic molecules
such as succinic acid, malonic acid, and maleic acid norfloxacin has formed salts. When
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complexed with isonicotinamide norfloxacin remained neutral thus generating a
cocrystal. The cocrystal was determined via single crystal X-ray diffraction to be a
chloroform solvate. Figure 1.11. highlights the key supramolecular synthons including
the persistent isonicotinamide dimer. Equilibrium solubility measurements were
conducted for anhydrous norfloxacin, the cocrystal solvate, and three hydrated salts. The
solubility of the cocrystal improved by ca. 3-fold and the solubility of the salts improved
ca. 20-45 fold.

Figure 1.11. Supramolecular synthons present in the norfloxacin isonicotinamide cocrystal
solvate highlighting the persistence of the amide dimer, solvent molecules have been
deleted for clarity

Another interesting complex from a supramolecular synthon perspective is the
pharmaceutical cocrystal of a monophosphate salt, illustrated in Figure 1.12.139 The
phosphoric acid cocrystal of a monophosphate salt is the first example of a salt
cocrystallized with an inorganic acid. Early attempts to develop a suitable crystal form of
the target API resulted in an unstable hydrochloride salt. Furthermore, attempts to
develop a stable crystalline form of the free base were unsuccessful. An extensive
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screening process provided the phosphoric acid cocrystal of the phosphate salt that
achieved a solubility greater than 250 mg/ml in water.

Figure 1.12. Phosphoric acid cocrystal of a monophosphate salt

Sildenafil, the active ingredient in Viagra®, was also a target for
cocrystallization.149 The currently marketed crystal form of Viagra® is the citric acid salt
of sildenafil that was synthesized to improve the poor aqueous solubility of sildenafil.
However, the citrate salt proved to be only moderately soluble in water. Zegarac and
coworkers have since developed an aspirin cocrystal of sildenafil with improved
solubility under acidic conditions. Specifically, the intrinsic dissolution rate for the
aspirin cocrystal was approximately twice that of the citrate salt. Due to the increased
solubility of the aspirin cocrystal under acidic conditions, the crystal form is particularly
amenable as an oral dosage form. Desiraju has also targeted sildenafil for the
development of novel crystal forms. Eleven different solvates of the saccharinate salt of
sildenafil were identified and characterized via single crystal X-ray diffraction. The
solubility of the solvated crystal forms was not determined.
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A study reported by Remenar et.al., highlighted the importance of excipients
when measuring the solubility of a cocrystal.150 The celecoxib nicotinamide cocrystal,
shown in Figure 1.13., was presented as an example. Celecoxib is a COX-2 inhibitor and
anti-inflammatory agent with an aqueous solubility of less than 1 μgram/ml and is known
to exist in four polymorphic forms. An examination of the literature of pure celecoxib
revealed that the bioavailability could be altered based upon the formulation technique
employed. The article attributed the differences in dissolution profiles, which varied with
the formulation technique, to the variability in bioavailability. The focus of Remenar’s
study was similar, except the dissolution study was of the celecoxib nicotinamide
cocrystal. The solubility of the cocrystal was measured in aqueous solutions containing
small percentages of sodium dodecyl sulfate on polyvinylpyrolle. It was found that the
cocrystal was more soluble in solutions containing higher levels of the excipients.

Figure 1.13. Hydrogen bonding of the celecoxib nicotinamide cocrystal
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The solubility and stability of twenty-seven carbamazepine cocrystals has also
been recently investigated.148 Carbamazepine has been extensively studied for cocrystal
formation (carbamazepine aspirin cocrystal shown in Figure 1.14.) and solution behavior
in the presence of cocrystal formers. The most recent contribution of carbamazepine
cocrystals incorporated both diacids and monoacids as cocrystal formers and in many
cases led to polymorphic cocrystals. While no numerical solubility values were given, it
was stated that the solubility of the cocrystal was dependent upon the cocrystal former
concentrations. The stability of the cocrystal was measured by testing the solid phase
post slurry. The cocrystals were stirred in water and allowed to reach equilibrium. The
remaining solid was tested post slurry and for thirteen cocrystals, was found to convert to
carbamazepine dihydrate. Seven of the cocrystals remained intact during the study.

Figure 1.14. Carbamazepine aspirin cocrystal

AMG 517, an API in development stages at Amgen for indications of chronic
pain was recently the target for cocrystallization. Ten cocrystals were developed
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employing cocrystal formers containing carboxylic acid moieties.146 The solubility of
AMG 517 is very low in 0.01N HCl but slightly higher in fasted simulated gastric fluid
(FSGF) (5 μg/mL) thus the dissolution profiles for AMG 517 and its cocrystals were
measured in FSGF. All cocrystals except for the tartaric acid cocrystal were examined.
Six of the nine cocrystals obtained their maximum solubility within 1-2 hours. Their
concentrations then decreased throughout the remainder of the study producing a spring
and parachute profile reminiscent of the fluoxetine HCl succinic acid cocrystal previously
mentioned. The solubility of the three remaining cocrystals was less than that of AMG
517. Interestingly, powder X-ray diffraction studies confirmed that the solids remaining
after the dissolution study were AMG 517 hydrate in all cases except for with the benzoic
acid cocrystal. While the spring and parachute type profile indicated that the benzoic
acid cocrystal had converted to the dihydrate, powder X-ray diffraction showed that the
remaining solid was in fact cocrystal. The DSC, however, suggested that the benzoic
acid was not present in the crystal lattice, but was instead in solution. This argument was
supported by HPLC analysis that indicated an increase in benzoic acid concentration in
solution.
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Figure 1.15. 2-point recognition supramolecular synthon of AMG 517 succinic acid cocrystal

The next study describes the cocrystallization of two steroid-type molecules,
exemestane and megestrol acetate, that could not be formulated as pharmaceutical salts
due to their lack of strongly acidic or basic functionalities.147 Exemestane is used to treat
breast cancer while megestrol acetate is used to reduce the suffering caused by some
cancers and treats the loss of appetite in some AIDS patients. The unique cocrystal
screening technique employed in this study involving dimethylsulfoxide slurries followed
by lyophilization produced two novel cocrystals, exemestane maleic acid and megestrol
saccharin. The solubility was obtained via intrinsic dissolution and loose powder
dissolution measurements. Intrinsic dissolution studies showed that the exemestane
maleic acid cocrystal solubility was of similar solubility to that of the pure drug while the
megestrol saccharin cocrystal was twice that of the pure drug. The free flowing powder
dissolution profiles indicate a similar solubility trend, with the megestrol cocrystal
achieving a six-fold increase in solubility. The influence of particle size of the cocrystal
was also measured but it did not have a strong impact upon the cocrystal solubility.
33

The most recent cocrystallization study that measures the solubility of the
cocrystals was reported by Bak et.al.145 AMG 517 was again employed but complexed
with alternative cocrystal formers containing either amide or carboxylic acid moieties. In
addition to AMG 517, six more transient receptor potential vanilloid 1 antagonist APIs
were targeted producing 15 cocrystals in total. AMG 517 produced 12 cocrystals while 3
(AMG 678809, AMG 831664, AMG 670129) of the additional 6 APIs each formed a
cocrystal with sorbic acid. The solubility and dissolution profiles were measured for all
15 cocrystals in fasted simulated intestinal fluid. Many of the cocrystals resulted in a
spring and parachute dissolution profile with the remaining solid converting to either the
free base or hydrated free base. However, two of the AMG 517 cocrystals remained
intact throughout the study. The most soluble cocrystal of AMG 517 was the L-malic
acid cocrystal, highlighting an increase from 5 μg/mL to 24 μg/mL. A comparison of the
two AMG 517 cocrystallization studies shows that both cocrystal formers containing
carboxylic acids or amides can improve the solubility of the API. The sorbic acid
cocrystals of AMG 678809, AMG 831664, and AMG 670129 also displayed marked
improvements in solubility with the most notable increase of 0.9 μg/mL to 14.8 μg/mL
for the AMG 670129 sorbic acid cocrystal.

1.8.3. Pharmaceutical Cocrystals with Animal Data
Many of the APIs targeted for cocrystallization are selected because of their low
solubility and/or poor bioavailability. Enhancing the solubility of a crystal form via
cocrystallization can translate to an increase in drug present in solution and available at
the absorption site in vivo. Depending on the mechanism of absorption, a more
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concentrated solution of API can ultimately lead to a higher bioavailability (i.e. increased
concentration of unchanged drug in the plasma). In each of the following case studies the
solubility of a low solubility drug was increased via cocrystallization. The effect of
solubility improvement upon drug absorption and bioavailability is summarized herein.
The first publically available study where an animal was administered a cocrystal
was performed at Transform Pharmaceuticals Inc. Itraconazole, an antifungal drug, was
the target API.267 The cocrystal with L-malic acid was dosed to dogs and found to reduce
the time required to reach the maximum concentration (Tmax) by 10-80% over the pure
drug. The maximum concentration (Cmax) and area under the curve (AUC) were also
increased by 10-80%. The bioavailability (reported as 40%) for the cocrystal was
equivalent to the currently administered amorphous form of itraconazole coated on
Sporanox beads.
Transform Pharmaceuticals Inc. also filed a patent in 2004 containing the results
of an in vivo testing of the modafinil malonic acid cocrystal.265 Modafinil, used for
indications of narcolepsy, is practically insoluble in water, however, the malonic acid
cocrystal dissolved at a faster rate than the pure API. The pharmacokinetic study
utilizing a capsule formulation of the cocrystal administered in a single dose study to
dogs highlighted an increase in Cmax and bioavailability. The Tmax was practically
unchanged despite the increase in solubility at early time points.
In 2006 Childs et al.,140 reported a set of five novel solid phases of 2-[4-(4-chloro2-fluorophenoxy)phenyl]pyrimidine-4-carboxamide, or CFPPC. CFPPC is a sodium
channel blocker used for alleviating pain with an aqueous solubility of < 0.1 μg/ml.
Interestingly, the cocrystal comprised of CFPPC and glutaric acid showed an intrinsic
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dissolution rate ca. 18 times greater than pure CFPPC. The dog pharmacokinetic study
resulted in an AUC increase from 374 to 1,234 ng h/ml for the 5 mg/kg dose and an
increase from 889 to 2,230 ng h/ml for the 50 mg/kg dose. Thus after a single oral dose
of the cocrystal the dogs exhibited an approximately 4-fold increase in plasma
concentration over the pure API.
Chronologically, the next cocrystal pharmacokinetic study details to appear in the
literature pertained to the carbamazepine saccharin cocrystal.141 The study was a single
dose administration of the cocrystal and the marketed Tegretol® tablet to beagle dogs.
The results showed higher Cmax and AUC values for the cocrystal and a Tmax value that
was one hour for the cocrystal and 1.75 hours for the Tegretol® tablet. Furthermore the
cocrystal reached slightly higher plasma levels than the marketed drug, but remained
within the standard error and therefore was not statistically significant.
The pharmaceutical cocrystal of a monophosphate salt with phosphoric acid,
previously mentioned for its improved solubility in comparison to the free base, is
noteworthy as it briefly mentions the results of a pharmacokinetic study. Unfortunately
there are no details concerning this portion of the study in the article. The article simply
claims that the cocrystal “exhibited excellent in vivo performance”. 139
In 2008 Bak and co-workers highlighted the ability of a series of pharmaceutical
cocrystals to improve the solubility of AMG 517.146,259 A particular focus was upon the
AMG 517 sorbic acid cocrystal and it was studied with respect to its stability in vitro as
well as its ability to modify the plasma concentration of AMG 517 in Sprague-Dawley
rats. It was found that after oral administration of a 500 mg dose of the cocrystal, the
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Cmax and AUC0-inf was 8 and 9 times greater, respectively, compared to oral
administration of the same dose of pure API.
The two most recent studies are from the patent literature. The first describes
tenofovir which is a nucleotide reverse transcriptase inhibitor for the treatment of HIV.261
The commercially available form of tenofovir is a fumarate salt however, the product
contains various mixture of solid forms in unpredictable ratios. In an attempt to solve the
commercial product problem, tenofovir was cocrystallized with fumaric acid resulting in
a 2:1 molecular complex that could be isolated cleanly. A pharmacokinetic study (a
single dose Male Wister rat study) comparing the cocrystal to the existing salt form
proved that the cocrystal was bioequivalent to the on the market product.
The most recent pharmacokinetic study of a pharmaceutical cocrystal describes
the cocrystal formed between a C-glycoside derivative and proline.264 Previously the
pure drug was found to crystallize as a clathrate hydrate that interconverts from an
anhydrous compound to a non-stoichiometric hydrate. The instability of the API led to
the develop the additional crystal forms. The resulting 1:1 C-glycoside derivative Lproline cocrystal was administered as a suspension to non-fasted mice. Levels of the
cocrystal and original API were measured in the blood concluding that the cocrystal was
present at a sufficient level to treat diabetes. The patent further claims that the patient
would experience the same or higher efficacy after administration of the cocrystal.
As was made evident in the previously mentioned studies, the crystal form of a
pharmaceutical can have a significant impact upon the solubility and pharmacokinetic
properties of an API. Table 1.3. provides a summary of the pharmacokinetic data
presented in this chapter.
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Table 1.3. Summary of the pharmacokinetic metrics for the presented pharmaceutical cocrystals

API

Cocrystal
former

Pharmacokinetic metrics

Itraconazole

L-Malic acid

Modafinil

Malonic acid

Bioavailability = 40%, Equivalent to amorphous
drug
Increase Cmax and bioavailability

CFPPC

Glutaric acid

Decrease Tmax, increase Cmax and AUC by 4-fold

Carbamazepine

Saccharin

Increase AUC and Cmax, however, not
statistically significant plasma level

Monophosphate salt

Phosphoric acid

No data, stated “excellent in vivo performance”

AMG 517

Sorbic acid

Increased Cmax and AUC by 8 and 9 fold

Tenofovir

Fumaric acid

Bioequivalent to commercially available drug

C-Glycoside
Derivative

L-proline

Cocrystal showed strong antihypoglycemic
action

1.8.4. Polymorphism and the Pharmaceutical Industry
A polymorph has been defined by McCrone as “a solid crystalline phase of a
given compound resulting from the possibility of at least two different arrangements of
the molecules of that compound in the solid state”.273 The number of compounds that
exhibit polymorphism is uncertain as McCrone argues that the number of polymorphic
compounds is proportional to the time and money spent in research on that compound.274
In an attempt to quantify the number of known polymorphs a search of the CSD was
conducted. The term “polymorph” retrieved 15,633 entries out of 481,521 or 3% of the
entire database.
An important aspect of polymorphism is the inherent differences in physical
properties between crystal forms.258, 275 Variations in properties such as solubility can
have a dramatic impact upon the pharmacokinetic behavior of an API. Thus crystal form
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screening is of utmost importance in the pharmaceutical industry. However, traditional
crystal form screening does not always reveal all possible polymorphs. The negative
impact that crystal form screening can have upon the pharmaceutical industry is
exemplified in the historic cases of ritonavir,276 ranitidine HCl,275 and paroxetine HCl.277
Ritonavir, marketed as Norvir®, was formulated as an oral liquid and a semi-solid
capsule. Since both formulations were solutions of ritonavir there was little concern with
crystal form. During early manufacturing of the capsules only the one crystal form of
ritonavir was found. However, years later, a new form was discovered that was much
less soluble than the original form. This new form was referred to as form II. Form II
was soon found at all manufacturing facilities, dramatically reducing the supply of the
original form. Form II was so much less soluble that it could not be used to make the oral
liquid or semi-solid capsule formulations via the current methods. Ultimately ritonavir
had to be reformulated due to the omnipotent less soluble form II.
Ranitidine HCl (Zantac®), a histamine H2 antagonist originally developed by
GlaxoSmithKline, was also found to be polymorphic. The polymorphic transformation
of what is now called form I to form II occurred during the scale up manufacturing
process. Form I was covered under an original synthesis patent and form II was
subsequently covered under an additional patent. Due to the success of the drug, many
generic companies were waiting for form I to go off patent to introduce their own generic
version on the market. Novopharm in particular attempted to reproduce form I from the
claimed method in the patent, however, Novopharm produced form II. Novopharm then
tried to invalidate Glaxo’s patent for form II citing that they had reported a method for
form I that actually produced form II; therefore form II would be anticipated from the
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earlier patent. Novopharm eventually lost the case as Glaxo was able to prove that their
method did lead to generation of form I in the original researchers’ notebook. However,
Novopharm was granted the ability to market a pure product of form I.
GlaxoSmithKline also entered into a legal battle over paroxetine HCl (Paxil®).
The original form developed was a hemihydrate of paroxetine marketed since 1993.
While waiting for Glaxo’s patent to expire, Apotex developed an anhydrate crystalline
form of paroxetine HCl. Glaxo was aware of the anhydrate and its conversion to the
hemihydrate under specific conditions that were claimed in their original patent. Glaxo
claimed that Apotex was operating under conditions that would partially convert the
anhydrate to the hemihydrate that was covered under their patent. The legal battle ensued
with the court ultimately ruling against Glaxo as they could not prove that Apotex would
make the hemihydrate in sufficient quantities.

1.9. Summary
Supramolecular chemistry has grown exponentially since the description of the
lock and key model in 1890. The subset of crystal engineering has also grown and
attracted interest from many different facets including academia and industry.
Contributing factors that have fueled the rapid development have been the advancements
in X-ray technology as well as augmented interest from large corporations and university
collaborations. In particular the pharmaceutical industry is currently infatuated with the
ability to fine tune a crystal form to possess desired physical and pharmacokinetic
properties. The potentials and pitfalls of polymorphism are also a topic of current
interest.
40

Cocrystals in solid-state synthesis and cocrystals in pharmaceutical development
both show great promise in their respective areas. Cocrystals as reaction intermediates or
photodimerization templates have afforded novel materials typically coupled with
increased reaction yields. Pharmaceutical cocrystals have also proven their utility with
their ability to change an API’s solubility and bioavailability. The ability to manipulate
the properties of a cocrystal to customize a product is still a future goal but as the field of
crystal engineering continues to grow and its applications extend, new materials will
emerge with inherent properties that will most likely be the result of a designed
experiment rather than serendipity.

1.10.
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Chapter 2 – Cocrystal Controlled Solid-State Synthesis of Imides

2.1. Preamble
The chemical industry has played a major role in the production and accumulation
of hazardous waste and toxins in the environment.1 Unfortunately, it was not until the
1960’s that the public became aware of the toxicity and harm to human health some
chemicals, such as DDT (dichlorodiphenyltrichloroethane),2-4 in the environment could
cause. The increased public awareness began the conscious effort to reduce chemical
waste and its presence in the environment. A giant leap forward was made in 1990 with
the Pollution Prevention Act5 which stated that one should strive to prevent or reduce
pollution whenever possible.6 This act facilitated the development of more
environmentally friendly chemical practices that lead to the creation of the chemical
genre of green chemistry.7-12 Green chemistry has been defined as “the utilization of a set
of principles that reduces or eliminates the use or generation of hazardous substances in
the design, manufacture, and application of chemical products”.13 Implementation of the
twelve principles of green chemistry can provide greater reaction yields and less
hazardous waste production, resulting in cheaper overall chemical synthetic
methodologies.14 With the consideration of these benefits in mind, many chemists have
strived to develop the field of solid-state synthesis, however, in some areas their focus
has been relatively narrow in scope.15-17 For example, the particular application of
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cocrystal controlled solid-state synthesis (C3S3) has thus far been limited to
photodimerizations or photopolymerizations18-27 and nucleophilic substitution.28 In the
case of the former, one cocrystal former typically serves to align or “template” the
reactant, which is the other cocrystal former. In the case of the latter both cocrystal
formers are reactants although there are examples in which the reactive moieties are in
the same molecule and therefore generate polymeric structures.29 In this chapter, the
details of an exploration into furthering the development of C3S3 are delineated for the
design and synthesis of novel materials.
C3S3, defined as the generation of a cocrystal in the solid-state which can then be
utilized to conduct a chemical reaction, typically condensation, in order to generate novel
materials, can be described as a two part process. The initial stage applies crystal
engineering30, 31 design principles to a recently developed low waste, high yield cocrystal
synthesis method which is followed by a traditional condensation reaction that has been
modified to be conducted in the solid-state. There are two strict sets of criteria for
conducting a reaction by C3S3: 1) the materials must posses the appropriate moieties to
sustain a reliable supramolecular synthon32, 33 and 2) the moieties required for the
supramolecular heterosynthon must be chemically reactive such that when heated they
lose a volatile component, typically water. Based upon the requirements imposed for
C3S3, there are six reactions that fit this criteria, aldehyde + primary amine to generate a
Schiff base,34 carboxylic acid + primary amine to make a secondary amide,35 carboxylic
acid + carboxylic acid to form an anhydride,36 carboxylic acid + alcohol to generate an
ester,37 alcohol + alcohol to make an ether,35 and anhydride + primary amine to form an
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imide.38 This contribution will focus upon imide formation employing an anhydride and
primary amine via C3S3 as illustrated schematically in Figure 2.1.

Figure 2.1. Reaction scheme for imide formation from primary amine
and carboxylic acid anhydride via cocrystallization

Imides represent a class of compound that is primarily synthesized in solution;39
however, there are prior examples that highlight the ability to synthesize imides in the
solid-state via microwave chemistry40-42 or upon a solid-phase support.43, 44 Both
methods prepare imides via condensation of carboxylic acid anhydrides and primary
amines (mechanism shown in Figure 2.2.) i.e. two functional groups that are
complementary and could form a supramolecular synthon45; however, prior to 2007, there
were only two entries (REFCODES: AMYGLA, BEFWEO) in the Cambridge Structural
Database (CSD)46 that exhibit both the amine and anhydride moieties in the same entry,
both of which were comprised of a single component therefore neither were cocrystals.
The lack of data in the CSD precludes a definitive statement concerning the reliability of
the supramolecular heterosynthon formation. C3S3 provides the opportunity to address
the occurrence of this supramolecular heterosynthon and its potential to generate novel
imides.
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Figure 2.2. Proposed reaction mechanism for carboxylic acid anhydride
and primary amine producing an imide

Cocrystals can be synthesized by various methodologies47-49 including the
established solvent-drop grinding technique, i.e. two or more solid cocrystal formers are
ground in the presence of a microliter amount of solvent.50-54 In the study presented
herein, the cocrystals will be synthesized via solvent-drop grinding as it is the most
environmentally friendly cocrystallization technique. The groups of acid anhydrides and
primary amines depicted in Figures 2.3. and 2.4. respectively that were selected for this
study include: AA1 = 1,4,5,8-naphthalenetetracarboxylic acid dianhydride (NTCDA),
AA2 = pyromellitic dianhydride, AA3 = maleic anhydride, AA4 = phthalic anhydride,
AA5 = 3,3’,4,4’-biphenyltetracarboxylic dianhydride, AA6 = 1,8-naphthalic anhydride,
AA7 = 3,4,9,10-perylenetetracarboxylic dianhydride, PA1 = 2-methyl-4-nitroaniline,
PA2 = 3-aminobenzoic acid, PA3 = melamine, PA4 = 1,4-phenylenediamine, PA5 = 1,5diaminonaphthalene, PA6 = 1-adamantylamine, and PA7 = triphenylmethylamine. All
combinations of the 7 anhydrides with 7 primary amines was investigated (49 total
reactions) to determine the following: if they form cocrystals via solvent-drop grinding
under ambient conditions; furthermore if the ground mixtures so obtained can be
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converted to imides simply by applying heat. A summary of the results after grinding
then heating are presented in Table 2.1. The majority of reactions studied were observed
to form imides after heating but it was not always possible to isolate a cocrystal.
However, three combinations of anhydride + amine were isolated as cocrystals that
resulted in high yield, low waste formation of imides and will be discussed herein. An
additional reaction where the imide condensation reaction intermediate was isolated in
high yield will also be discussed. The analysis for reactions 1-4 includes reaction
conditions and discussion of the differential scanning calorimetry (DSC) traces, UV-vis
spectra, and color schemes for reactants, cocrystals, and imides where appropriate. In
addition the use of DSC to discover cocrystal formation in situ will be addressed.
Finally, the use of characterization techniques such as powder X-ray diffraction (PXRD)
and Fourier transform infrared (FT-IR) spectroscopy will be discussed for the detection
of cocrystal and imide formation with a broad set of amines and anhydrides.
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Figure 2.3. Carboxylic acid anhydrides

Figure 2.4. Primary amines
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Table 2.1. Table of 49 reactions color coded to differentiate outcomes after
solvent-drop grinding and heating

2.2. Results and Discussion
2.2.1. Reaction 1 2-methyl-4-nitroaniline and NTCDA
2.2.1.1. Synthetic Techniques and Characterization
As revealed in Figure 2.8, 1,4,5,8-naphthalenetetracarboxylic dianhydride
(NTCDA) and 2-methyl-4-nitroaniline form a 1:2 cocrystal, 1a, which converts cleanly to
diimide, 1b, when heated at 180 °C for 3 hours in 75% yield. Conversion to 1b is
expected as the distance between the amino moiety and carbonyl carbon of the anhydride
is ca. 3.42 Å, which is less than the 4.2 Å restriction of the topochemical postulate. 1b
crystallized from DMF and DMSO, affording solvated single crystals of 1b. Figure 2.11.
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represents the DMSO solvate of 1b and is presented in detail herein. The DMF solvate of
1b is not covered in detail as the solvate is isostructural to the DMSO solvate.
The cocrystal of NTCDA and 2-methyl-4-nitroaniline (1a) is purple in color. The
purple color of 1a contrasts the starting materials (pale yellow) and reaction product
(orange) and is indicative of charge transfer complex.55 The solid-state UV-Vis spectrum
of 1a exhibits a broad band at ca. 600nm and is shown in Figure 2.5. The UV-Vis
spectrum of 2-methyl-4-nitroaniline, NTCDA, and an ethanol grind are also shown for
comparison purposes.

Figure 2.5. UV-Vis spectrum of DMF solvent drop grind versus
Methanol grind, NTCDA, and 2-methyl-4-nitroaniline

1a can be prepared from solution, solvent-drop grinding with DMF or solventdrop grinding followed by heating and is sustained by charge transfer interactions
between the aromatic rings of NTCDA and 2-methyl-4-nitroaniline. Toda et al. has also
shown the ability to generate charge transfer complexes from solid-state grinding.56
Interestingly, solvent-drop grinding with other solvents (chloroform, cyclohexane,
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DMSO, ethyl acetate, methanol, toluene, and water) affords mixtures of NTCDA and 2methyl-4-nitroaniline. However, heating of a mixture above the melting point of 2methyl-4-nitroaniline results in formation of 1a and additional heating at 150 °C for three
hours affords 1b. These observations suggest that formation of 1a is a key step for
facilitating or even controlling the condensation process.
The progression of the reaction can be monitored in the DSC (Figure 2.6.). The
DSC trace for 1a (shown on the right in Figure 2.6.) exhibits only one phase transition as
the cocrystal melts and converts to the diimide 1b. However, the DSC trace of a mixture
(shown on the left in Figure 2.6.) shows two phase transitions. Once the mixture reaches
the melting point of the 2-methyl-4-nitroaniline (130 ºC) the first phase transition occurs.
Here the amine melts and recrystallizes to form the cocrystal. The second phase
transition corresponds to the melt of the cocrystal at ca. 155 ºC. After the melt of the
cocrystal the dehydration occurs and the resulting solid is the diimide. The color changes
due to the phase transitions from both 1a and the physical mixture (Figure 2.7) can be
monitored in a Mel-temp® device. 1a (purple) becomes orange after heating past 160 ºC
and the yellow mixture turns purple as it converts to 1a. 1a then becomes orange as it
converts to the diimide.
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Figure 2.6. DSCs highlighting the phase transitions that occur for mixtures (left)
and cocrystal (right). All temperatures are in degrees Celsius.

Figure 2.7. Color changes for reaction 1

2.2.1.2. Analysis of Crystal Structures
The 2-methyl-4-nitroaniline NTCDA cocrystal, 2:1 (1a) crystallizes in the
space group Pī. The basic supramolecular unit contains two 2-methyl-4-nitroaniline
molecules and one NTCDA molecule. The self complementary hydrogen bonding
capability of 2-methyl-4-nitroaniline between the primary amine donor and nitro acceptor
moieties is the primary driving force sustaining 1a. The amino moieties that hydrogen
bond to neighboring nitro moieties allow for an NHO hydrogen bond distance of
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2.946(6) Å [N22-H22BO21: NO 2.946(6) Å, HO 2.178 Å, N-HO 145.47º]
resulting in infinite chains of 2-methyl-4-nitroaniline molecules along the b-axis. The
chains are related by an inversion center located in the center of an NTCDA molecule
positioned between two 2-methyl-4-nitroaniline chains. The centroid-plane distance
between the 2-methyl-4-nitroaniline and NTCDA is ca. 3.32 Ǻ, which is within the
typical π-π interaction range and further supports the charge transfer interaction. The
carbonyl carbon atom of the NTCDA and the amine nitrogen atom of the 2-methyl-4nitroaniline are separated by only 3.42 Ǻ, i.e. well within the 4.2 Ǻ limit of the
topochemical postulate.57, 58 The intermolecular interactions sustaining 1a are shown in
Figure 2.8. The hydrogen bonding and charge transfer interactions exhibited by 1a
collectively generate a lattice that can be envisioned as two chains of 2-methyl-4nitroaniline molecules with NTCDA molecules inserted in between the chains stacking in
an AABAAB fashion as is shown in Figure 2.9. Furthermore, this 2:1 cocrystal supports
the required stoichiometry and conformation for the topochemical reaction.

Figure 2.8. Intermolecular interactions sustaining 1a. 1a obeys the topochemical
postulate as the shortest distance between the nitrogen atoms of the amine
moieties and the carbon atoms of the carbonyl moieties is 3.42Ǻ.
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Figure 2.9. Crystal packing of 1a viewed down the c-axis

Heating the cocrystal and recrystallizing the resulting imide from DMSO
produces the solvated diimide of 1b shown in Figure 2.10. and 2.11. There are three
independent diimides and one DMSO molecule in the asymmetric unit. Diimide A
(Figure 2.12. red) interacts via CHπ from the center of the molecule to the central π
region of neighboring diimide C (Figure 2.12. green) with a CH to ring centroid distance
of 3.52 Å. Diimide B (Figure 2.12. blue) is held in position via a CHπ interaction of
3.21 Å sustained between the central CH region and the aromatic benzene ring of
neighboring diimide A (Figure 2.12. red). Diimides A and C continue in infinite chains
parallel to the b-axis, packing in an alternating ABAB motif. Diimide B also forms
infinite chains along the b-axis; however, the cavity between chains is filled by two
equivalent DMSO molecules. Diimide B and DMSO also pack in an alternating ABAB
motif. The dihedral angles of diimides A, B, and C are 82.41 º, 85.12 º, and 79.18 º,
respectively.
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Figure 2.10. Molecular structure of diimide 1b as generated
via recrystallization of 1b from DMSO

Figure 2.11. Crystal packing of 1b DMSO solvate (3:2)
obtained via recrystallization from DMSO
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Figure 2.12. Color coded crystal packing of 1bDMSO:
diimide A = red, diimide B = blue, diimide C = green, DMSO = yellow

2.2.2. Reaction 2 3-aminobenzoic acid and NTCDA
2.2.2.1. Synthetic Techniques and Characterization
NTCDA and 3-aminobenzoic acid also form a purple cocrystal (2a) via solventdrop grinding with DMF. Solvent-drop grinding with other solvents leads to mixtures of
starting materials. Attempts at crystallization resulted in the formation of the less
reactive 1,4-dioxane solvate of the cocrystal, 2a1,4-dioxane, shown in Figure 2.16.
The solid-state UV-Vis spectrum of 2a, shown in Figure 2.13., exhibits a broad band at
550 nm which is consistent with a charge-transfer complex. Furthermore, the distance
between the reactive moieties (amine nitrogen and the carbonyl) was 3.14 Å. Therefore
2a also obeys the topochemical postulate as it converts to diimide 2b after heating for 24
hours at 200 °C in 99% yield. Interestingly, the cocrystal also undergoes dehydration to
the corresponding diimide after a few days under ambient conditions. Crystallization
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attempts of 2b were arduous due to the low solubility of the diimide in many common
organic solvents. However, 2b can be recrystallized from pyridine as the pyridine solvate
of the 1:2 complex of 4 with pyridine.

Figure 2.13. UV-Vis spectrum of DMF solvent-drop grind versus
3-aminobenzoic acid, methanol solvent-drop grind, and NDTCA

The dehydration of 2a to 2b was also monitored in the DSC; however, it was not
as straightforward as the previously described dehydration of 1a to 1b. The DSC (shown
in Figure 2.14., left) indicates that the cocrystal melt occurs at ca. 127 ºC; however, the
first phase transition of the mixture (shown in Figure 2.14., right) does not occur until ca.
155 ºC. The melting points do not correlate due to the melting point of the cocrystal
occurring before the melt of the lowest melting starting material (3-aminobenzoic acid).
Thus, the DSC of the mixture is a unique case highlighting the ability of the material to
melt, rearrange to the cocrystal which instantaneously melts and dehydrates to complete
the condensation reaction generating 2b. The array of colors that are seen for this
reaction (Figure 2.15.) are similar to that of reaction 1 where the same anhydride is
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employed and the cocrystal is a purple charge transfer complex, however, the resulting
imide (2b) is gold whereas 1b is orange.

Figure 2.14. DSCs highlighting the phase transitions that occur for cocrystal (left)
and mixture (right). All temperatures are in degrees Celsius

Figure 2.15. Colors of 3-aminobenzoic acid, NTCDA, dry grinding product,
DMF grinding product, and final imide 2b

2.2.2.2. Analysis of Crystal Structures
The 3-aminobenzoic acid NTCDA cocrystal 1,4-dioxane solvate (2a1,4dioxane) crystallizes in a 2:1:1 stoichiometry in the space group Pī with two molecules
of 3-aminobenzoic acid, one molecule of NTCDA, and one molecule of 1,4-dioxane in
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the asymmetric unit. Similarly to 1a, the primary amine molecule assists in the formation
of infinite chains, however, in 2a1,4-dioxane the primary amine molecules require the
insertion of a 1,4-dioxane molecule to sustain the chain. The 3-aminobenzoic acid
molecules do not favor the head to tail chain most likely because of the meta-positioning
of the amino moiety. The preferred orientation is a centrosymmetric dimer centered
above and below the NTCDA molecule. The 3-aminobenzoic acid centrosymmetric
dimer is sustained via NHO=C [N11-H11AO11: NO 3.066(4) Å, HO 2.245 Å,
N-HO 155.15º] hydrogen bonds which link to additional dimers through 1,4-dioxane
molecules [O12-H12O31: OO 2.643(3) Å, HO 1.807 Å, N-HO 172.36º] to
generate chains that stack along the a-axis. As shown in Figure 2.16., NTCDA molecules
stack in between the 3-aminobenzoic acid dimers with an amine-carbonyl distance of ca.
3.14 Å. The distance between these reactive groups is much less than the requirement for
the topochemical postulate therefore the condensation reaction should occur. In addition,
the distance measured between a centroid in the center of the 3-aminobenzoic acid dimer
and the plane of a neighboring NCDTA molecule was found to be 3.17 Å. This distance
is well within the typical π-π interaction and further supports the potential for charge
transfer interactions. The 1,4-dioxane molecules can be removed with heat to obtain
anhydrous 2a. However, a single crystal structure of the anhydrous cocrystal could not
be obtained as the sample did not retain crystallinity after heating.
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Figure 2.16. Crystal packing of cocrystal 2a1,4-dioxane

Attempts at crystallization of the 3-aminobenzoic acid NTCDA diimide (2b)
resulted in a pyridine solvate of the 1:2 complex of 2b with pyridine. The solvate of 2b
crystallizes in the space group Pī . The basic supramolecular unit is comprised of one
diimide, two pyridine molecules hydrogen bonded to the carboxylic acid moieties of the
diimide, and one disordered pyridine molecule centered in the cavity between two
diimide molecules. The crystal packing is sustained by various weak interactions
including multiple CHO interactions such as pyridyl CH to carbonyl of the imide (ca.
3.25 Å) and C=O of the carboxylic acid to the central CH region of the imide (ca. 3.49
Å). As shown in Figure 2.17. and 2.18., additional weak interactions (π system overlap
of 6-memebered aromatic rings) sustain the diimide molecules as they progress along the
c-axis. The dihedral angle between the naphthyl and benzene rings of the diimide is
79.04º.
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Figure 2.17. Simplified crystal packing of the 1:2 complex of 2b with pyridine

Figure 2.18. Crystal packing of the pyridine solvate of the 1:2 complex of 2b with pyridine
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2.2.3. Reaction 3 2-methyl-4-nitroanilne and pyromellitic anhydride
2.2.3.1. Synthetic Techniques and Characterization
Interestingly, solvent-drop grinding with DMF of 2-methyl-4-nitroaniline and
pyromellitic anhydride does not give a purple cocrystal. The cocrystal (3a) is orange
most likely due to the reduction of the conjugated ring system from naphthyl (NTCDA)
to benzyl (pyromellitic anhydride). 3a can be synthesized from various techniques
including solvent-drop grinding with DMF or methanol, solution crystallization, and
grinding with heating. The UV-Vis absorbance maximum for 3a is ca. 400 wavenumbers
which is expected for an orange complex, but is similar to the absorbance of the π
systems used for the reactants and therefore is not included. The single crystal structure
of 3a illuminates the bond distances from the amino group to the carbon of the carbonyl
group on a neighboring anhydride. Based upon the topochemical postulate, the distance
between the reactive groups in 3a (ca. 3.78 Å) is within range for the condensation
reaction to occur. Furthermore, 3a can be converted cleanly to 3b in approximately 80 %
yield after heating for ca. 2 days at 150 ºC. The different solid-state reaction rates of 1a,
2a1,4-dioxane solvate, the unsolvated form of 2a, and 3a is presumably an artifact of
crystal packing.
DSC traces for 3a and a mixture of the reactants are shown in Figure 2.19. with
3a on the left and the mixture on the right. The DSC trace of the cocrystal shows two
phase transitions at 138 ºC and 247 ºC. The literature melting point of 2-methyl-4nitroaniline (130 ºC) is similar to the first phase transition suggesting that either the
cocrystal may begin to disassociate at a similar temperature or some excess amine may be
present. Additional characterization techniques (FT-IR, PXRD calculated vs.
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experimental) confirm that the solid is at least 90% cocrystal. Thus it is likely that the
melting point of the cocrystal is merely a few degrees higher than the melting point of 2methyl-4-nitroaniline. 3a continues to rearrange on the molecular level in the DSC as it
converts to the diimide (3b), indicated by the undulating baseline. The second phase
transition at ca. 248 ºC is attributed to the melt of 3b. The mixture shown on the right in
Figure 2.19. shows the melt of the amine at ca. 131 ºC followed by a sharp
recrystallization as the cocrystal (3a) is formed. 3a then melts around 200 °C and
rearranges to generate 3b which melts at ca. 243 ºC. The color changes as the starting
materials are heated to produce 3a then subsequently to 3b can be followed in the Meltemp® device. Representative vials are shown in Figure 2.20.

Figure 2.19. DSCs highlighting the phase transitions that occur for cocrystal (left)
and mixture (right). All temperatures are in degrees Celsius.
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Figure 2.20. Stepwise reaction of 2-methyl-4-nitroaniline and pyromellitic anhydride
highlighting cocrystal formation (SDG = solvent-drop grind)

2.2.3.2. Analysis of Crystal Structures
The 2-methyl-4-nitroaniline pyromellitic anhydride cocrystal (3a) crystallizes
in the space group P21/n. The basic supramolecular unit is comprised of two 2-methyl-4nitroaniline molecules and one pyromellitic anhydride molecule. As was seen in 1a, the
2-methyl-4-nitroaniline molecules in 3a form head-to-tail chains sustained by hydrogen
bonds. The 2-methyl-4-nitroaniline molecules hydrogen bond via amine-nitro NHO
interactions [N12-H12AO12: NO 2.943(5) Å, HO 2.159 Å, N-HO 148.06 º] that
translate along the 2-fold axis. Pyromellitic anhydride molecules are inserted between
the 2-methyl-4-nitroaniline chains interacting via NHO hydrogen bonds [N12H12BO22: NO 3.089(5) Å, HO 2.307 Å, N-HO 147.98 º] and N-OO-C
interactions (ca. 2.90 Å). A centroid to plane distance measured between the center of
the 2-methyl-4-nitroaniline molecule and pyromellitic anhydride plane was found to be
3.26 Å, which is within the range for π-π interaction. The distance from the reactive
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amino group to the carbon of the anhydride carbonyl is ca. 3.78 Å which is within the
distance requirements set by the topochemical postulate.

Figure 2.21. Crystal structure of cocrystal 3a formed between
2-methyl-4-nitroaniline and pyromellitic anhydride

The diimide 3b, synthesized from the dehydration of cocrystal 3a, crystallizes in
the space group P21/c. The asymmetric unit contains half of the molecule with the
inversion center located at its center. 3b translates along the b-axis at an angle such that
the translation about the 21 screw axis results in a herringbone motif. The interplanar
spacing between the central region of the diimide molecules is ca. 3.28 Å and is sustained
mainly via CHO interactions, specifically from CHO=C (ca. 3.34 Å) and CHO-N
(ca.3.10 Å). The dihedral angle between the central and exterior rings of the diimide is
75.82 º.
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Figure 2.22. Molecular structure of diimide 3b

Figure 2.23. Crystal packing of 3b

2.2.4. Reaction 4 1-adamantylamine and phthalic anhydride
2.2.4.1. Synthetic Techniques and Characterization
When performing synthetic reactions the experimental outcome is not always
what is expected. Reaction 4 was an exemplary case where a synthetic pathway led to
the unexpected isolation of the condensation reaction intermediate instead of the imide.
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The amic-acid condensation intermediate of 1-adamantylamine and phthalic
anhydride (4a) has been isolated from traditional solution methods for this particular
reaction in 48% yield;59 however, in the solid-state under the conditions described herein,
the intermediate can be isolated cleanly in ca. 90 % yield. 4a is synthesized via solventdrop grinding of 1-adamanytlamine and phthalic anhydride together in a stoichiometric
ratio followed by heating of the solid at 110 ºC for 1.5 hours. Suitable quality single
crystals for of 4a single crystal X-ray analysis were obtained from recrystallization of the
heated material. The intermediate can then be heated further at 120 ºC for ca. 1 week to
afford the imide 4b. 4b was previously reported in the literature and appears in the CSD
under refcode: QUSKUK.
The DSC of 4a shows two phase transitions (Figure 2.24.). The initial phase
transition corresponds to the literature melting point of 185 ºC.59 The breadth of the
second phase transition is indicative of an impure material but it could also be caused by
degradation after the melt of 4a. An additional factor that must be considered is that the
imide condensation reaction is reversible. 4a can hydrolyze due to excess moisture in the
air producing phthalic acid and 1-adamantylamine which melt at 210 ºC and 205 ºC,
respectively. Therefore the second phase transition may be caused in part by the
presence of either material. Heating 4a in an oven in the solid-state can result in the
formation of 4b following the conditions previously mentioned. A DSC of the solid after
heating confirms the synthesis of 4b as the DSC trace (Figure 2.25.) has one phase
transition at ca. 142 ºC which corresponds to the literature melting point of 140 ºC.60
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Figure 2.24. DSC of 4a

Figure 2.25. DSC of 4b
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2.2.4.2. Analysis of Crystal Structures
The intermediate 4a formed from the reaction of 1-adamantylamine and
phthalic anhydride crystallizes with one molecule in the asymmetric unit. 4a
crystallizes in the space group P21/c and is primarily sustained by an atypical 2-point
recognition dimer. The dimer is centrosymmetric and incorporates two carboxylic acid
moieties and the carbonyl of the adjacent secondary amide. The carboxylic acid-carbonyl
OHO hydrogen bond distance is 2.682(3) Å [O12-H12O11: OO 2.682(3) Å, HO
1.868 Å, N-HO 171.61 º] and the carbonyl-carbonyl intramolecular bond distance is ca.
3.01 Å. Additional molecules of 4a are generated by a 21 rotation around the b-axis and a
reflection about the c-axis followed by a translation. A depiction of the crystal packing is
shown in Figure 2.26.
To determine the probability of this particular synthon formation, a CSD search
was conducted. The CSD revealed 803 entries that contained a carboxylic acid and a
secondary amide.61 However when the search was restricted by two criteria: the moieties
must both be on the same molecule and the amide must also be ortho to the acid the
number of entries reduced to 43. Of those 43 entries only 1 was sustained by the same
synthon that is shown. If the amide is not restricted to a secondary amide then an
additional 6 entries are revealed. Based upon the relatively low number of entries in the
CSD, the supramolecular heterosynthon highlighted in Figure 2.26. can be considered
rare in the presence of carboxylic acid and amide moieties.

88

Figure 2.26. Crystal packing of 4a
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Table 2.2. Crystal structure parameters for cocrystals 1a-4a
Chemical
formula

1a
(C7H8N2
O2)2
C14H4O6

1b
(C28H16N4
O8)3(C2H
6SO)2
1765.60

2a
(C7H7NO
2)2
C14H4O6
C4H8O2
824.58

2b
(C28H14N2
O8)0 5
C5H5N
C5H5N
726.66

794.53

3a
(C7H8N2O
2) 2
C10H2O6

3b
C24H14N4
O8

4a
C18H21NO

980.41

486.39

299.36

Monoclini
c
P21/c

Monoclini
c
P21/c

3

Form
weight
Crystal
System
Space
group
a (Å)

Triclini
c
Pī

Triclinic

Triclinic

Triclinic

Pī

Pī

Pī

Monoclini
c
P21/n

8.307(2)

11.309(3)

7.006(2)

7.1569(14)

7.373(3)

8.207(4)

13.045(7)

b (Å)

8.894(2)

12.204(4)

9.990(3)

8.1962(17)

13.969(6)

16.594(8)

9.761(5)

c (Å)

9.179(2)

16.403(5)

10.190(4)

15.448(3)

11.025(3)

7.753(4)

12.785(7)

α ( o)

110.230
(4)
103.873
(5)
97.109(
5)
601.6(3)

89.651(6)

83.081(7)

98.287(4)

90

90

90

77.343(5)

81.603(7)

102.202(4)

93.695(8)

92.169(9)

64.623(6)

76.866(8)

96.564(4)

90

90

110.402(8
)
90

684.2(4)

866.6(3)

1133.2(7)

1055.1(8)

1.580

1985.8(10
)
1.476

1.530

1.392

1.531

1.531

1
2412

1
8259

1
2810

1
3645

2
2623

2
2622

Independen
t reflections
Observed
reflections
T (K)
R1

1923

6472

2188

2852

1361

985

3420

996

1558

1549

1549

986

724

1471

100
0.0788

100
0.0915

100
0.0677

100
0.0869

100
0.0593

100
0.0766

293
0.0535

wR2

0.2227

0.2108

0.1546

0.2019

0.1405

0.1667

0.1242

GOF

1.042

0.741

1.047

1.018

0.884

1.095

0.896

β

(o)

γ (o)
Vol (Å3)
Dcal (g cm3
)
Z
Reflections
collected

90

1525.7(14
)
1.303
4
8766

2.2.5. C3S3 for the General Formation of Imides
Whereas C3S3 can only be confirmed in the three reactions for which isolation of
an anhydride-amine cocrystal occurred, conversion of solvent-ground anhydride-amine
mixtures to imides was a more general occurrence. 32 out of the total 49 reactions
resulted in imide formation. 17 reactions did not produce an imide. A summary of the
results is presented in Table 2.1. Solvent-drop grinding followed by heating therefore
appears to represent a feasible and general methodology for the preparation of imides. In
the following segments the reaction purity and percent yield will be addressed via DSC
and 1HNMR. Additionally, the ability to monitor the reactions by FT-IR and PXRD will
be discussed as well as the possibility of cocrystal formation in situ in the DSC.

2.2.5.1. Imide Purity
Initial monitoring for reaction completion included FT-IR and PXRD
measurements. Additional characterization was conducted on the 32 successful imide
formation reactions via DSC and 1HNMR. A typical DSC scan was 10 ºC/min from ca.
30 ºC-350 ºC. Analysis of the 32 samples indicated that 20/32 melted below 350 ºC;
however, 6/32 showed no clear melt in the DSC which is most likely indicative of imide
formation due to the lack of melt from either starting material. Unfortunately 13/32
samples gave either multiple or broad phase transitions, reducing the number of high
purity reactions to 19. However, literature melting points were compared to experimental
DSC melts when possible resulting in 7/7 correlating melting points. A potential cause
for some of the low purity reactions could be the ratio at which the reactions were
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conducted. 5 of the reactions were performed in the presence of excess amine (PA4 or
PA5) in an attempt to terminate the potentially polymeric reaction with free amines.
1

HNMR characterization was attempted on the 32 samples; however, due to the

limited solubility of some of the imides, six (PA1+AA2, PA2+AA2, PA2+AA5,
PA2+AA6, PA4+AA1, PA4+AA4) of the 1HNMR’s could not be obtained. In general
the purity of the imides was relatively high based on the low incidence of occurrence of
excess signals in the 1HNMR. In reactions PA5+AA6, PA4+AA5, and PA4+AA2 the
purity level appears lower but the additional peaks can be associated with the excess
amine that was input into the reaction. The purity could perhaps be improved by
following the heating with a washing step with an organic solvent such as methanol.
Additionally, six samples (PA1+AA3, PA1+AA5, PA2+AA3, PA4+AA3, PA5+AA4,
PA7+AA4) had a signal at ca.10 ppm which is indicative of the amic-acid reaction
intermediate. Due to the reversibility of the reaction, the presence of some of the
intermediate is not unlikely, especially after long term sample storage.62 The six samples
that contained some intermediate could most likely be converted to the imide cleanly
upon further heating. A summary of the DSC and 1HNMR data is presented in Table 2.3.
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Table 2.3. Summary of DSC and 1HNMR data (S.M. = starting materials, int. = intermediate,
Lit. = literature value of melting point)
Reactants
PA1+AA1

DSC Mixture
S.M. to Cocrystal to Imide

DSC Imide Melt
>350

Lit. Imide
N/A

PA1+AA2

S.M. to Cocrystal to Imide

247

PA1+AA3

S.M.

PA1+AA4

S.M.

PA1+AA5
PA2+AA1

1

HNMR
imide

Input
2:1

N/A

insoluble

2:1

137-broad

N/A

int. present

1:1

202

20263

imide

1:1

S.M. to Imide

263

N/A

int. present

2:1

S.M. to Cocrystal to Imide

>350

N/A

imide

2:1

PA2+AA2

S.M. to Imide

237-broad

N/A

insoluble

2:1

PA2+AA3

S.M. to Imide

230

23064

int. present

1:1

PA2+AA4

S.M. to Cocrystal to Imide

289

29065

imide

1:1

PA2+AA5

S.M.

>350

N/A

insoluble

2:1

PA2+AA6

S.M.

350

N/A

insoluble

1:1

PA3+AA2

S.M.

>350

N/A

impurities

2:3

PA3+AA3

S.M.

>350

N/A

impurities

3:1

PA3+AA4

S.M. to Imide

276-broad

N/A

imide

1:3

PA4+AA1

S.M. to Cocrystal to Imide

>350

N/A

insoluble

1:1

PA4+AA2

S.M.

>350

N/A

excess amine

5:1

PA4+AA3

S.M.

268

N/A

int. present

1:2

PA4+AA4

S.M.

246-broad

24766

insoluble

1:2

PA4+AA5

S.M.

350-broad

N/A

excess amine

5:1

PA4+AA6

S.M. to Cocrystal to Imide

285

N/A

imide

1:1

PA5+AA1

S.M.

320-broad

N/A

excess amine

5:1

PA5+AA2

S.M.

233-broad

N/A

imide, low conc.

1:1

PA5+AA3

S.M. to Cocrystal to Imide

210-broad

N/A

minor impurities

1:2

int. present

1:2

250

67

PA5+AA4

S.M. to Imide

240

PA5+AA5

S.M.

298-broad

N/A

excess amine

5:1

PA5+AA6

S.M.

>350

N/A

excess amine

5:1

PA6+AA3

S.M. to Imide

242-broad

N/A

minor impurities

1:1

imide

1:1
1:1

60

PA6+AA4

S.M.

142

140

PA7+AA2

S.M.

>350

N/A

minor impurities

PA7+AA3

S.M.

206-broad

N/A

minor impurities

1:1

PA7+AA4

S.M.

154

17268

int. present

1:1

PA7+AA5

S.M.

>350

N/A

imide, low conc.

1:1
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2.2.5.2. Monitoring the Condensation Reaction via DSC
The DSC has been an invaluable tool for the discovery and development of C3S3.
The DSC can illuminate the phase transformation of a mixture of an amine and an
anhydride to an imide by first capturing the melt of the lower melting component as it
converts to the cocrystal then showing the cocrystal melt as it converts to the imide.
Examples illustrating the process were presented in Figures 2.6, 2.14, and 2.19. With
these details in mind, two questions are posed: can a cocrystal that could not be made by
solvent-drop grinding be made in situ after melting the lower melting starting material in
the DSC? Also, can the DSC run produce an imide that had otherwise failed from the
synthetic method of applying heat in an oven?
To address the initial question, stoichiometric mixtures of starting materials were
weighed out and ground together by hand without solvent. The physical mixtures of 46
reactions were analyzed via DSC at a scan rate of 10 ºC/min from ca. 30 ºC to 350 ºC.
The results from this screen are shown in Table 2.3. Many of the DSC traces showed
phase transitions corresponding to the melts of the individual starting materials and some
were followed by a melt of the imide. Interestingly, seven of the physical mixtures
showed a phase transition that occurred after the melt of the lower melting component
and did not correspond to either starting material or to the imide. Based upon the
prototypal DSC traces from reactions 1-3, this phase transition is most likely the melt of a
cocrystal, thus revealing 4 additional condensation reactions controlled by a cocrystal
intermediate.
In situ cocrystal formation was possibly observed for reactions of 3-aminobenzoic
acid with phthalic anhydride (PA2-AA4), 1,4-phenylenediamine with NTCDA (PA494

AA1), 1,4-phenylenediamine with 1,8-naphthalic anhydride (PA4-AA6), and 1,5naphthalenediamine with maleic anhydride (PA5-AA3). Figure 2.27. illustrates the
mixture of 3-aminobenzoic acid and phthalic anhydride. The melting point of phthalic
anhydride is 130 ºC, which correlates to the first phase transition of the DSC. The
recrystallization immediately following that transition is believed to be the cocrystal
formation which is quickly followed by the melt of the cocrystal. The last sharp phase
transition occurs at 289 ºC and is associated with the melt of the imide.

Figure 2.27. DSC trace of mixture of 3-aminobenzoic acid and phthalic anhydride

Figure 2.28. highlights the DSC trace of the mixture of 1,4-phenylenediamine and
NTCDA. Of the seven anhydrides employed in this study, NTCDA appears to be the
strongest supporter of the supramolecular synthon as it is utilized in the formation of two
out of the three cocrystals, thus considering the formation of additional cocrystals with
NTCDA is quite likely. The melting point of the amine is 145 ºC which can be attributed
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to the first endothermic melt. The initial exothermic phase transitions that occurs at ca.
100 ºC is unique to this sample and may be an artifact of the amine. However, after the
melt of 1,4-phenylenediamine a recrystallization occurs wherein the cocrystal is most
likely formed. The cocrystal is then heated until melting at ca. 257 ºC. The DSC does
not show a melt for the imide as the melting point is greater than 350 ºC.

Figure 2.28. DSC trace of a mixture of 1,4-phenylenediamine and NTCDA

The DSC trace of a mixture of 1,4-phenylenediamine and 1,8-naphthalic
anhydride is shown in Figure 2.29. The initial sharp phase transition can be attributed to
the melt of 1,4-phenylenediamine which melts at 145 ºC. The recrystallization that occurs
thereafter is associated with cocrystal formation. The melt at 178 ºC does not correspond
to either starting material or the imide and is therefore most likely the melt of the
cocrystal. Once the cocrystal melts the condensation reaction occurs generating the
imide. The melting point of the synthesized imide was 284 ºC which is within a few
degrees of the final phase transition from the mixture.
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Figure 2.29. DSC trace of a mixture of 1,4-phenylenediamine and 1,8-naphthalic anhydride

Figure 2.30. depicts the DSC trace of a mixture or 1,5-naphthalenediamine and
maleic anhydride. Maleic anhydride was the lowest melting anhydride but also proved to
be the most reactive as solvent-drop grinding with DMF or DMSO lead to imide
formation in many reactions. Due to solvent-drop grinding generating the imide instead
of the cocrystal, the potential for isolation of a cocrystal was low. However, using a
mixture of anhydride and amine may have generated a cocrystal in situ in the DSC. The
first phase transition corresponds to the melt of maleic anhydride (51 ºC). Unlike the
previous examples, only a subtle recrystallization is present after the melt. But a phase
transition that does not correlate to either starting materials occurs at 140 ºC and is
therefore attributed to the melt of the cocrystal. The final phase change at 209 ºC is
consistent with the melt of the imide.
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Figure 2.30. DSC trace of a mixture of 1,5-naphthalenediamine and maleic anhydride

The possibility of synthesizing an imide that could not be generated in the oven
during the temperature ramp run in the DSC was also addressed. Unfortunately, analysis
of the 17 DSC traces of the mixtures (PA1+AA6, PA1+AA7, PA2+AA7, PA3+AA1,
PA3+AA5, PA3+AA6, PA3+AA7, PA4+AA7, PA5+AA7, PA6+AA1, PA6+AA2,
PA6+AA5, PA6+AA6, PA6+AA7, PA7+AA1, PA7+AA6, PA7+AA7) concluded that no
new imides were generated as there were no unidentifiable phase transitions.

2.2.5.3. Analysis of Cocrystals and Imides via PXRD
PXRD diffractograms were collected at two points during the reaction: once after
solvent-drop grinding and again after heating. For the three reactions described in detail
in sections 2.2.1-2.2.3 the PXRD diffractogram from the bulk ground cocrystal sample
could be compared to the calculated PXRD diffractogram from the single crystal
structure. An example of this is featured in Figure 2.31. The limitation of PXRD of the
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ground material is that without the calculated diffractogram, it is unclear what the new
diffractogram corresponds to. The calculated diffractogram for the imide can be
compared to the resulting imide to confirm bulk sample reaction completion, such as in
Figure 2.32. However, to employ PXRD to confirm imide formation, a calculated pattern
is also required. Therefore, coupled with single crystal analysis of the imide, PXRD can
be a powerful tool for analysis of a C3S3 type reaction.

Figure 2.31. PXRD diffractograms of eight solvent drop grinds,
starting materials, and calculated cocrystal
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Figure 2.32. PXRD diffractograms of solvent drop grinds after
heating for ca. 2 days at 150 ºC

2.2.5.4. Monitoring the Condensation Reaction via FT-IR
Monitoring the C3S3 reaction by FT-IR was an excellent method for determining
cocrystal formation after solvent-drop grinding due to the predictable shift in strong
carbonyl peaks to higher wavenumbers coupled with variable shifts in the NH2 region.
An exemplary case is shown in Figure 2.33. After heating the ground solid in the oven
the FT-IR spectrum was again collected and examined. Imide formation was easily
monitored by further examination of two specified regions. Disappearance of the NH2
peaks and a shift to lower wavenumbers for the carbonyl peak (typically ca. 40
wavenumbers lower), shown in Figure 2.34., was indicative of imide formation.
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Figure 2.33. Infrared spectra (FT-IR) of NTCDA and 2-methyl-4-nitroaniline
DMF solvent drop grind (red) compared to anhydride (purple) and amine (blue)

Figure 2.34. FT-IR of imide (red) with starting materials
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For reactions where there was no cocrystal formation from the solvent-drop
grinding the FT-IR spectra appeared as compilations of the respective amine and
anhydride starting material. For reaction 4 where the solvent-drop grinding produced the
amic-acid reaction intermediate, i.e. the anhydride ring opens affording a carboxylic acid
and the amine covalently binds to the carbonyl producing a secondary amide, the
carbonyl peak in the FT-IR spectrum is shifted to a lower wavenumber (Figure 2.35.)
which could be confused with the imide formation, however, additional heating shifts the
carbonyl region even lower by ca. 30 wavenumbers as shown in Figure 2.36.

Figure 2.35. FT-IR of intermediate (red) formed from phthalic anhydride
(purple) and 1-adamantylamine (green)
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Figure 2.36. FT-IR of imide (red) generated from 1-adamantylamine and phthalic anhydride

2.3. Conclusions
Cocrystal controlled solid-state synthesis is an invaluable synthetic methodology
for the generation of new molecules with very little solvent waste and with high yield.
Additionally, the incorporation of cocrystallization into organic synthesis is exemplary
evidence for the vast utility of cocrystals. Of the 49 reactions attempted in this study 32
resulted in imide formation while 17 showed no reactivity. 3 of the 32 also proved to be
controlled by a reactive cocrystal intermediate that, once heated, dehydrated to form the
imide. The formation of the cocrystals was facilitated via the well established technique
of solvent-drop grinding. Once the cocrystals were generated they were heated until the
condensation reaction was completed. The temperatures and reaction times varied
depending upon the starting materials, however, the sample was always heated above the
melting point of the lowest melting component. Interestingly, a total of 4 additional
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cocrystals may have been isolated from heating a mixture of the reactants in the DSC,
illustrating that the cocrystal can also be generated in situ as a reactive intermediate that
can ultimately lead to imide formation.
The development of novel materials via C3S3 with the isolation of a cocrystal as a
reactive intermediate provides additional insight into the method by which the reaction
occurs. The greater understanding of the solid-state synthesis reaction of imides gained
in this study serves as a model to be applied to other solid-state or solution based
reactions. The expansion of the field of solid-state organic synthesis will lead to the
reduction of hazardous waste production, increase reaction yields, and make the overall
synthetic process cheaper and more environmentally friendly.

2.4. Materials and Methods
2.4.1. Materials
All materials were used as received without further purification from SigmaAldrich or Alfa Aesar.

2.4.2. Synthetic Methods
A typical reaction involved solvent-drop grinding with chloroform, cyclohexane,
DMSO, DMF, ethyl acetate, methanol, toluene, and water for ca. 4 minutes by hand with
an agate mortar and pestle. The solid was then transferred to a glass vial and heated in an
oven at a temperature above the melting point of the lowest melting component to
facilitate imide formation. Reaction conditions for each of the 32 successful imide
formations are provided below:
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2-methyl-4-nitroaniline and NTCDA (PA1+AA1):
100 mg (0.66 mmol) of 2-methyl-4-nitroaniline and 88mg (0.33mmol) of NTCDA
were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4 minutes.
The resulting purple cocrystal was then heated for 3 hours at 180 ºC to produce the imide.
The imide was synthesized in ca. 75% yield.
2-methyl-4-nitroaniline and pyromellitic anhydride (PA1+AA2):
100 mg (0.66 mmol) of 2-methyl-4-nitroaniline and 72 mg (0.33 mmol) of
pyromellitic anhydride were ground with ca. 20μL of DMF by hand in an agate mortar
and pestle for 4 minutes. The resulting orange cocrystal was then heated for 50 hours at
150 ºC to produce the imide. The imide was synthesized in ca. 80% yield.
2-methyl-4-nitroaniline and maleic anhydride (PA1+AA3):
100 mg (0.66 mmol) of 2-methyl-4-nitroaniline and 64 mg (0.65 mmol) of maleic
anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4
minutes. The resulting solid was then heated for 40 hours at 60 ºC to produce the imide.
The imide was synthesized in ca. 92% yield.
2-methyl-4-nitroaniline and phthalic anhydride (PA1+AA4):
100 mg (0.66 mmol) of 2-methyl-4-nitroaniline and 98 mg (0.65 mmol) of
phthalic anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and
pestle for 4 minutes. The resulting solid was then heated for 16 hours at 150 ºC to
produce the imide. The imide was synthesized in ca. 73% yield.
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2-methyl-4-nitroaniline and 3,3’,4,4’-biphenyltetracarboxylic acid dianhydride
(PA1+AA5):
100 mg (0.66 mmol) of 2-methyl-4-nitroaniline and 97 mg (0.33 mmol) of
3,3’,4,4’-biphenyltetracarboxylic acid dianhydride were ground with ca. 20μL of DMF
by hand in an agate mortar and pestle for 4 minutes. The resulting solid was then heated
for 21 hours at 120 ºC to produce the imide. The imide was synthesized in ca. 87% yield.
3-aminobenzoic acid and NTCDA (PA2+AA1):
100 mg (0.73mmol) of 3-aminobenzoic acid and 98 mg (0.36 mmol) of NTCDA
were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4 minutes.
The resulting purple cocrystal was then heated for 14 hours at 150 ºC to produce the
imide. The imide was synthesized in ca. 99% yield.
3-aminobenzoic acid and pyromellitic anhydride (PA2+AA2):
100 mg (0.73mmol) of 3-aminobenzoic acid and 79 mg (0.36 mmol) of
pyromellitic anhydride were ground with ca. 20μL of DMF by hand in an agate mortar
and pestle for 4 minutes. The resulting solid was then heated for 16 hours at 180 ºC to
produce the imide. The imide was synthesized in ca. 90% yield.
3-aminobenzoic acid and maleic anhydride (PA2+AA3):
100 mg (0.73mmol) of 3-aminobenzoic acid and 72 mg (0.35 mmol) of maleic
anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4
minutes. The resulting solid was then heated for 19 hours at 150 ºC to produce the imide.
The imide was synthesized in ca. 92% yield.
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3-aminobenzoic acid and phthalic anhydride (PA2+AA4):
100 mg (0.73mmol) of 3-aminobenzoic acid and 108 mg (0.73 mmol) of phthalic
anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4
minutes. The resulting solid was then heated for 26 hours at 150 ºC to produce the imide.
The imide was synthesized in ca. 88% yield.
3-aminobenzoic acid and 3,3’,4,4’-biphenyltetracarboxylic dianhydride
(PA2+AA5):
100 mg (0.73mmol) of 3-aminobenzoic acid and 107 mg (0.36 mmol) of
3,3’,4,4’-biphenyltetracarboxylic dianhydride were ground with ca. 20μL of DMF by
hand in an agate mortar and pestle for 4 minutes. The resulting solid was then heated for
14 hours at 150 ºC to produce the imide. The imide was synthesized in ca. 85% yield.
3-aminobenzoic acid and 1,8-naphthalic anhydride (PA2+AA6):
100 mg (0.73mmol) of 3-aminobenzoic acid and 145 mg (0.73 mmol) of 1,8naphthalic anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and
pestle for 4 minutes. The resulting solid was then heated for 23 hours at 150 ºC to
produce the imide. The imide was synthesized in ca. 79% yield.
melamine and pyromellitic anhydride (PA3+AA2):
200 mg (1.6 mmol) of melamine and 519 mg (2.4 mmol) of pyromellitic
anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4
minutes. The resulting solid was then heated for 75 hours at 180 ºC and 26 hours at 150
ºC to produce the imide. The imide was synthesized in ca. 88% yield.

107

melamine and maleic anhydride (PA3+AA3):
100 mg (0.79 mmol) of melamine and 26 mg (0.26 mmol) of maleic anhydride
were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4 minutes.
The resulting solid was then heated for 23 hours at 115 ºC to produce the imide. The
imide was synthesized in ca. 79% yield.
melamine and 1,8-naphthalic anhydride (PA3+AA4):
100 mg (0.79 mmol) of melamine and 471 mg (2.4 mmol) of 1,8-naphthalic
anhydride were ground with ca. 40μL of DMF by hand in an agate mortar and pestle for 4
minutes. The resulting solid was then heated for 23 hours at 115 ºC to produce the imide.
The imide was synthesized in ca. 70% yield.
1,4-phenylenediamine and NTCDA (PA4+AA1):
100 mg (0.92 mmol) of 1,4-phenylenediamine and 247 mg (0.92 mmol) of
NTCDA were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4
minutes. The resulting solid was then heated for 5 hours at 115 ºC to produce the imide.
The imide was synthesized in ca. 98% yield.
1,4-phenylenediamine and pyromellitic anhydride (PA4+AA2):
200 mg (1.8 mmol) of 1,4-phenylenediamine and 81 mg (0.36 mmol) of
pyromellitic anhydride were ground with ca. 20μL of DMF by hand in an agate mortar
and pestle for 4 minutes. The resulting solid was then heated for 68 hours at 180 ºC to
produce the imide. The imide was synthesized in ca. 78% yield.
1,4-phenylenediamine and maleic anhydride (PA4+AA3):
100 mg (0.92 mmol) of 1,4-phenylenediamine and 45 mg (0.46 mmol) of maleic
anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4
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minutes. The resulting solid was then heated for 23 hours at 115 ºC to produce the imide.
The imide was synthesized in ca. 71% yield.
1,4-phenylenediamine and phthalic anhydride (PA4+AA4):
100 mg (0.92 mmol) of 1,4-phenylenediamine and 98 mg (0.46 mmol) of phthalic
anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4
minutes. The resulting solid was then heated for 5 hours at 115 ºC to produce the imide.
The imide was synthesized in ca. 85% yield.
1,4-phenylenediamine and 3,3’,4,4’-biphenyltetracarboxylic dianhydride
(PA4+AA5):
100 mg (0.92 mmol) of 1,4-phenylenediamine and 54 mg (0.18 mmol) of
3,3’,4,4’-biphenyltetracarboxylic dianhydride were ground with ca. 20μL of DMF by
hand in an agate mortar and pestle for 4 minutes. The resulting solid was then heated for
68 hours at 180 ºC to produce the imide. The imide was synthesized in ca. 82% yield.
1,4-phenylenediamine and 1,8-naphthalic anhydride (PA4+AA6):
100 mg (0.92 mmol) of 1,4-phenylenediamine and 183 mg (0.93 mmol) of 1,8naphthalic anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and
pestle for 4 minutes. The resulting solid was then heated for 64 hours at 150 ºC to
produce the imide. The imide was synthesized in ca. 78% yield.
1,5-diaminonaphthalene and NTCDA (PA5+AA1):
100 mg (0.63 mmol) of 1,5-diaminonaphthalene and 34 mg (0.12 mmol) of
NTCDA were ground with ca.10 μL of DMF by hand in an agate mortar and pestle for 4
minutes. The resulting solid was then heated for 68 hours at 180 ºC to produce the imide.
The imide was synthesized in ca. 86% yield.
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1,5-diaminonaphthalene and pyromellitic anhydride (PA5+AA2):
100 mg (0.63 mmol) of 1,5-diaminonaphthalene and 137 mg (0.63 mmol) of
pyromellitic anhydride were ground with ca.20 μL of DMF by hand in an agate mortar
and pestle for 4 minutes. The resulting solid was then heated for 107 hours at 120 ºC to
produce the imide. The imide was synthesized in ca. 84% yield.
1,5-diaminonaphthalene and maleic anhydride (PA5+AA3):
100 mg (0.63 mmol) of 1,5-diaminonaphthalene and 31 mg (0.31 mmol) of
maleic anhydride were ground with ca.20 μL of DMF by hand in an agate mortar and
pestle for 4 minutes. The resulting solid was then heated for 23 hours at 115 ºC to
produce the imide. The imide was synthesized in ca. 79% yield.
1,5-diaminonaphthalene and phthalic anhydride (PA5+AA4):
100 mg (0.63 mmol) of 1,5-diaminonaphthalene and 47 mg (0.31 mmol) of
phthalic anhydride were ground with ca.20 μL of DMF by hand in an agate mortar and
pestle for 4 minutes. The resulting solid was then heated for 19 hours at 115 ºC to
produce the imide. The imide was synthesized in ca. 82% yield.
1,5-diaminonaphthalene and 3,3’,4,4’-biphenyltetracarboxylic dianhydride
(PA5+AA5):
100 mg (0.63 mmol) of 1,5-diaminonaphthalene and 37 mg (0.13 mmol) of
3,3’,4,4’-biphenyltetracarboxylic dianhydride were ground with ca.20 μL of DMF by
hand in an agate mortar and pestle for 4 minutes. The resulting solid was then heated for
68 hours at 180 ºC to produce the imide. The imide was synthesized in ca. 77% yield.

110

1,5-diaminonaphthalene and 1,8-naphthalic anhydride (PA5+AA6):
100 mg (0.63 mmol) of 1,5-diaminonaphthalene and 25 mg (0.12 mmol) of 1,8naphthalic anhydride were ground with ca.20 μL of DMF by hand in an agate mortar and
pestle for 4 minutes. The resulting solid was then heated for 68 hours at 180 ºC to
produce the imide. The imide was synthesized in ca. 73% yield.
1-adamantylamine and maleic anhydride (PA6+AA3):
100 mg (0.66 mmol) of 1-adamantylamine and 64 mg (0.66 mmol) of maleic
anhydride were ground with ca.20 μL of DMF by hand in an agate mortar and pestle for 4
minutes. The resulting solid was then heated for 20 hours at 120 ºC to produce the imide.
The imide was synthesized in ca. 92% yield.
1-adamantylamine and phthalic anhydride (PA6+AA4):
100 mg (0.66 mmol) of 1-adamantylamine and 97 mg (0.66 mmol) of phthalic
anhydride were ground with ca.20 μL of DMF by hand in an agate mortar and pestle for 4
minutes. The resulting solid was then heated for 144 hours at 120 ºC to produce the
imide. The imide was synthesized in ca. 96% yield.
triphenylmethylamine and pyromellitic anhydride (PA7+AA2):
100 mg (0.39 mmol) of triphenylmethylamine and 84 mg (0.66 mmol) of
pyromellitic anhydride were ground with ca.20 μL of DMF by hand in an agate mortar
and pestle for 4 minutes. The resulting solid was then heated for 48 hours at 140 ºC to
produce the imide. The imide was synthesized in ca. 77% yield.
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triphenylmethylamine and maleic anhydride (PA7+AA3):
100 mg (0.39 mmol) of triphenylmethylamine and 38 mg (0.39 mmol) of maleic
anhydride were ground with ca.20 μL of DMF by hand in an agate mortar and pestle for 4
minutes. The resulting solid was then heated for 23 hours at 115 ºC to produce the imide.
The imide was synthesized in ca. 86% yield.
triphenylmethylamine and phthalic anhydride (PA7+AA4):
100 mg (0.39 mmol) of triphenylmethylamine and 57 mg (0.39 mmol) of phthalic
anhydride were ground with ca.20 μL of DMF by hand in an agate mortar and pestle for 4
minutes. The resulting solid was then heated for 26 hours at 115 ºC to produce the imide.
The imide was synthesized in ca. 90% yield.
triphenylmethylamine and 3,3’,4,4’-biphenyltetracarboxylic dianhydride
(PA7+AA5):
100 mg (0.39 mmol) of triphenylmethylamine and 113 mg (0.39 mmol) of
3,3’,4,4’-biphenyltetracarboxylic dianhydride were ground with ca.20 μL of DMF by
hand in an agate mortar and pestle for 4 minutes. The resulting solid was then heated for
48 hours at 140 ºC and 29 hours at 180 ºC to produce the imide. The imide was
synthesized in ca. 86% yield.
Single crystal growth of 2-methyl-4-nitroaniline NTCDA cocrystal (1a):
Purple single crystals were obtained from dissolving approximately 20 mg of the
cocrystal in 2 ml of 1,4-dioxane. The solution was partially covered with parafilm left to
slowly evaporate under ambient conditions. Single crystals of 1a were afforded within
14 days in ca. 20 % yield.
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Single crystal growth of 2-methyl-4-nitroaniline NTCDA diimide (1b):
Orange single crystals were obtained by dissolving approximately 35 mg of 1b in 1 ml of
DMSO. The solution was partially covered with parafilm left to slowly evaporate under
ambient conditions. Single crystals of 1bDMSO were afforded within 7 days in ca. 60
% yield.
Single crystal growth of 3-aminobenzoic acid NTCDA cocrystal (2a):
Purple single crystals were obtained from dissolving approximately 20 mg of the
cocrystal in 2 ml of 1,4-dioxane. The solution was partially covered with parafilm left to
slowly evaporate under ambient conditions. Single crystals of 2a were afforded within 3
days in ca. 43 % yield.
Single crystal growth of 3-aminobenzoic acid NTCDA diimide (2b):
Yellow single crystals were obtained from dissolving approximately 15 mg of 2b in 2 ml
of pyridine. The solution was partially covered with parafilm left to slowly evaporate
under ambient conditions. Single crystals of 2bpyridine were afforded within 20 days
in ca. 55 % yield.
Single crystal growth of 2-methyl-4-nitroaniline pyromellitic anhydride cocrystal
(3a): Orange single crystals were obtained from dissolving approximately 20 mg of the
cocrystal 3a in 2 ml of a 1:1 solvent mixture of chloroform and ethyl acetate. The
solution was partially covered with parafilm left to slowly evaporate under ambient
conditions. Single crystals of 3a were afforded within 22 days in ca. 15 % yield.
Single crystal growth of 2-methyl-4-nitroaniline pyromellitic anhydride diimide
(3b): Yellow single crystals were obtained from dissolving approximately 30 mg of 3b in
1 ml of DMF. The solution was partially covered with parafilm left to slowly evaporate
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under ambient conditions. Single crystals of 3b were afforded within 14 days in ca. 36 %
yield.
Single crystal growth of 1-adamantylamine phthalic anhydride intermediate (4a):
Single crystals of the intermediate were obtained from dissolving approximately 50 mg
(0.33 mmol) of 1-adamanytlamine and 49 mg (0.33 mmol) of phthalic anhydride in 4 ml
of methanol. The solution was partially covered with parafilm left to slowly evaporate
under ambient conditions. Single crystals of 4a were afforded within 6 days in ca. 68 %
yield.
Single crystal growth of 1-adamantylamine phthalic anhydride imide (4b):
Single crystals of the imide product were obtained by dissolving the heated material in
ca. 2ml of distilled methanol and slow evaporation over several days. The unit cell
parameters match the crystal structure of Refcode QUSKUK as deposited in the
Cambridge Structural Database.

2.4.3. Characterization Methods
Single-Crystal X-ray Diffraction: Single crystals were obtained for nine
compounds. Attempts to crystallize 3 did not afford crystals suitable for single crystal Xray crystallographic analysis. Single crystal analysis for 1, 2, and 5-10 was performed on
a Bruker-AXS SMART APEX CCD diffractometer with monochromatized Mo Kα
radiation (λ = 0.71073 Å) connected to a KRYO-FLEX low-temperature device. Data for
1, 2, and 5-10 were collected at 100 K or 298 K. Lattice parameters were determined
from least-squares analysis, and reflection data were integrated using SAINT.69
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Structures were solved by direct methods and refined by full matrix least squares based
on F2 using the SHELXTL package.70 All non-hydrogen atoms were refined with
anisotropic displacement parameters. All hydrogen atoms bonded to carbon, nitrogen,
and oxygen atoms were placed geometrically and refined with an isotropic displacement
parameter fixed at 1.2 times Uq of the atoms to which they were attached. Hydrogen
atoms bonded to methyl groups were placed geometrically and refined with an isotropic
displacement parameter fixed at 1.5 times Uq of the carbon atoms.
Powder X-Ray Diffraction (PXRD): 2-8 were characterized by a D-8 Bruker Xray Powder Diffractometer using a Cu Kα radiation (λ = 1.54178 Å), 50kV, 40mA. Data
was collected over an angular range of 3° to 40° 2θ value in continuous scan mode using
a step size of 0.05° 2θ value and a scan speed of 1.0 º/min.
Calculated PXRD: Calculated PXRD diffractograms were generated from the
single crystal structures using Mercury 1.5 (Cambridge Crystallographic Data Centre,
UK).
Differential Scanning Calorimetry (DSC): Differential Scanning Calorimetry
was performed on a TA Instruments 2920 DSC with a typical scan range of 35 ºC – 350
ºC, scan rate of 10 ºC/min, and nitrogen purge of ca. 70 psi.
Fourier Transform Infrared Spectroscopy (FT-IR): FT-IR analysis was
performed on a Nicolet Avatar 320 FT-IR spectrometer equipped with a solid-state ATR
accessory.
UV-Vis Spectrophotometer (UV-vis): Purple co-crystals from reactions 1 and 2
were additionally characterized by UV-vis from 350-800nm on a PerkinElmer Lambda
900 UV/Vis/NIR spectrometer
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Table 2.4. Hydrogen bond distances and parameters
Compound

1a

2a

Hydrogen Bond

d(H...A)/ Å

d(D...A)/ Å

θ/ º

N-HO

2.18

2.946(6)

145.5

N-HO

2.55

3.194(7)

130.3

N-HO

2.39

3.255(8)

166.9

N-HO

2.24

3.066(4)

N-HO

2.46

3.217(4)

144.4

O-HO

1.81

2.643(3)

172.3

N-HO

2.16

2.943(5)

148.1

N-HO

2.31

3.089(5)

148.0

O-HO

1.87

2.682(3)

171.6

N-HO

2.34

3.318(3)

157.5

155.2

3a

4a
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Chapter 3: Lamotrigine Crystal Forms: Synthesis, Characterization, and
Evaluation

3.1 Preamble
Crystal form development for an active pharmaceutical ingredient (API) typically
results in a plethora of crystal forms including salts,1 cocrystals,2 solvates,3 hydrates,4 etc.
which can be beneficial to the pharmaceutical industry.
Pharmaceutical salts are materials formed by an ionic API and a suitable,
pharmaceutically acceptable counterion.1, 5 They have been a part of crystal form
selection for decades as they offer diversity of composition and can therefore exhibit a
wide range of physicochemical properties.1 Pharmaceutical cocrystals6 are a relatively
new technology with the first pharmaceutical cocrystal developed within the decade. The
current focus of pharmaceutical cocrystallization is, much like a pharmaceutical salt, their
inherent ability to change the properties of an API. A review of the literature reveals that
there have been eight 7-14 pharmaceutical cocrystal case studies with pharmacokinetic
details reported to date, all of which support that pharmaceutical cocrystals are a viable
option to enhance the clinical performance of a poorly soluble API. Pharmaceutical
cocrystals are a particularly attractive crystal form option because they maintain the
criteria for patentability. That is, they are novel, non-obvious, and of utility to the
pharmaceutical industry.
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The importance of hydrates and solvates in pharmaceutical development has also
been recognized.4, 15 Various examples have demonstrated that the formation of hydrates
and solvates can significantly alter the physicochemical properties of APIs, such as
chemical stability, solubility and dissolution rate.16-19
With this in mind, we report a study of lamotrigine (6-(2,3-dichlorophenyl)-1,2,4triazine-3,5-diamine), a triazine drug amenable to crystal engineering design strategies
that exhibits poor solubility and dissolution rate in its pure crystalline form. Lamotrigine
is marketed as Lamictal® by GlaxoSmithKline for oral administration as a compressed or
chewable tablet. It is primarily used as an anti-convulsant drug for the treatment of
epilepsy as well as in the treatment of psychiatric disorders such as bipolar disorder.20, 21
In particular, lamotrigine is used for the treatment of generalized seizures associated with
Lennox-Gastaud syndrome22 and it can be used in conjunction with other anti-epileptic
drugs such as carbamazepine, phenytoin, phenobarbital, primidone or valproate.23 An
additional and perhaps less common use for lamotrigine is for the treatment of
neuropathic pain, cluster headaches, and migraines.24 Lamotrigine, a white to pale
cream-colored powder with a pKa of 5.7, is very slightly soluble in water (0.17 mg/mL at
25 °C) and only slightly soluble in 0.1 M HCl (4.1 mg/mL at 25 °C).25 Various attempts
have been made to solve the use limitations of lamotrigine due to its poor solubility.
Briefly, these approaches have involved the exploration of a plethora of crystal forms,26-30
including salt forms, and reduction of the particle size.31 Recently eight novel crystal
forms of lamotrigine were reported by Galcera et al.,32 with only two salt forms
(saccharinate and DL-hemitartrate dimethylsulfoxide solvate) reaching a greater
maximum aqueous solubility than pure lamotrigine. A benzoate dimethylformamide
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solvate,33 hydrogen phthalate dimethylformamide solvate,34 methanol solvate,35
isoethoinate,36 dimethylformamide solvate,37 methanesulfonate,38 and a monohydrate39
have also been reported; however only limited solubility data is available concerning
these crystal forms. Some of the aforementioned crystal forms, particularly those
involving certain salt forms, are undesirable for certain routes of administration, such as
parenteral, due to their acidity. Other formulations contain ingredients that are not safe
for human consumption such as dimethylformamide. Clearly, there is a strong scientific
and clinical need to develop novel forms of lamotrigine that have significantly improved
physicochemical properties, including aqueous solubility, which can be formulated for
use in various delivery routes, such as oral administration.
To generate novel crystal forms of lamotrigine an analysis based upon crystal
engineering40-42 molecular recognition,43 and supramolecular synthons,44 was conducted
to determine complementarities between a number of pharmaceutically acceptable and
approved materials containing carboxylic acid, alcohol, and primary amide moieties and
lamotrigine. It showed that lamotrigine can form complexes with two dominant
supramolecular synthon motifs, with or without the aminopyridine dimer. Among all
pharmaceutically acceptable and/or approved compounds with hydrogen-bonding
functionality, a variety of guest molecules that were likely to form either of these two
motifs with lamotrigine were selected for this study and are shown in Figure 3.1. All
selected guest molecules except butylated hydroxyanisole successfully formed complexes
with lamotrigine, resulting in ten novel lamotrigine crystal forms. Details of the
supramolecular synthon approach and the development of ten crystal forms of
lamotrigine from established cocrystallization techniques45-48 are presented herein.
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Additionally, solubility and pharmacokinetic studies were conducted upon a subset of
these crystal forms and are described herein.

3.2 Results and Discussion
3.2.1 Salt vs Cocrystal
Lamotrigine has the ability to form both salts and cocrystals due to its relatively
basic nature (pKa = 5.7). By selecting cocrystal formers with a range of varying acidities,
the formation of lamotrigine pharmaceutical salts or cocrystals would be expected. The
pKa difference between lamotrigine and the adduct, ΔpKa (i.e. ΔpKa = pKa base - pKa
acid), is widely accepted as the key to predicting whether a salt or a cocrystal will form.5,
49, 50

It is generally considered that if ΔpKa > 3 the resulting compound will be a salt

(exemplified in this study by saccharin); whereas the result is typically a cocrystal if
ΔpKa < 0. For ΔpKa between 0 < ΔpKa < 3 the outcome can be either a salt or
cocrystal or a complex with partial proton transfer.51 The pKa and ΔpKa values52-55
involved in this study are summarized in Table 3.1. It is noted that the ΔpKa values of
three cocrystal formers (i.e. adipic acid, L-malic acid and nicotinic acid) fall in the
variable region. Interestingly, all of these cocrystal formers produce lamotrigine salts, as
evidenced by the proton location and bond length analysis from the single crystal X-ray
diffraction data. Analysis of the carbonyl region of the solid-state FTIR spectrum also
supports the formation of lamotrigine salts.
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Table 3.1. pKa values and the resulting ΔpKa values for the lamotrigine salts

pKa

∆pKa

Adipic acid

4.43

1.27

L-Malic acid

3.44

2.26

Nicotinic acid

4.92

0.78

1.60

4.10

Acid

Saccharin

Figure 3.1 Molecular structures of cocrystal and salt formers

3.2.2 CSD Analysis
In order to prepare novel crystal forms of lamotrigine, a crystal engineering40-42
study incorporating supramolecular design and the molecular functionality of
lamotrigine, i.e. the supramolecular synthon approach, was conducted. The crystal
structure of pure lamotrigine exhibits two dominant supramolecular synthon motifs, the
aminopyridine dimer (motif 1) and the amine-aromatic nitrogen synthon (motif 2). Motif
1 and motif 2 are depicted in Figure 3.2.
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Figure 3.2 Motif 1 involves breaking the aminopyridine dimer and motif 2 retains the
aminopyridine dimer but breaks the exterior bifurcated interaction

The introduction of an additional complementary component to the crystal lattice
of lamotrigine could lead to an interruption of motifs 1 or 2 by either: breaking the
aminopyridine dimer (breaking motif 1) or breaking the exterior bifurcated interactions
between the aromatic nitrogen moieties of one lamotrigine to the primary amine moieties
of two additional lamotrigine molecules (breaking motif 2). An analysis of the
Cambridge Structural Database (CSD)56, 57 indicates that breaking either motif is feasible
given a complementary secondary component. Disruption of motif 1 occurs in 26 out of
81 aminopyridine entries (32%) and disruption of motif 2 occurs in 39 out of those 81
entries, or 48% of the time. In order to understand the hydrogen bonding of the primary
amine moiety of the diaminopyridine moiety, the 39 entries that break motif 2 were
analyzed. Among those entries 95% (37/39) show the exterior amine moiety hydrogen
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bonding to the second molecule while only 2 entries (5%) show the exterior amine
moiety hydrogen bonding to a molecule of the same kind, i.e. another diaminopyridine
(Refcodes: AMCQUN, GICWOF). Based on these CSD statistics,57 breaking the
supramolecular synthons of motif 1 and motif 2 is feasible, however, there remains a
tendency towards persistence of the aminopyridine dimer.
Identification of complementary cocrystal formers for lamotrigine by statistical
examination of the percentage of occurrence of supramolecular homosynthons versus
supramolecular heterosynthons was also addressed via a CSD analysis.57 Interactions
between an aminopyridine moiety and carboxylic acid, primary amide, and alcohol
moieties were examined in order to determine if the supramolecular heterosynthon or the
supramolecular homosynthon would be more prominent (Table 3.2., aminopyridine was
chosen instead of diaminopyridine to provide a larger dataset for the statistical analysis).
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Table 3.2 Comparison of supramolecular homosynthon versus supramolecular
heterosynthon with aminopyridines and complementary moieties
Complem

No. of

%

%Homosynth

%Heterosyntho

Heterosynthon

entary

entries

Homosynthon

on

n occurrence

Distance Range (Å)

Moiety

w/

occurrence:

occurrence:

refined dataset

Refined dataset

both

Aminopyridine

Cocrystal

group

Refined dataset

former

s

(distance

Refined

rangeÅ)

dataset

42/91-acid

N(py) O 2.50-2.80

(46%)

N(am) O 2.71-3.10

28/91-

(acid and

carboxylate

carboxylate)

(distance
rangeÅ)
Carboxyli

91

c acid

40/91 (44%)

0

(N N 2.92-3.17)

(31%)
Primary

15

amide
Alcohol

307

2/15 (13%)

1/15 (6%)

(N N 3.04-3.077)

(N O 2.98)

66/307 (21%)

78/307 (25%)

(N N 2.92-3.17)

(O O 2.61-

1/15 (6%)

N(py) N 2.97
N(am) O 3.06

100/307 (33%)

N(py) O 2.67-2.90
N(am) O 2.78-3.19

2.92)

To conduct the supramolecular homosynthon and heterosynthon analysis, a broad
distance range was initially selected and then reduced by visual inspection to determine
the appropriate ranges for defining hydrogen bond contact limits. The values given in
Table 3.2. are a refined dataset which includes only aminopyridine and one additional
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moiety sustained by a specified supramolecular hetero- or homosynthon interaction
within a defined distance range. Our analysis concluded that, in general, the
supramolecular heterosynthons were more dominant than the homosynthons. The
alcohol moiety was the most statistically favored to interact with the aminopyridine
moiety as there was 33% (100/307) versus 21% (66/307) occurrence for the
supramolecular heterosynthon and homosynthon, respectively. However, the addition of
a carboxylic acid to a molecule sustained via an aminopyridine supramolecular
homosynthon has previously been explored and successfully resulted in the formation of
cocrystals and salts.58, 59 Thus it is not surprising that there was also a preference for the
aminopyridine-acid supramolecular heterosynthon, with a higher percentage of
occurrence attributed to the carboxylic acid group (43/91, 46%) than the carboxylate
group (28/91, 31%).

Interestingly, the carboxylic acid homosynthon does not occur in

the presence of the aminopyridine functional group. There are 15 structures that contain
aminopyridine and primary amide moieties, 2 of which form the aminopyridine
supramolecular homosynthon, 1 forms the amide dimer, and 1 forms the aminopyridineamide supramolecular heterosynthon. Unfortunately, this paucity of data precludes
determination of the reliability of the aminopyridine-amide supramolecular
heterosynthon. However, the CSD analysis indicates that aminopyridines are likely to
form supramolecular heterosynthons with molecules containing alcohols and carboxylic
acids. A general observation when searching for entries with an aminopyridine was the
numerous examples of aminopyridines with barbituric acid derivatives. Specifically, the
CSD contains a set of 35 aminopyridine-barbituric acid derivative cocrystals synthesized
by Whitesides et al.60-62 This dataset indicates that the aminopyridine-amide
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supramolecular heterosynthon is a reliable synthon. However, due to the nature of the
study, cocrystal formers that are utilized must at least be on the generally regarded as safe
(GRAS) list, precluding the selection of cocrystal formers containing amide moieties.
Thus a range of carboxylic acids, alcohols, and amides were chosen for crystal form
development however, only six resulted in novel crystal forms. Figure 3.1. illustrates the
formers that resulted in novel crystal forms.

3.2.3 Motif 1 versus Motif 2
The crystal forms presented herein break either motif 1 or motif 2 present in pure
lamotrigine by incorporating a complementary cocrystal former. Motif 1 is broken in 4
out of 9 structures while the remaining crystal forms contain motif 1 but break motif 2.
Specifically, crystal forms 2, 4, 7, 9, and 10 break motif 2 while forms 1, 5, 6, and 8
break motif 1. The individual motifs and how they impact the physicochemical
properties of the crystal form are discussed in the following segments.

3.2.4 Crystal Structure Descriptions
Cocrystals of lamotrigine methylparaben form I (1) crystallize in the space
group P21/n. 1 crystallizes concomitantly in the presence of pure methylparaben and
lamotrigine tetrahydrofuran solvate. The asymmetric unit contains one lamotrigine and
one methylparaben molecule. The lamotrigine aminopyridine dimer is not observed in 1
(Figure 3.3.). Instead the structure is a corrugated tape comprised of individual chains of
alternating lamotrigine methylparaben molecules sustained primarily by two hydrogen
bonds (Figure 3.4.). Specifically, the aromatic nitrogen N2 of the triazine ring is
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hydrogen bonded to the hydroxyl moiety of the methylparaben [O1-H10ON2: ON
2.651(4) Å, HN 1.831 Å, O-HN 164.8 º] and the amine in the 5-position of
lamotrigine is hydrogen bonded to the carbonyl group of the ester moiety of
methylparaben [N5-H3NO2: NO 2.823(4) Å, HO 1.971 Å, N-HO 162.7 º]. The
chains of extend parallel to the 2-fold axis. Neighboring chains are related by a center of
inversion and are held together by various weak interactions including C-HN and
ClCl interactions to form a corrugated tape. The phenyl rings of the lamotrigine
molecule are twisted to a dihedral angle of 88.03 º.

Figure 3.3 Supramolecular synthons exhibited by 1
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Figure 3.4 1 breaks motif 1 as shown in the hydrogen bonding pattern

Lamotrigine methylparaben form II (2) can be obtained via grinding, slurry, or
melt. Crystals of 2 exist in space group Pī with one lamotrigine and one methylparaben in
the asymmetric unit (Figure 3). The chlorinated phenyl ring backbone of lamotrigine is
disordered over two distinct positions with 40% and 60% occupancies, respectively. The
attached chlorine atoms are refined over three positions with occupancies of 40%, 40%
and 20%, respectively. A comparison of the crystal structures of 1 and 2 reveals that they
exhibit different molecular packing arrangements. Unlike 1, 2 exhibits lamotrigine
centrosymmetric aminopyridine dimers [N3-H3BN4: NN 3.121(4) Å, HN 2.246
Å, N-HN 172.3 º]. The lamotrigine dimers connect to neighboring dimers via
methylparaben molecules, thereby forming supramolecular ribbons that extend parallel to
the a-axis [N5-H5AO1: NO 3.036(4) Å, HO 2.205 Å , N-HO 157.3 º; O1134

H1CN2: ON 2.711(4) Å, HN 1.876 Å, O-HN 173.3 º]. The methylparaben
molecule also serves as a bridge to join these supramolecular ribbons via N-HO
interactions [N5-H5BO2: NO 2.931(4) Å, HO 2.129 Å, N-HO 151.2 º].

Figure 3.5 Breaking motif 2 shown in the hydrogen bonding of 2
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Figure 3.6 Crystal packing of 2

The cocrystal of lamotrigine and nicotinamide (3) was prepared from a melt of
a 1:1 ratio of lamotrigine and nicotinamide, as evidenced by PXRD characterization.
Efforts to prepare quality single crystals of 3 for single crystal XRD analysis are
unsuccessful to date.
4 (lamotrigine nicotinamide monohydrate) crystallizes in the space group Pī,
with the asymmetric unit consisting of one molecule of lamotrigine, one molecule of
nicotinamide and one water molecule. Motif 2 is broken by the double insertion of water
molecules while the lamotrigine aminopyridine dimer persists [N3-H2NN4: NN
3.039(2) Å, HN 2.243 Å, N-HN 154.2 º]. The water molecules facilitate the
formation of a supramolecular ribbon motif. The ribbon is formed along the b-axis as the
lamotrigine dimers are linked by water molecules via N-HO and O-HN interactions
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[N5-H3NO1-H5ON2: NO 2.930(2) Å, HO 2.089 Å, N-HO 165.3 º, ON
2.822(2) Å, HN 1.967 Å, ON 171.7 º]. In addition, nicotinamide molecules form
centrosymmetric amide dimers that pack perpendicularly in between the lamotrigine
water ribbons forcing a separation between the supramolecular ribbons approximately the
length of two nicotinamide molecules (Figure 3.7.) [N7-H8NO2: NO 2.915(3) Å,
HO 2.056 Å, N-HO 176.7 º]. The water molecules within the supramolecular
ribbons also hydrogen bond to the nicotinamide dimers via additional O-HN
interactions that are highlighted in Figure 3.8. [O1-H6N6: ON 3.039(3) Å, HN
2.162 Å, O-HN 166.5 º]. The voids generated by the nicotinamide dimers separating
the supramolecular ribbons are filled by additional supramolecular ribbon-nicotinamide
dimer units. These supramolecular units are stabilized by π-π interactions between the
chlorinated lamotrigine ring and the nicotinamide aromatic ring.

Figure 3.7. Supramolecular synthons present in 4

137

Figure 3.8. Crystal packing of 4 interrupting motif 2

The salt of lamotrigine and saccharin (5) crystallizes in space group P21/c. The
asymmetric unit contains one lamotrigine cation and one saccharin anion. The structure
of 5 does not contain the aminopyridine dimer; however, formation of the dimer is
possible with protonation of the most basic nitrogen (N2) as it is not incorporated in the
lamotrigine dimer. The basic supramolecular unit in 5 is a tetramer formed between two
lamotrigine and two saccharin ions where the N2 is protonated. Lamotrigine and
saccharin are associated via two 2-point recognition aminopyridine-sulfonamide
supramolecular heterosynthons [N2+-H1NN6: NN 2.819(2) Å, HN 1.940 Å, N+HN 177.5 º ; N3-H2NO1: NO 2.830(2) Å, HO 1.954 Å, N-HO 173.5 º]. The
C3-N2-N1 angle of the triazine ring in the crystal structure of 5 is 123.4 º which
correlates to the previously reported values for protonated lamotrigine63 and the expected
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trend for protonated aminopyridines, i.e. higher angles than those of a neutral
aminopyridine.63, 64 The tetramer is formed from two adjacent supramolecular
heterosynthon dimers, shown in Figure 3.9., that are further connected by primary aminecarbonyl interactions [N3-H3NO1: NO 2.818(2) Å, HO 2.054 Å, N-HO 144.7
º]. Each tetramer is hydrogen bonded to four additional tetramers via either sulfonylamine or sulfonyl-chlorine interactions [N5-H4NO2: NO 2.889(2) Å, HO 2.194 Å,
N-HO 135.5 º; Cl1O3 3.068(3) Å]. A view of the overall crystal packing can be
seen in Figure 3.10.

Figure 3.9. Tetrameric motif present in 5

139

Figure 3.10. Crystal packing of 5

6 (lamotrigine adipate salt) crystallizes in space group of P21/c with two
lamotrigine cations and one adipate anion in the asymmetric unit (Figure 3.11.). The
molecular packing of 6 is based upon 2-point supramolecular heterosynthons between the
aminopyridinium and carboxylate moieties, involving an N-HO hydrogen bond [N3H3NO1: NO 2.942(2) Å, HO 2.110 Å, N-HO 157.5 º] and a N+-HO– chargeassisted hydrogen bond [N2+-H1NO2-: NO 2.627(2) Å, HO 1.790 Å, N-HO
158.1 º]. Proton transfer is evidenced by the C-O bond distances of the carboxylate group
(1.248(2) Å and 1.272(2) Å) and the geometry of the lamotrigine triazine ring. The C3N2-N1 angle of the triazine ring in the crystal structure of 6 is 122.4(2) º. Each discrete
unit, comprised of two lamotrigine cations and one adipate anion, is hydrogen bonded to
140

eight nearby lamotrigine-adipate units through the lamotrigine NH2 moieties and
neighboring carboxylate [N3-H2NO1: NO 2.861(2) Å, HO 2.057 Å, N-HO
151.5 º; N5-H4NO2: NO 2.760(2) Å, HO 1.931 Å, N-HO 156.5 º]. Each
adipate anion is hydrogen bonded to four additional discrete units via C-OH-N
interactions. The overall packing can be viewed in Figure 3.12. as staggered
supramolecular units of lamotrigine-adipate running parallel to either (010) or (001) with
Clpi interactions.

Figure 3.11. Supramolecular synthons of 6 do not form motif 1
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Figure 3.12. Crystal packing of 6

The lamotrigine and L-malic acid salt (7) crystallizes in P21/c. The asymmetric
unit is comprised of two lamotrigine cations and one L-malate anion (Figure 3.13.).
Lamotrigine dimers are formed via a noncentrosymmetric dimer sustained by N-HN
hydrogen bonds [N5-H5NN14: NN 2.956(6) Å, HN 2.078 Å, N-HN 174.6 º;
[N15-H15N4: NN 3.082(6) Å, HN 2.215 Å, N-HN 168.6 º]. The L-malate anion
hydrogen bonds to the lamotrigine dimer such that a supramolecular chain is formed.
Proton transfer occurs between both carboxylate groups (C20-O1: 1.275(5); C20-O2:
1.235(6); C23-O4: 1.257(6); C23-O5: 1.275(6)) of L-malate and aromatic nitrogen atoms
of lamotrigine [N12+-H12NO1-: NO 2.632(5) Å, HO 1.766 Å, N-HO 167.8 º;
C19-N12-N11 angle 123.16 º]. The lengths of the C-O bonds are typical of a carboxylate
moiety and the C19-N12-N11 angle of 123.2 º is consistent with that of a protonated
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aromatic nitrogen. The supramolecular chains, generated from two lamotrigine cations
alternating with one l-malate anion, hydrogen bond to an additional l-malate anion
forming a sheet perpendicular to the bc-plane. The sheets interact via NHO hydrogen
bonds [N3-H3NAO1: NO 2.790(5) Å, HO 2.086 Å, N-HO 136.3 º; N13H13AO5: NO 2.928(5) Å, HO 2.135 Å, N-HO 149.6 º] to chains that run
through the ac-plane, thereby generating a 3D structure. Figure 3.14. highlights the
supramolecular sheet with only one row of perpendicular chains present for clarity.

Figure 3.13. Supramolecular synthons of 7 generating motif 1, breaking motif 2
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Figure 3.14. Crystal packing of 7 highlighting a chain running perpendicular to the sheet

The dimethanol solvate of the salt formed by lamotrigine and nicotinic acid
(8) crystallizes in space group P21/c with proton transfer observed from the carboxylic
acid group to N2 on the triazine ring [N2+-H1NO2-: NO 2.729(3) Å, HO 1.880 Å,
N-HO 161.7 º; C3-N2-N1 angle 122.8 º]. The basic supramolecular unit is comprised
of one lamotrigine cation, one nicotinate anion, and two methanol molecules. The
structure of 8 reveals that the nicotinate anion breaks the lamotrigine dimer. Similarly to
5, two pairs of lamotrigine nicotinate adducts interact to form tetrameric motifs sustained
by charge assisted N+-HO- and N-HO hydrogen bonds (Figure 3.15.) [N3-H2NO3:
NO 2.764(3) Å, HO 1.9223 Å, N-HO 159.4 º, N3-H3NO3: NO 2.872(3) Å
HO 2.061 Å N-HO 152.8 º]. In addition, four methanol molecules attach to the
exterior of each tetramer by hydrogen bonding to lamotrigine cations and nicotinate
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anions. Two methanol molecules interact with carboxylate groups via O-HO hydrogen
bonds [O1S-H6SO2: OO 2.777(2) Å, HO 1.974 Å, O-HO 159.7 º], while the
other two methanol molecules are inserted between N5 and the aromatic nitrogen of the
nicotinate [N5-H4NO4S: NO 2.755(3) Å, HO 1.881 Å, N-HO 171.8 º, O4SH7SN6: ON 2.699(3) Å, HN 1.863 Å, ON 172.7 º]. The methanol molecules
that interact with the carboxylate moiety act as hydrogen bond donors to the carboxylate
while also accepting a hydrogen bond from a lamotrigine of an adjacent tetramer
disposed perpendicularly [N5-H5NO1S: NO 2.816(3) Å, HO 2.012 Å, N-HO
151.3 º]. The crystal packing of the tetrameric units is shown in Figure 3.16.

Figure 3.15. Breaking motif 1 shown in the hydrogen bonded assembly of 8
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Figure 3.16. Crystal packing of tetrameric units of 8

A small set of lamotrigine solvates, including a monomethanol solvate, have
previously been reported in the literature. Details of the monomethanol solvate crystal
packing that supports the overall structure were also provided. Herein the crystal
structures of the monomethanol solvate and a novel dimethanol solvate are explored. The
lamotrigine dimethanol solvate (9) was obtained from an attempted cocrystallization of
lamotrigine and butylated hydroxyanisole from methanol. 9 crystallizes in C2/c with the
asymmetric unit comprised of one lamotrigine and two methanol molecules. 9 retains the
lamotrigine dimer motif and the supramolecular unit consists of one lamotrigine dimer
and two separately hydrogen bonded methanol molecules. The lamotrigine
supramolecular homosynthon dimer in 9 is centrosymmetric [N3-H1NN4: NN
3.084(3) Å, HN 2.213 Å, N-HN 170.6 º]. In addition, N3 and N5 amines form
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hydrogen bonds with methanol molecules (Figure 3.17.) [N3-H2NO2: NO 2.824(2)
Å, HO 2.210 Å, N-HO 126.6 º ; N5-H3NO2: NO 2.862(2) Å, HO 2.109 Å, NHO 143.1 º]. Hydrogen bonds are also observed between methanol molecules and
aromatic nitrogen atoms N1 and N2 [O1-H6ON1: NO 2.987(2) Å, HN 2.159 Å,
N-HO 168.6 º; O2-H5ON2: NO 2.654(2) Å, HN 1.824 Å, N-HO 169.9 º].
The lamotrigine dimers and methanol molecules hydrogen bond to form a ribbon that
extends along the c-axis. A ribbon is highlighted in yellow in Figure 3.18. Two
inversion center related ribbons interact via CH-N and Cl-π interactions thus forming a
ribbon bilayer. The bilayers stack along the b-axis in an abab motif, as shown in Figure
3.18.

Figure 3.17. Crystal form 9 breaking motif 2
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Figure 3.18. Bilayers formed in crystal packing of 9

Comparison of literature monomethanol solvate (Refcode KADPAG)
The methanol solvate preexisting in the literature from 198935 contains one
lamotrigine and one methanol molecule in the basic supramolecular unit and crystallizes
in the P21/n space group. The lamotrigine dimethanolate presented herein (Figure 3.17
and 3.18) sustains a 1:2 ratio (lamotrigine:methanol) and crystallizes in the C2/c space
group. Interestingly, the monomethanol and dimethanol solvate both crystallize by
breaking motif 2. The centrosymmetric lamotrigine aminopyridine dimer is exhibited by
both solvates; the distinction can clearly be seen when looking at the ribbons of
lamotrigine aminopyridine dimers. In the dimethanol solvate, the ribbon is flat extending
along the b-axis (Figure 3.18., yellow ribbon), however, in the monomethanol solvate the
ribbon is corrugated with a dihedral angle of 65.14º (Figure 3.19., yellow ribbon).
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Variations can also be found in the hydrogen bonding scheme of the amine moieties in
the 3 and 5-positions. Notably the amine in the 3-position is hydrogen bonded to a
methanol in the dimethanol solvate, whereas in the monomethanol solvate the methanol
exhibits a short contact to a neighboring chlorine atom.

Figure 3.19. Crystal packing of KADPAG in CSD highlighting a corrugated
chain of lamotrigine methanol units

Crystals of 10 (lamotrigine ethanolate monohydrate) form in space group P21/c
with an asymmetric unit that is comprised of one lamotrigine, one ethanol and one water
molecule. 10 exhibits the lamotrigine dimer as shown in Figure 3.20. In the crystal
structure of 10, the basic supramolecular unit is the lamotrigine aminopyridine dimer
sustained by two symmetrically related hydrogen bonds [N3-H2NN4: NN 3.006(2)
Å, HN 2.191 Å, N-HN 153.7 º]. The lamotrigine dimers are further hydrogen
bonded via water molecules [N3-H1NO1: NO 2.928(2) Å, HO 2.295 Å, N-HO
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128.8 º ; N5-H3NO1: NO 2.848(2) Å, HO 1.973 Å, N-HO 173.2 º] and ethanol
molecules [N5-H4NO2: NO 3.042(2) Å, HO 2.346 Å, N-HO 136.2 º] to form a
supramolecular ribbon that translates along the 2-fold axis. The ribbons, shown in Figure
3.21., illustrate the water hydrogen bonding in the central region of the ribbon while the
ethanol molecules hydrogen bond to the exterior. Individual supramolecular ribbons
interact via Cl-π interactions to form a corrugated layer. The layers are connected
through hydrogen bonds that occur between water and ethanol molecules [O1-H9OO2:
OO 2.829(2) Å, HO 1.942 Å, O-HO 178.8 º], thereby generating a brickwall motif.
The supramolecular synthons involved in the structure of 10 are reminiscent of pure
lamotrigine; however, the insertion of the water and ethanol molecules force neighboring
lamotrigine dimers further apart than in the pure crystalline material.

Figure 3.20. Crystal form 10 interrupting motif 2
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Figure 3.21. Ethanol water lamotrigine ribbons
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Table 3.3 Crystallographic data and structure refinement parameters for compounds 1-2, 4-10
1
C9H7Cl2N5
C8H8O3

2
C9H7Cl2N5
C8H8O3

5
C9H8Cl2N5
C7H5NO3S

6
C9H8Cl2N5
(C6H9O4)0 5

7
(C9H8Cl2N5)2
C4H5O5

408.24

4
C9H7Cl2N5
C6H6N2O
H2O
396.24

Formula
weight
Crystal
System
Space
group
a (Å)
b (Å)

408.24

439.28

329.17

Monoclinic

Triclinic

Triclinic

Monoclinic

P21/n

Pī

Pī

5.2729(9)
14.330(3)

8.8957(18)
11.409(2)

c (Å)

23.822(4)

12.040(2)

α (o)
β (o)
γ (o)
Vol (Å3)
Dcal (g cm3
)
Z
Reflections
collected
Independen
t reflections
Observed
reflections
T (K)
R1

90
92.795(3)
90
1797.9(6)
1.508

Chemical
formula

646.28

8
C9H8Cl2N5
C6H4NO2
(CH4O)2
443.29

9
C9H7Cl2N5
(CH3OH)2
320.18

10
C9H7Cl2N5
C2H5OH
H2O
320.18

Monoclinic

Monoclinic

Monoclinic

Monoclinic

Monoclinic

P21/c

P21/c

P21

P21/c

C2/c

P21/c

7.3047(6)
8.4939(7)

18.447(5)
6.954(2)

13.068(3)
7.498(2)

10.728(2)
10.2003(19)

7.648(3)
15.863(6)

19.326(4)
17.584(3)

7.1308(14)
8.3566(16)

14.762(4)

14.069(3)

12.721(2)

16.803(7)

8.2698(15)

24.018(5)

107.05(3)
102.10(3)
112.50(3)
1005.0(4)
1.349

14.6964(12
)
105.081(5)
90.580(5)
95.244(5)
876.21(12)
1.502

90
107.978(4)
90
1801.2(9)
1.620

90.00
96.755(4)
90.00
1369.0(6)
1.597

90
107.634(13)
90
1326.6(4)
1.618

90
90.072 (6)
90
2038.5(15)
1.444

90
97.820(3)
90
2784.2(9)
1.528

90
94.565(3)
90
1426.7(5)
1.491

4
8611

2
4879

2
7400

4
9108

4
6576

2
9647

4
10331

8
5746

4
8317

3159

3370

2842

3273

2407

3848

3642

2421

3273

2056

2420

2406

3033

2230

3499

2698

2127

2886

100
0.0626

100
0.0642

296
0.0352

100
0.0338

100
0.0317

100
0.0461

100
0.0419

100
0.0341

100
0.0367

wR2

0.1002

0.1380

0.0920

0.0893

0.0894

0.1271

0.0938

0.0889

0.0917

GOF

1.095

1.070

1.024

1.043

1.040

1.097

1.021

1.054

1.022

152

3.3. Solubility and Dissolution Study
As shown in Figures 3.22. and 3.23., solubility and dissolution studies were
0.5
0.45
0.4

Concentration (mg/mL)

0.35
0.3
0.25
0.2
0.15
Lamotrigine:Saccharin (5)
Lamotrigine

0.1

Lamotrigine nicotinamide (3)
Lamotrigine methylparaben form II (2)

0.05

Lamotrigine nicotinamide hydrate (4)

0
0

50

100

150

200

Time (min)

Figure 3.22. Dissolution profiles in water for lamotrigine and crystal forms 2-5
Lamotrigine

5

Lamotrigine:nico inamide (3)
4.5
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4
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3
2.5
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1
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50
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Figure 3.23. Dissolution profiles at pH = 1 for lamotrigine and crystal forms 2-5

conducted for 2, 3, 4, 5 and pure lamotrigine. The solubility of 5 has been reported
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elsewhere32 and is re-examined in this study. The maximum concentration of pure
lamotrigine in water and pH 1 HCl solution differ by approximately 10% with the higher
solubility of lamotrigine exhibited under more acidic conditions. The dissolution study in
water revealed that 5 reached a maximum concentration of ca. 0.45 mg/ml. This
observation is in agreement with the reported literature aqueous solubility.65 However,
given that the solubility of lamotrigine increases under more acidic conditions, the
improved solubility of 5 in water might be rationalized by the inadvertent decrease in pH
due to the dissolution of saccharin. The maximum concentrations of the other crystal
forms in water were ca. 0.21 mg/ml, 0.30 mg/ml, 0.23 mg/ml, and 0.28 mg/ml for 2, 3, 4,
and pure lamotrigine, respectively. It was also found that 4 exhibited the lowest
concentration in water after 4 hours, which is not surprising as hydrates are typically
considered to be less soluble than the corresponding anhydrate.4, 66
An examination of the dissolution profiles generated at pH 1 indicates that 2
sustains the highest concentration throughout the four-hour study achieving a maximum
concentration of ca. 3.8 mg/ml. 4, however, also reaches a maximum concentration of ca.
3.8 mg/ml after only 5 minutes, but it then proceeds to decline over the remainder of the
study. This particular type of profile is a product of the “spring and parachute effect” and
has been exhibited by a number of pharmaceutical cocrystals reported recently.13, 67, 68
This profile is significant because it shows that a greater concentration of API can be
achieved at a much faster rate depending upon the crystal form. A similar trend is also
exhibited by 4 under aqueous conditions; however, the maximum concentration of 4 was
less than that of pure lamotrigine. A slurry of 3, stirred for 5 minutes in acidic media,
achieved a concentration ca. 36% greater than pure lamotrigine. Interestingly, 5 which
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exhibits the highest concentration in aqueous solution, achieves the lowest concentration
in acidic media (1.3 mg/ml). Overall, the dissolution profiles revealed that, in pure water,
5 is the most soluble crystal form but under acidic conditions (pH = 1), 2 is the more
soluble crystal form.
A recently published article suggests that the solubility of the cocrystal is directly
proportional to the solubility of its components,69 more specifically, the solubility ratio
plotted against the solubility of the cocrystal former divided by the solubility of the API
should result in a linear relationship. A similar analysis of crystal forms 2-5 reported
herein, however, does not generate a linear plot. In fact, within this set of case studies, no
clear correlation exists with respect to the solubility of the salt/cocrystal former and the
solubility of the resulting crystal form. The aqueous solubility of nicotinamide is ca. 1
g/ml, the highest of all cocrystal formers studied (methylparaben = 1 g/400ml and
saccharin = 1 g/290ml), and it is also a hydrotrope that is frequently used for solubility
improvement,70 however, the crystal forms containing nicotinamide (3 and 4) are not the
most soluble in aqueous solutions. Instead 5 is the most soluble crystal form most likely
due to the acidic saccharin molecule altering the pH of the solution to favor the
dissolution of lamotrigine. The low correlations may be due to the small dataset or the
inclusion of both protonated and unprotonated species in the dataset.
Correlations between solubility and crystal packing were also investigated. 5,
which breaks motif 1, achieved a greater concentration in water than under acidic
conditions (pH = 1). 2 and 4 which break motif 2, show markedly improved
concentrations in the acidic solution (pH = 1) but exhibited much lower concentrations in
water. Based on this dataset it can be concluded that, for this particular case study,
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lamotrigine cocrystals that break motif 2 are more soluble than pure lamotrigine under
acidic conditions (pH = 1) while lamotrigine salts that break motif 1 are more soluble
than pure lamotrigine in aqueous solutions. However, the enhanced aqueous solubility of
5 may be attributed to the inherent acidity of saccharin.

3.4. Animal Pharmacokinetic (PK) Study
A single dose rat pharmacokinetic study was conducted by Vasyl Sava and Shijie
Song at the James A. Haley VA hospital in Tampa. The serum concentration of
lamotrigine that resulted from single-dose oral gavage of 3, 4, 5, and pure lamotrigine
was measured in Sprague-Dawley rats over a 24-hour time period (Figure 3.24). 2 was
not studied due to its instability after three months of aging at 40 ºC in variable humidity.
An examination of the serum concentrations after dosing with 3, 4, and 5 shows that the
PK profile can be substantially altered via cocrystal or salt formation. Two hours after
dosing the average serum concentration of 5 was 3.5 μg/ml which is ca. 1.5 times the
level shown for pure lamotrigine (2.3 μg/ml). 3 and 4 showed a decrease in the serum
concentration by ca. 40% and 68%, respectively, compared to the pure lamotrigine. The
area under the curve (AUC0-24hr) for 3, 4, 5 and pure lamotrigine was calculated to be 37,
26, 66, and 60 μg/ml, respectively. A comparison of the average serum concentrations
reveals that 5 is clearly the desired crystal form for further pharmaceutical development
as 5 exhibits the highest initial serum concentration and achieves the greatest AUC0-24hr.
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Figure 3.24. Rat serum concentrations of lamotrigine, 3, 4 and 5

An analysis of the serum concentrations for 3, 4, and 5 in the rat in terms of
crystal packing concluded that 5, which broke motif 1, experienced an initial boost in
serum concentration of lamotrigine. Meanwhile, serum levels for cocrystals 3 and 4,
which retained the aminopyridine dimer and broke motif 2, were an average of ca. 54%
less than that of pure lamotrigine, thus suggesting that crystal forms that break motif 1
could exhibit higher serum concentrations than forms that break motif 2. Interestingly,
the greatest improvements in the PK study and the dissolution study occur when the
aminopyridine dimer is broken. This case study also illustrates that pharmaceutical
cocrystals and salts can have a significant impact upon drug development as they can
greatly alter the PK profile of the parent drugs.
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3.5 Conclusions
In summary, the work presented herein exemplifies how salt or cocrystal formers
can generate novel crystalline forms of preexisting APIs with different physicochemical
properties. Lamotrigine was targeted for crystal form development with the goal of
improving its solubility and clinical performance. Ten crystal forms of lamotrigine were
developed via the supramolecular synthon approach. The new crystal forms differed from
pure lamotrigine in that either supramolecular synthon motif 1 (the aminopyridine dimer)
or motif 2 (the amine-aromatic nitrogen hydrogen bond) were broken. Motif 2 was
broken in 5 out of 10 structures (50%) while only 4 out of 10 structures (40%) broke
motif 1. Interestingly, the majority of the crystal forms that did not contain motif 1, with
the exception of 1, were all lamotrigine salts.
Several crystal forms were tested to determine solubility, dissolution rate and rat
PK profiles. Out of ten crystal forms, four (2, 3, 4 and 5) were selected for dissolution
studies and three (3, 4 and 5) were selected for PK studies. The solubility/dissolution
study was conducted under aqueous conditions and under acidified (pH = 1) aqueous
conditions. The dissolution profiles for 2 and 4 achieved concentration levels similar to
lamotrigine in aqueous media while 3 maintained a concentration equivalent to the
maximum solubility of lamotrigine. The average concentrations achieved from 2, 3, 4
and 5 during dissolution measurements from the acidic media surpassed the levels of pure
lamotrigine by ca. 48%, 19%, 18%, and 58% respectively. In the rat PK study, the serum
concentrations for 3 and 4 were less than pure lamotrigine by 37% and 26%, respectively.
5, however, exhibited an initial increase in the serum concentration of ca. 66%. After
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approximately 3 hours the serum concentration of 5 reduced to a level similar to that of
pure lamotrigine.
The influence of a particular cocrystal former upon solubility and rat PK was
examined. The analysis compared the solubility of the cocrystal former and the solubility
and serum concentration of the subsequent crystal form. For this dataset, the most
soluble cocrystal former did not lead to the most soluble crystal form. In addition, a
comparison of the rat PK data to the solubility of the crystal form revealed that the crystal
forms that achieved the greatest aqueous solubility also reached the highest
concentrations in the rat PK data. The solubility of the crystal form in the acidic solution
did not correspond to the PK data.
The influence of supramolecular synthon motif upon solubility and PK was also
examined. Of the crystal forms where the solubility and rat PK was measured (3, 4, 5)
the only crystal form that broke the aminopyridine dimer (5) also achieved the highest
concentration in aqueous solution and rat serum, suggesting that breaking the lamotrigine
aminopyridine dimer can lead to crystal forms with desirable physicochemical properties.
Therefore when considering both aqueous dissolution and animal PK data of the crystal
forms presented herein collectively, 5 exhibited the targeted physicochemical properties
with substantial improvements, and would be an appropriate candidate for further
development.
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3.6 Materials and Methods
3.6.1 Materials
Lamotrigine was supplied by Jai Radhe Sales, India with a purity of 99.79% and
was used without further purification. All other chemicals were supplied by SigmaAldrich and used without further purification.

3.6.2 Synthesis of Compounds 1-10
Lamotrigine was reacted with six compounds shown in Figure 3.1, namely
methylparaben, nicotinamide, saccharin, adipic acid, L-malic acid, and nicotinic acid,
resulting in the formation of ten crystalline cocrystals, salts, or solvates of lamotrigine.
Synthesis of lamotrigine methylparaben cocrystal form I (1:1), 1. 0.0117 g
(0.046 mmol) lamotrigine and 0.0750 g (0.490 mmol) methylparaben were dissolved in
ca. 2 ml tetrahydrofuran (THF) and left to evaporate at room temperature. Colorless
crystals were afforded within seven days. 1 crystallized concomitantly with
methylparaben and lamotrigine THF solvate. Single crystals of 1 were isolated from this
mixture.
Synthesis of lamotrigine methylparaben cocrystal form II (1:1), 2. This
cocrystal was made via multiple methods: (i) solvent-drop grinding – 0.0722 g (0.282
mmol) lamotrigine was ground with 0.0458 g (0.301 mmol) methylparaben with 40 μl of
THF for 30 minutes in a mechanical ball-mill with ca. 100% conversion; (ii) slurry –
0.0486 g (0.190 mmol) lamotrigine and 0.0294 g (0.193 mmol) methylparaben were
slurried with ca. 3 ml water at room temperature for 24 hours. 2 was isolated via
filtration in 70% yield; (iii) melt – 0.0751 g (0.293 mmol) lamotrigine and 0.0485 g
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(0.319 mmol) methylparaben were placed in an oven at 115 ºC for 2 hours. 2 was
obtained via slow cooling to room temperature in 97% yield. Single crystals of X-ray
diffraction quality were obtained from slow cooling of the melt.
Synthesis of lamotrigine nicotinamide cocrystal (1:1), 3. This cocrystal was
prepared via multiple methods: (i) solvent-drop grinding – 0.2081 g (0.813 mmol)
lamotrigine and 0.2056 g (1.68 mmol) nicotinamide were ground with 40 μl of methanol
for 30 minutes in a mechanical ball-mill with ca. 100% conversion; (ii) melt – 0.7105 g
(2.77 mmol) lamotrigine and 0.3496 g (2.86 mmol) nicotinamide were heated at 125 ºC
for 2.5 hours resulting in 98% yield; (iii) lamotrigine nicotinamide cocrystal hydrate, 4
can be dehydrated to isolate 3 after heating at 160 ºC for 6 hours.
Synthesis of lamotrigine nicotinamide cocrystal monohydrate (1:1:1), 4. This
cocrystal was made from two methods: (i) slurry – 0.0641 g (0.250 mmol) lamotrigine
and 0.0614 g (0.503 mmol) nicotinamide (1:2 molar ratio) were slurried with ca. 1 ml
ethyl acetate for 24 hours. The resulting solid was isolated and filtered for further use
with 92% yield; (ii) solution – 0.1021 g (0.399 mmol) lamotrigine and 0.0515 g (0.422
mmol) nicotinamide dissolved in 600 μl of n-butanol and left to slowly evaporate at room
temperature. Colorless crystals of 4 were formed within two weeks in 95% yield. The
crystals were dehydrated in an oven at 160 ºC for 6 hours to form anhydrous cocrystal 3.
Synthesis of lamotrigine saccharinate salt (1:1), 5. This salt was made via
multiple methods: (i) slurry – 50.20 g (196 mmol) lamotrigine and 35.50 g (194 mmol)
saccharin were slurried in 500 mL water overnight under ambient conditions. The solid
was isolated via filtration in 83% yield. (ii) solution – 0.0102 g (0.040 mmol)
lamotrigine and 0.0103 g (0.056 mmol) saccharin were dissolved in ca. 2 ml methanol
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and slowly evaporated at room temperature. Colorless crystals of 5 were afforded within
seven days in 94% yield.
Synthesis of lamotrigine adipate salt (2:1), 6. 0.0158 g (0.062 mmol)
lamotrigine and 0.0108 g (0.074 mmol) of adipic acid were dissolved in ca. 2 ml
methanol and left to slowly evaporate at room temperature. Colorless crystals of 6
appeared within seven days in 91% yield.
Synthesis of lamotrigine malate salt (1:1), 7. 0.0199 g (0.078 mmol)
lamotrigine and 0.0120 g (0.089 mmol) L-malic acid were dissolved in ca. 2 ml methanol
and left to slowly evaporate at room temperature. Colorless crystals of 7 appeared within
seven days in 92% yield.
Synthesis of lamotrigine nicotinate dimethanol solvate (1:1:2), 8. A solution of
ca. 2 ml methanol, 0.0148 g (0.058 mmol) lamotrigine and 0.0075 g (0.061 mmol)
nicotinic acid was left at room temperature to slowly evaporate. Colorless crystals of 8
formed after two days in 78% yield.
Synthesis of lamotrigine dimethanol solvate (1:2), 9. 0.0213 g (0.083 mmol)
lamotrigine and 0.0148 g (0.082 mmol) butylated hydroxyanisole were dissolved in ca. 2
ml methanol and left to slowly evaporate at room temperature. Colorless crystals of 9
were afforded within five days in 93% yield.
Synthesis of lamotrigine ethanol monohydrate (1:1:1), 10. 0.0819 g (0.320
mmol) lamotrigine and 0.0415 g (0.340 mmol) nicotinamide were dissolved in ca. 3 ml of
a 1:1 ethanol:water solution mixture while heating followed by rapid cooling. The
sample was left at room temperature and allowed to slowly evaporate. Colorless crystals
of 10 were afforded within two weeks in 74% yield.
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3.6.3 Crystal Form Characterization
Single-Crystal X-ray Diffraction: Single crystals were obtained for nine
compounds. Attempts to crystallize 3 did not afford crystals suitable for single crystal Xray crystallographic analysis. Single crystal analysis for 1, 2, and 5-10 was performed on
a Bruker-AXS SMART APEX CCD diffractometer with monochromatized Mo Kα
radiation (λ = 0.71073 Å) connected to a KRYO-FLEX low-temperature device while 4
was collected using Cu Kα radiation (λ = 1.54178 Å). Data for 1, 2, and 5-10 were
collected at 100 K. Data for 4 was collected at 296 K. Lattice parameters were
determined from least-squares analysis, and reflection data were integrated using
SAINT.71 Structures were solved by direct methods and refined by full matrix least
squares based on F2 using the SHELXTL package.72 All non-hydrogen atoms were
refined with anisotropic displacement parameters. All hydrogen atoms bonded to carbon,
nitrogen, and oxygen atoms were placed geometrically and refined with an isotropic
displacement parameter fixed at 1.2 times Uq of the atoms to which they were attached.
Hydrogen atoms bonded to methyl groups were placed geometrically and refined with an
isotropic displacement parameter fixed at 1.5 times Uq of the carbon atoms.
Powder X-Ray Diffraction (PXRD): 2-8 were characterized by a D-8 Bruker Xray Powder Diffractometer using a Cu Kα radiation (λ = 1.54178 Å), 40kV, 40mA. Data
was collected over an angular range of 3° to 40° 2θ value in continuous scan mode using
a step size of 0.05° 2θ value and a scan speed of 1.0 º/min. Crystal form 1 could not be
made in sufficient quantities to collect an experimental PXRD.
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Calculated PXRD: Calculated PXRD diffractograms were generated from the
single crystal structures using Mercury 1.5 (Cambridge Crystallographic Data Centre,
UK) for the following complexes: 1-2, 4-10.
Differential Scanning Calorimetry (DSC): Differential Scanning Calorimetry
was performed on a Perkin Elmer Diamond DSC with a typical scan range of 25 ºC – 280
ºC, scan rate of 10 ºC/min, and nitrogen purge of ca. 30 psi.
Fourier Transform Infrared Spectroscopy (FT-IR): FT-IR analysis was
performed on a Perkin Elmer Spectrum 100 FT-IR spectrometer equipped with a solidstate ATR accessory.
Ultraviolet-Visible Spectroscopy (UV/Vis): UV/Vis analysis was performed on
a Perkin Elmer Lambda 25 UV/Vis spectrophotometer.
High Performance Liquid Chromatography (HPLC): Analysis was performed
on an HPLC system (Perkin Elmer Instruments LLC) comprising the following units: a
series 200 Gradient Pump; a 785A UV/VIS Detector; a series 200 Autosampler; an NCI
900 Network Chromatography Interface and a 600 Series Link. The system was operated
by a Total Chrome Workstation. The sample holder temperature was kept at 4 ºC with a
flow rate of 1 mL/min. The column was a Microsorb-MV 300-5 C-18 (250 x 4.6 mm x
1/4”). The mobile phase consisted of a mixture of phosphate buffer (pH 3.0) with
methanol (1/1, v/v). The phosphate buffer was prepared from 50 mmol/L Na2HPO3 water
solution with pH-controlled HCl titration.
Thermal Gravimetric Analysis (TGA): TGA analysis was performed on a
Perkin Elmer STA 6000 with a typical scan range of 30 ºC – 300 ºC, scan rate of 10
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ºC/min, and nitrogen purge of ca. 20 psi. The resulting thermograms were processed
using Pyris version 9.

3.6.4 Solubility and Dissolution Study
Dissolution studies were performed on 2, 3, 4, and 5 allowing for representative
crystal forms from different crystal form categories (i.e. salt, cocrystal and solvate) to be
compared against the original API. Both deionized water (25 ºC) and pH 1 aqueous
solution (0.1 M HCl, 37 ºC) were used. The crystal forms were sieved to achieve a
particle size between 53 and 75 μm. The dissolution study was conducted using an
excess of free flowing solid in ca. 100 ml solvent that was stirred with a magnetic stir bar
at a rate of ca. 200-300 rpm. Aliquots were filtered with 0.45 μm filters after 5, 10, 20,
30, 40, 50, 60, 75, 90, 105, 120, 150, 180, and 240 minutes. The resulting solution was
processed and the concentration of lamotrigine was measured using a UV-Vis
spectrophotometer. The experiment was repeated twice to allow for statistical analysis.

3.6.5 Animal Pharmacokinetic (PK) Study
Twenty-four hour animal PK studies were conducted using a single-dose oral
administration of lamotrigine as well as 3, 4, and 5. 5 male Sprague-Dawley rats (225250 g) with pre-implanted indwelling jugular vein catheters were used for each crystal
form. The animals were allowed water ad libitum and fasted overnight before drug
administration. The crystal forms were administered via oral gavage with a dosage of 10
mg/kg lamotrigine or its equivalent, in the suspension vehicle of a 5% PEG and 95%
methyl cellulose aqueous solution. After dosing, 0.2 ml of blood was withdrawn at 0, 30,
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60, 120, 180, 240, 480, 720, and 1440 minutes. The blood samples were processed and
analyzed by HPLC according to the literature.73

Table 3.4. Hydrogen bond distances and parameters
Compound

1

2

4

5

Hydrogen Bond

d(H...A)/ Å

d(D...A)/ Å

θ/ º

NHO

1.97

2.823(4)

162.7

OHN

1.83

2.651(4)

164.7

OHN

2.72

3.545(4)

167.1

NHO

2.20

3.036(4)

157.4

NHO

2.13

2.931(4)

151.3

NHO

2.49

3.116(4)

129.1

NHN

2.25

3.121(4)

172.3

OHN

1.88

2.711(4)

173.3

NHO

2.06

2.915(3)

176.7

NHN

2.43

3.192(3)

148.3

NHO

2.09

2.930(2)

165.3

NHN

2.35

3.164(3)

157.5

NHO

2.28

2.944(2)

133.7

NHN

2.24

3.039(2)

154.1

OHN

1.97

2.822(2)

171.7

OHN

2.16

3.039(3)

166.4

NHO

2.05

2.818(2)

144.7

NHO

1.95

2.830(2)

173.5

NHN

1.94

2.819(2)

177.5

NHO

2.19

2.889(2)

135.5
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6

7

8

9

NHO

1.93

2.760(2)

156.5

NHO

2.06

2.861(2)

151.5

NHO

2.11

2.942(2)

157.4

NHO

1.79

2.6270(19)

158.0

NHN

2.08

2.956(6)

174.6

NHO

2.22

2.792(5)

122.2

NHO

2.09

2.790(5)

136.3

NHO

1.91

2.786(6)

174.5

NHO

1.86

2.707(5)

161.9

NHN

2.21

3.082(6)

168.6

NHO

2.11

2.968(5)

164.1

NHO

2.14

2.928(5)

149.5

NHO

1.88

2.754(5)

175.0

NHO

1.77

2.632(5)

167.8

OHO

2.09

2.744(5)

134.6

NHO

1.88

2.729(3)

161.7

NHO

1.88

2.755(3)

171.9

NHO

2.01

2.816(3)

151.3

NHO

2.06

2.872(3)

152.8

NHO

1.92

2.764(3)

159.4

OHO

1.97

2.777(2)

159.6

OHN

1.86

2.699(3)

172.7

NHO

2.21

2.824(2)

126.7

NHN

2.19

3.059(2)

170.0

NHO

2.11

2.8621(18)

143.1

NHO

2.24

2.930(2)

135.7

167

10

OHN

1.82

2.654(2)

169.9

OHN

2.16

2.9874(19)

168.6

NHO

2.35

3.0422(18)

136.2

NHO

1.97

2.8481(18)

173.2

NHO

2.29

2.9276(18)

128.8

NHN

2.19

3.0055(19)

153.7

OHN

2.10

2.9014(18)

158.5

OHO

1.94

2.8288(17)

178.8

OHN

1.95

2.7919(18)

168.2

NHO

2.52

3.1870(18)

133.2
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Chapter 4 - Meloxicam crystal forms: Synthesis, Characterization, and Evaluation

4.1. Preamble
The ability to alter the physicochemical properties of an active pharmaceutical
ingredient (API) by changing the crystal form has had a major impact upon the
pharmaceutical industry 1-3 and has lead to the development of a crystal form screening
process that is now a routine technology implemented to discover crystal forms
including, but not limited to, salts,4 hydrates,5 solvates,6 and cocrystals7 with desired
properties.8, 9 In this chapter a crystal engineering10-12 based crystal form screening
process will be exploited to generate novel crystal forms of meloxicam with a particular
focus upon generating pharmaceutical cocrystals13 with desired physicochemical
properties.
Meloxicam or (4-hydroxy-2-methyl-N(5-methyl-1,3-thiazol-2yl)-2H-1,2benzothiazin-3-carboxamide,1,1-dioxide) is a non-steroidal anti-inflammatory (NSAID)
and antipyretic drug used for indications of rheumatoid and osteoarthritis,14 postoperative
pain15, 16 and fever.17 Originally developed by Boehringer Ingleheim, meloxicam is
marketed in Europe under the brand names Melox or Recoxa. Meloxicam is available as
a tablet (7.5 or 15 mg dose) and as an oral suspension (7.5mg/5ml dose).18 The pure
active pharmaceutical ingredient (API) is a yellow solid that is practically insoluble in
water, but a greater solubility can be achieved under more basic conditions. Meloxicam
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is also very slightly soluble in various organic solvents.19 The variability in solubility
related to change in pH is due to the different crystal forms of meloxicam. Under acidic
conditions meloxicam is present in solution in its cationic form and in basic solutions
meloxicam is present in its anionic form. Under more neutral pH conditions meloxicam
will either be in its zwitterionic or enolic form, depending on the polarity of the
solvent.20, 21 The different crystal forms are shown in Figure 4.1.
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Figure 4.1 Anionic, Cationic, and Zwitterionic forms of Meloxicam

Meloxicam is effective at relieving various types of pain and patients experience
fewer side effects with meloxicam than with other NSAIDS,22, 23 however, the drug can
take more than two hours to reach a therapeutic concentration in humans.24 This may be
caused by the inherently low solubility of meloxicam under acidic conditions such as
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inside the stomach. Meloxicam dissolves and is absorbed once in the more basic
conditions of the small intestines, achieving a bioavailability of 89% with substantial
protein binding.25 For meloxicam, the poor solubility of the API has been determined to
be the rate limiting step in the absorption, distribution, metabolism, and excretion
(ADME) process.26 Enhancement of meloxicam’s low aqueous solubility has been the
subject of many publications resulting in various solvates,27 ethanolamine salts,28
cyclodextrin inclusion complexs,26 or metal complexes with potassium and calcium.29
Other crystal forms include ammonium salts and sulfate salts.20 Preparation of different
polymorphic crystal forms of meloxicam21 and improvements to the dissolution profile30,
31

are also discussed in recent patent literature. Due to the low solubility of meloxicam

impairing the absorption, the goal is to improve the solubility of meloxicam via
pharmaceutical cocrystallization to potentially reduce the time needed for absorption.
With a faster absorption rate the patient will reach therapeutic levels in the bloodstream
and achieve efficacy in less than two hours.

4.2. Results and Discussion
4.2.1. Reliability of Cocrystal or Salt Formation
A literature search for crystal forms of meloxicam provided numerous examples
including pharmaceutical salts such as those generated via complexation with mono-, di-,
and triethanolamine.28, 32 Due to the plethora of preexisting salt forms in the scientific
literature that do not show earlier efficacy, the purpose of this study was to generate
pharmaceutical cocrystals of meloxicam as studies have shown that they can increase the
plasma concentration at early time points.33-40 The pKa values for meloxicam are 1.09
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and 4.18.32 The 1.09 is associated with the enolic OH group while the 4.18 is linked to
the nitrogen on the sulfathiazole ring. The enolic OH is much less accessible from a
crystal engineering perspective as it is involved in intramolecular hydrogen bonding to
the neighboring ketone or NH moieties. Therefore a set of molecules containing
carboxylic acid moieties were chosen as cocrystal formers for their ability to potentially
interact with the sulfathiazole ring.
It is generally accepted as a rule that the difference in the pKa of the base minus the pKa
of the acid must be less than zero if the desired outcome is a neutral complex (i.e.
cocrystal).41, 42 To generate a salt one would select two molecules with a difference in
pKa of three or more units.43, 44 For the region in between (ΔpKa 0-3) the ability to
predetermine whether the resulting complex will be neutral or charged is difficult.45 Due
to the relatively acidic nature of the sulfathiazole moiety, there remains a fairly large
library of molecules that possess a carboxylic acid moiety that are also generally regarded
as safe (GRAS) that can be employed to form pharmaceutical cocrystals of meloxicam.
The carboxylic acids that were chosen for this study include: 1-hydroxy-2-naphthoic acid
(HNA), glutaric acid, L-malic acid, aspirin, and salicylic acid. The acids are represented
by line drawings in Figure 4.2. The pKa’s of the carboxylic acids that were chosen and
the difference in pKa between meloxicam and the former are shown in Table 4.1.46-50
Based upon the rules described above all of the crystal forms reside in the ambiguous
region thus a detailed analysis of the resulting crystal form will be required to determine
salt or cocrystal formation.

178

Table 4.1. pKa values and ΔpKa values for meloxicam and a set of carboxylic acids

Acid
Meloxicam

0

4.18
3.02

1.16

4.13

0.05

L-Malic acid

3.46

0.72

Asprin

3.50

0.68

Salicylic acid

2.90

1.28

HNA
Glutaric acid

O

∆pKa

pKa
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O

OH

HO
HO

O
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L-Malic acid

O

Aspirin

Salicylic acid

Figure 4.2. Line drawings of the carboxylic acids used to form
pharmaceutical cocrystals with meloxicam
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4.2.2. Cambridge Structural Database (CSD) Analysis
A key step in developing pharmaceutical cocrystals is to analyze the target active
pharmaceutical ingredient (API) from a crystal engineering10 perspective, i.e. to analyze
the molecule from a supramolecular synthon approach. This methodology partitions the
target molecule into its simplest functionalities and statistically examines the percentage
of occurrence of supramolecular homo- and heterosynthons. The targeted
supramolecular synthons are typically sustained via hydrogen bonds as they are strong
and directional in nature.
The supramolecular synthon approach can be applied for the synthesis of novel
pharmaceutical cocrystals of meloxicam. The strategy involves an understanding of the
supramolecular chemistry of meloxicam including the feasibility of supramolecular
synthon formation therefore requiring an analysis of the supramolecular synthons present
in pure meloxicam. Form I of meloxicam, found in the Cambridge Structural Database
(CSD)51 (Refcode: SEDZOQ) indicates that meloxicam forms chains that are sustained
by sulfonyl-amide dimers and sulfathiazole-alcohol supramolecular synthons, shown in
Figure 4.3. The chains are held together by various weak interactions, stacking along the
a-axis in a slipped fashion.
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Figure 4.3. Meloxicam chains sustained by sulfonyl-amide dimers
and sulfathiazole-alcohol supramolecular synthons

Thus for cocrystallization, one or all of these supramolecular synthon motifs must
be interrupted. A target moiety for meloxicam is the aromatic nitrogen of the
sulfathiazole and the NH of the neighboring amide. When in the proper conformation,
these moieties have the ability to provide an ideal two-point recognition site for an
additional molecule that contains a donor and an adjacent acceptor such as a carboxylic
acid or amide moiety.
A CSD analysis52 was conducted that examined the percentage of supramolecular
synthon formation of the amino-azole functionality (5-membered ring containing a
nitrogen and primary amine) with carboxylic acid, primary amide, and alcohol moieties.
Specifically the analysis examined the likelihood of supramolecular homosynthon versus
supramolecular heterosynthon formation. A search of the CSD for entries containing the
amino-azole moiety revealed 505 hits. Interestingly 214/505 or 42% exhibited the 2-pt
recognition amino-azole supramolecular homosynthon dimer. Examining the CSD for
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entries containing both amino-azole and carboxylic acid moieties afforded 7 entries. The
amino-azole supramolecular homosynthon was seen in only 1 out of the 7 entries (14%).
The carboxylic acid dimer or catemer supramolecular homosynthon was not present in
any of the 7 entries. The supramolecular heterosynthon, however, was exhibited in 4/7 or
57% of the time. Thus the amino-azole – carboxylic acid supramolecular heterosynthon
is more likely to occur than the supramolecular homosynthon. Due to the potential for
meloxicam to generate salts or neutral complexes the potential for the amino-azole to
generate a supramolecular heterosynthon with a carboxylate was also examined. A
search for crystal structures that contain both moieties resulted in 24 hits. The aminoazole supramolecular homosynthon appeared in only 1 entry (4%) where a carboxylate
was also present. The carboxylate – amino-azole 2-pt recognition supramolecular
heterosynthon dimer was much more prominent, appearing in 13/24 or 54% of the
entries. Thus the supramolecular heterosynthon is more likely to occur than the
supramolecular homosynthon for an amino-azole in the presence of a carboxylate. The
occurrence of supramolecular homosynthon versus heterosynthon was also questioned in
the presence of a primary amide moiety. However, only 1 entry was revealed in the CSD
that contained both functionalities and neither supramolecular synthon was present
precluding a conclusion of the reliability of supramolecular synthon formation. A search
of the CSD for entries containing an amino-azole and alcohol was also conducted. The
two moieties were present in 38 entries with the amino-azole supramolecular
homosynthon being the dominant interaction. The alcohol supramolecular synthon
occurs in 5 out of 38 entries or 13% of the time. The supramolecular heterosynthon
occurs in 6/38 entries (16%) while the amino-azole supramolecular homosynthon occurs
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in 13/38 entries (43%). Clearly with the supramolecular homosynthon occurrence greater
than the supramolecular heterosynthon, the potential for cocrystal formation is low by
employing a cocrystal former that contains an alcohol functional group. A summary of
the results from the amino-azole moiety supramolecular homosynthon and heterosynthon
formation is presented in Table 4.2.
A closer look at the data gathered from the CSD reveals that many of the searches
for the amino-azole moiety coupled with an additional functional group consisted of a
relatively small number of entries. Furthermore, the conclusions from the data could be
considered not statistically significant due to the lack of information. Therefore further
CSD analysis was conducted employing a simple azole (5-membered ring containing a
nitrogen). The reliability of supramolecular heterosynthon versus homosynthon
formation between an azole and a carboxylic acid, primary amide, and alcohol were
examined in the CSD. Due to the inability of the azole to form a supramolecular synthon
with itself; only the homosynthon formation of the carboxylic acid, primary amide, and
alcohol moieties in the presence of an azole was examined. A search of the CSD for
entries that contained an azole and a carboxylic acid moiety resulted in 269 hits. A closer
look at the 269 entries revealed that the carboxylic acid dimer or catemer occurred in 41
entries, or 15% of the time. However, when the 269 entries were investigated for the
presence of the azole-carboxylic acid supramolecular heterosynthon 120 entries were
identified, suggesting that the heterosynthon will occur 45% of the time. Thus when an
azole and carboxylic acid are present in the same crystal structure the supramolecular
heterosynthon is statistically more likely to occur. When complexing a carboxylic acid to
a basic moiety were the ΔpKa is large, the acid will protonate the basic moiety, resulting
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in a carboxylate. Due to the possibility of protonation with meloxicam, carboxylate-azole
interactions were also searched in the CSD. 56 entries contained both moieties. 20
(36%) contained the carboxylate-azole supramolecular heterosynthon in the crystal
structure, suggesting that it is a viable target supramolecular heterosynthon. A search of
the CSD for the azole and primary amide moiety in the same crystal structure revealed
115 entries. 66 (58%) of those entries were found to contain the amide dimer or catemer
while only 37 (32%) were sustained via the amide-azole supramolecular heterosynthon.
These statistics elucidate the strength of the amide supramolecular homosynthon in the
presence of the azole functional group and further indicate that a cocrystal of meloxicam
with a molecule containing a primary amide moiety is unlikely to occur. The complexing
of alcohols and azoles was also studied in the CSD. There were 977 entries that
contained both moieties. 21% (202) possess the alcohol homosynthon but 40% (386)
were sustained by the supramolecular heterosynthon formation. Statistically this suggests
that the supramolecular heterosynthon is almost twice as likely to form as the
homosynthon. Collectively comparing the occurrence of the supramolecular
homosynthon to the heterosynthon, the heterosynthon formation dominates in all cases
except when in the presence of a primary amide. Carboxylic acid and alcohol
functionalities proved to be quite reliable for generating supramolecular heterosynthons
and can be complexed with an azole moiety ca. 40% of the time. The results of these
searches are depicted in Table 4.3.
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Table 4.2. Percent occurrence for supramolecular homosynthons and heterosynthons with aminoazoles in the presence of carboxylic acids, carboxylates, primary amides, and alcohols

Complemen
tary
Moiety

No. of
entries w/
both
groups

%
Homosynthon
occurrence:
amino-azole

%
Homosynthon
occurrence:
Cocrystal
former

%
Heterosynthon
occurrence

Heterosynthon
Distance Range
(Å)

Carboxylic
acid

7

1/7 (14%)

0

4/7 (57%)

2.60-2.80

Carboxylate
Primary
amide

24

1/24 (4%)

N/A

13/24 (54%)

2.60-2.80

1

0

0

0

N/A

Alcohol

38

13/38 (43%)

5/38 (13%)

6/38 (16%)

2.60-3.00

Table 4.3. Percent occurrence for supramolecular homosynthons and heterosynthons with azoles
in the presence of carboxylic acids, carboxylates, primary amides, and alcohols

Complementary
Moiety

No. of
entries w/
both groups

% Homosynthon
occurrence:
Cocrystal former

%
Heterosynthon
occurrence

Heterosynthon
Distance Range
(Å)

Carboxylic acid

269

41/269 (15%)

120/269 (45%)

2.50-2.90

Carboxylate

56

N/A

20/56 (36%)

2.60-2.90

Primary amide

115

66/115 (58%)

37/115 (32%)

2.60-3.30

Alcohol

977

202/977(21%)

386/977 (40%)

2.60-3.00

Based on the success rate of supramolecular heterosynthon formation with azoles
and carboxylic acids, a meloxicam cocrystal screen with cocrystal formers containing
carboxylic acid moieties was conducted. Meloxicam was reacted with 1-hydroxy-2naphthoic acid, glutaric acid, L-malic acid, aspirin, and salicylic acid. The
cocrystallization attempts resulted in seven crystal forms, namely meloxicam 1-hydroxy2-naphthoic acid cocrystal, meloxicam glutaric acid cocrystal, meloxicam L-malic acid
cocrystal of a salt, meloxicam aspirin cocrystal, meloxicam salicylic acid cocrystal form
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I, II, and III. All crystal forms were analyzed in terms of supramolecular synthons as
well as physical and pharmacokinetic properties and are presented herein.

4.2.3. Crystal Structure Descriptions
The meloxicam 1-hydroxy-2-naphthoic acid cocrystal, 1 crystallizes in the
space group Pī. The asymmetric unit contains one meloxicam and one 1-hydroxy-2naphthoic acid molecule. The basic supramolecular unit is comprised of two meloxicam
molecules and two 1-hydroxy-2-naphthoic acid molecules with the inversion center
located in the center of the meloxicam dimer (shown in Figure 4.4.). The meloxicam
dimer is a common motif found in many meloxicam cocrystals and is sustained by two
planar meloxicam molecules interacting via electrostatic interactions between the alcohol,
ketone and sulfathiazole moieties. In 1 meloxicam sustains intramolecular alcoholketone interactions and binds to the neighboring meloxicam via an SOH interaction at
a distance of 3.148(6) Å to form the meloxicam dimer. The exterior of the meloxicam
dimer hydrogen bonds to two 1-hydroxy-2-naphthoic acid molecules via two 2-point
recognition carboxylic acid-thiazole/NH interactions [O2-H2N1: ON 2.596(6) Å,
HN 1.763 Å, O-HN 170.90 º, N2-H2O2: NO 2.935(6) Å, HO 2.086 Å, NHO 161.66 º]. This two point recognition supramolecular synthon motif is quite robust
as it is found in all cocrystal forms reported herein. The hydroxyl group of the 1hydroxy-2-naphthoic acid ortho to the carboxylic acid moiety is involved in
intramolecular hydrogen bonding which is expected based upon Etter’s rules.53 The
overall packing, illustrated in Figure 4.5 is sustained by supramolecular units of
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meloxicam and 1-hydroxy-2-naphthoic acid molecules that stack upon each other along
the a-axis in a slipped fashion with an interplanar spacing of 3.735 Å.

Figure 4.4. Supramolecular unit of 1

Figure 4.5. Crystal packing of four supramolecular units of 1

Crystal form 2 is the meloxicam glutaric acid cocrystal. The asymmetric unit of
2 is comprised of one meloxicam and one glutaric acid molecule and crystallizes in the
space group Pī. The meloxicam centrosymmetric dimer is also present in 2 and is
sustained by an SOH interaction between two planar meloxicam molecules with a
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distance of 3.224(2) Å. Meloxicam also participates in OHO (ca. 2.62 Å)
intramolecular hydrogen bonding. Interestingly, glutaric acid utilizes one of its
carboxylic acid moieties to form a centrosymmetric carboxylic acid dimer [O4-H4O3:
OO 2.646(2) Å, HO 1.808 Å, O-HO 175.96º] with a neighboring glutaric acid.
The second free carboxylic acid moiety hydrogen bonds to the meloxicam molecule
resulting in the unexpected 1:1 stoichiometery. The carboxylic acid-azole
supramolecular heterosynthon dimer is sustained by hydrogen bond interactions that
afford the common 2-point recognition motif. The OHN and NHO interaction are
shown in Figure 4.6. [O2-H2N1: ON 2.675(2) Å, HN 1.837 Å, O-HN 174.24º;
N2-H2O1: NO 2.849(2) Å, HO 1.990 Å, 165.07º]. The culmination of
supramolecular homosynthon and heterosynthon dimers ultimately results in the
formation of a zig-zag chain that cuts through the ac-plane. The chains stack along the aaxis and are separated by a meloxicam plane to plane distance of 3.502 Å. Figure 4.7.
highlights the crystal packing of multiple chains with the meloxicam dimers and glutaric
acid dimers disposed in a columnar arrangement. The angle sustained between the C1C2-C3 of the glutaric acid molecule in 2 is atypical. The C1-C2-C3-C4 torsion angle in
both polymorphs of pure glutaric acid is ca.170º, however, in 2; the same angle is 52.89º.
A search of the CSD for additional glutaric acid cocrystals afforded multiple hits
however; examining the glutaric acid molecules for the similar smaller torsion angle
resulted in only two hits: caffeine glutaric acid cocrystal (REFCODE: EXUQUJ) and
theophylline glutaric acid cocrystal (REFCODE: XEJXIU). The conformations of the
glutaric acid molecules present torsion angles of 79.34º and 65.18º, respectively.
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Figure 4.6. Meloxicam glutaric acid cocrystal (2) supramolecular synthons
highlighting the meloxicam and glutaric acid dimers

Figure 4.7. Crystal packing of multiple chains of 2
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The asymmetric unit of the meloxicam L-malic acid cocrystal of a salt (3)
contains one meloxicam cation, one neutral meloxicam, and one L-malate anion. 3 is
therefore considered a cocrystal of a salt and crystallizes in the space group P1. Based
upon the ΔpKa it was not predicted that the L-malic acid would protonate meloxicam,
however, crystal forms do not always follow the ΔpKa general guidelines. In 3 the
meloxicam dimer persists but is unique as it is comprised of one cation and one neutral
meloxicam and is sustained by two SOH interactions (3.20(2) Å, 3.28(2) Å). Figure
4.8. illustrates the interactions between the anion, cation, and neutral molecule. 3 is
primarily sustained by the L-malate anion acting as a bridge to connect the meloxicam
dimers ultimately forming a chain. The L-malate bridge protonates the sulfathiazole ring
via the O-+HN interactions [O1-+H1-N1: O-+N 2.70(3) Å, HO 1.849 Å, O-+HN 168.90º ; O2-+H2-N2: O-+N 2.89(3) Å, HO 2.045 Å, O-+H-N 168.31º] and
hydrogen bonds to the sulfathiazole of the neutral meloxicam via OHN and NHO
interactions [O4-H4N4: ON 2.73(3) Å, HN 1.919 Å, O-HN 172.42 º ; O5H5N5: ON 2.90(3) Å, HO 2.078 Å, O-HN 160.08 º]. Thus the L-malate and
meloxicams generate a 2D structure comprised of chains that stack parallel along the aaxis with an interplanar spacing of 3.176 Å, shown in Figure 4.9. The supramolecular
chains exhibited by 3 are reminiscent of those seen in 2 which is unsurprising due to the
employment of a diacid as a cocrystal former in both cocrystallization experiments. The
supramolecular synthon analysis of 3 proves that the sulfathiazole ring and the NH of the
amide is an excellent synthon recognition point for both carboxylic acids and
carboxylates.
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Figure 4.8. Supramolecular synthons in 3 showing a neutral
and cationic meloxicam and an anionic L-malate

Figure 4.9. Stacked layers of the meloxicam L-malic acid cocrystal of a salt (3),
L-malate anions are shown in green.

The meloxicam aspirin cocrystal (4) crystallizes in the space group P21/c. The
asymmetric unit contains one meloxicam molecule and one aspirin molecule, shown in
Figure 4.10. The meloxicam dimer is again present in 4; however, the planar meloxicam
molecules are held into the dimer conformation at a distance of 3.632(2) Å apart by weak
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interactions. This distance is the furthest distance of all the cocrystals in this study that
contain the dimer. The primary interactions sustaining the cocrystal are the hydrogen
bonds present between the carboxylic acid moiety of the aspirin molecule and the
sulfathiazole/NH moiety of the meloxicam. The resulting supramolecular heterosynthon
is the 2-point recognition hydrogen bonded dimer which affords the basic
meloxicam:aspirin supramolecular unit shown in Figure 4.10. The OHN hydrogen
bond distance is 2.665(3) Å[O2-H2N1: ON 2.665(3) Å, HN 1.850 Å, O-HN
173.36º] and the NHO distance is 2.856(3) Å [N2-H2O1: NO 2.856(3) Å, HO
2.015 Å, N-HO 165.60 º]. Additional meloxicam:aspirin supramolecular units are
generated by translation along the 21 screw axis running parallel to the a-axis (Figure
4.11.). As the meloxicam:aspirin units extend along the a-axis they simulate a corrugated
sheet that propagates with a dihedral angle of 73.69 º. The corrugated sheets then stack
upon each other separated by a distance of ca. 3.87 Å producing a herringbone motif.

Figure 4.10. Meloxicam aspirin cocrystal (4) basic supramolecular unit
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Figure 4.11. Units of the meloxicam aspirin cocrystal (4) translating along a 21 screw axis

The supramolecular unit of the meloxicam salicylic acid cocrystal form III (5)
is comprised of one molecular meloxicam and one molecular salicylic acid, shown in
Figure 4.12. and crystallizes in the space group P21/c. The cocrystal is primarily
sustained by the salicylic acid hydrogen bonding to the meloxicam via the carboxylic
acid to sulfathiazole/NH supramolecular heterosynthon. The carboxylic acidsulfathiazole OHN hydrogen bond distance is 2.627(5) Å[O2-H2N1: ON 2.627(5)
Å, HN 1.836 Å, O-HN 161.74 º] and the NH-carboxylic acid NHO distance is
2.975(5) Å [N2-H2O1: NO 2.975(5) Å, HO 2.139 Å, N-HO 164.02º]. This
hydrogen bonding motif generates a discrete unit containing one meloxicam and one
salicylic acid molecule. The salicylic acid OH moiety is involved in intramolecular
hydrogen bonding with its carboxylic acid. The meloxicam dimer does not exist in 5 as
the meloxicam molecules in the neighboring supramolecular units are perpendicular
rather than parallel. The supramolecular units in 5 translate along the 21 screw axis at a
dihedral angle of 88.80º and are sustained by various weak interactions (Figure 4.13.). 5
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is the only cocrystal reported herein that does not exhibit the meloxicam dimer. The
absence of the dimer may contribute to its unique solubility and pharmacokinetic
properties. Single crystals of suitable quality for single crystal X-ray diffraction of the
meloxicam salicylic acid form I (7) or form II (6) could not be obtained.

Figure 4.12. Meloxicam salicylic acid cocrystal form III (5)
2-point recognition supramolecular synthon

Figure 4.13. Meloxicam salicylic acid units translating along a 21 screw axis
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Table 4.4. Crystal structure parameters for cocrystals 1-5

Form weight
Crystal
System
Space group
a (Å)

539.60
Triclinic

483.51
Triclinic

3
C14H14N3O4S2
C14H13N3O4S2
C4H5O5
836.88
Triclinic

Pī
6.978(2)

Pī
7.202(3)

P1
7.278(9)

P21/c
6.8015(7)

P21/c
11.1028(9)

b (Å)

12.135(2)

8.462(3)

8.550(2)

19.1397(2)

11.8549(9)

c (Å)

15.189(2)

18.428(7)

15.150(2)

18.752(2)

16.4728(2)

α( )
β (o)
γ (o)

113.07(3)
92.68(3)
95.85(2)

80.761(7)
85.486(7)
70.877(6)

84.11(2)
81.62(4)
70.489(15)

90
94.907(8)
90

90
97.255(6)
90

Vol (Å3)
Dcal (g cm-3)
Z
Reflections
collected
Independent
reflections
Observed
reflections
T (K)
R1

1172(3)
1.529
2
2414

1046.9(7)
1.534
2
6350

877.6(19)
1.583
1
3902

2432.1(4)
1.452
4
17777

2150.8(3)
1.509
4
15380

2414

4554

3151

4302

3662

1875

3752

1719

3163

2281

100
0.0471

100
0.0375

298
0.1124

293
0.0411

293
0.0556

wR2

0.1075

0.0973

0.2846

0.1015

0.1526

GOF

0.991

1.009

1.253

0.987

1.072

Chemical
formula

o

1
C14H13N3O4S2
C11H8O3

2
C14H13N3O4S2
C5H8O4

4
C14H13N3O4S2
C9H8O4

5
C14H13N3O4S2
C7H6O3

531.55
Monoclinic

489.50
Monoclinic

4.2.4. Melting Point Analysis
It has been shown that the melting point of the cocrystal can typically be found in
between the melt of the cocrystal former and the target active pharmaceutical
ingredient.54, 55 Recent literature has also attempted to predict melting points56 and
correlate melting points of materials to chemical structure of small simple molecules with
some success.57 However, predicting melting points of larger molecules such as
pharmaceuticals proves to be a nontrivial task.
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The melting points of the meloxicam crystal forms 1-7 were measured via
differential scanning calorimetry (DSC) and compared to the melting points of both
meloxicam and the respective cocrystal former. The melting points of the cocrystal
formers were obtained from materials safety datasheets.58-62 A summary of the results are
presented in Table 4.5. The melting points for all the cocrystals were found to follow the
trends found in the literature. The cocrystals melted above the melt of the cocrystal
former and below the melting point of meloxicam. The polymorphic salicylic acid
cocrystals resulted in similar melting points with little variation between crystal forms. A
graphical representation of the data is shown in Figure 4.12. where the melting point of
the cocrystal is plotted vs. the melting point of the cocrystal former. The R2 value was
calculated to be 0.7335 thus showing an overall good correlation between the melting
points of the two materials.

Table 4.5. Melting points for meloxicam, cocrystal formers, and there corresponding cocrystals
Melting point
of former
ºC
254

Melting point
of cocrystal
ºC
254

1-Hydroxy-2-naphthoic
acid
Glutaric acid

183

225

95

149

L-Malic acid

101

200

Aspirin

136

164

Salicylic acid form III

159

210

Salicylic acid form I

159

205

Salicylic acid form II

159

206

Crystal form
Meloxicam
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Melting point of cocrystal former vs. cocrystal
Meloxicam:Salicylic acid form I (6)

Melting point of cocrysta

265

2

R = 0.7335

245

Meloxicam:Salicylic acid form III (5)

225

Meloxicam:L-Malic acid (3)

205

Meloxicam:1-Hydroxy-2-naphthoic acid
(1)
Meloxicam:Aspirin (4)

185
165

Meloxicam:Glutaric acid (2)

145

Meloxicam

125
0

50

100

150

200

250

300

Meloxicam:Salicylic acid form II (7)

Melting point of cocrystal former

Figure 4.14. Plot for analysis of melting point of cocrystal versus
melting point of cocrystal former

4.2.5. Solubility and Dissolution Study
Solubility and dissolution measurements of five cocrystal forms (1-5) and pure
meloxicam were conducted at 37 ºC in pH 8 phosphate buffer. A pH 8 buffer was chosen
because it is believed that meloxicam is absorbed in the more basic conditions of the
intestine where the most basic regions can reach a pH of 8.26, 63 A phosphate buffer was
employed so that the pH of the solution could not vary with the addition of acidic
cocrystal formers. 6 was not tested because the cocrystal could not be made in gram
level quantities. 7 was also not tested because it did not pass 1 month of the accelerated
stability test (40 ºC, uncontrolled humidity). The dissolution profiles are shown in Figure
4.15.
The maximum solubility achieved for pure meloxicam after four hours was ca. 0.8
mg/mL which is similar to the reported literature solubility of (ca. 1 mg/mL in a pH 8
solution).27 The cocrystal that achieved the highest and lowest solubility after four hours
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was 1 and 2, respectively. Since the project goal was to reduce the time it takes for the
meloxicam to reach therapeutic levels, the cocrystals that obtained the highest
concentrations at the earliest time points were the most desirable. 3 reached a
concentration of 1.06 mg/ml at the 5 minute time point, the highest of all the cocrystals
tested. 5 was second with a concentration of 0.967 mg/ml after 5 minutes. Cocrystals 1,
2, and 4 obtained similar low concentrations (ca. 0.4 mg/ml) and pure meloxicam reached
a 0.100 mg/ml concentration after 5 minutes.
The dissolution profile for 3 was an exemplary “spring and parachute” model that
unfortunately experienced a receding concentration that decreased by half after 1 hour.
The inflated early concentration was most likely due to the high solubility of the cocrystal
former, L-malic acid, which was the most soluble cocrystal former in the pH 8 buffer
solution (961 mg/ml).
The spring and parachute type dissolution profile is becoming more of a common
occurrence amongst cocrystals.55, 64-66 First shown by Childs in the dissolution of
fluoxetine HCl succinic acid cocrystal,64 the spring and parachute model portrays the
ability of the cocrystal former to improve the solubility of the API at early time points.
This can be advantageous for decreasing the time required for the API to reach maximum
concentration. Over time, at a rate that is cocrystal dependant, the cocrystal falls apart
and the concentration in solution reduces back down to a level similar to that of the pure
API. It has been postulated by Rodríguez-Hornedo that the change in solubility of the
API is related to the solubility of the cocrystal former. Specifically, the solubility of the
cocrystal former is directly proportional to the solubility of the related cocrystal.67 Her
theory is predicated upon the analysis of a selected set of carbamazepine, theophylline,
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and caffeine cocrystals. To determine if her findings were more of a general occurrence
or an anomaly, the solubility of the cocrystal formers employed herein were compared to
the solubility of the resulting cocrystals.
The solubility of glutaric acid, aspirin, 1-hydroxy-2-naphthoic acid, and salicylic
acid were measured at 741, 14, 11, and 10 mg/ml, respectively. Based upon the
observations with L-malic acid one would expect that 2 (meloxicam glutaric acid
cocrystal) would achieve the second highest initial solubility, but it did not. 5, with a
cocrystal former solubility of 10 mg/ml was second, with a dissolution profile that was
also a spring and parachute. Therefore the solubility of the cocrystal former did not
correlate to the solubility of the cocrystals presented here. These findings are
contradictory to recently published results.67
The maximum concentration achieved by 5 was 1.29 mg/ml after 20 minutes of
slurring, which was greater than a 3-fold improvement over meloxicam. This
improvement in solubility could provide the improved absorption required for patients to
reach an earlier efficacy. Interestingly, the dissolution profile for 5 and 4 merge after
approximately 1 hour and both cocrystals maintain a similar concentration for the
remainder of the study. This may be due to the hydrolysis of aspirin to salicylic acid in
aqueous solutions.
The dissolution profile for 1 was unique as the thermodynamic solubility was not
obtained after 4 hours of slurring. The maximum concentration measured for 1 in this
study was 1.35 mg/ml. 1 was also intriguing because the solid material remaining after
the dissolution study was intact cocrystal based on powder X-ray diffraction. The
remaining solids post dissolution study for 2-5 and pure meloxicam were found to be
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meloxicam form I also based upon powder X-ray diffraction. The stability of 1 in
solution is most likely a reflection of its high melting point which is indicative of high
lattice energy68 (225 ºC, the highest of all reported cocrystals).

Dissolution Profiles Meloxicam Crystal forms pH 8, 37C
1.4

Pure Meloxicam
Concentration (mg/mL

1.2

Meloxicam:Aspirin (4)
1

Meloxicam:Salicylic acid form III
(5)
Meloxicam:1-Hydroxy-2naphthoic acid (1)
Meloxicam:Glutaric acid (2)

0.8
0.6
0.4

Meloxicam:L-Malic acid (3)

0.2
0
0

50

100

150

200

250

Time (min)

Figure 4.15. Dissolution profiles for meloxicam and five crystal forms in pH 8 buffer, 37 ºC

4.2.6. Animal Pharmacokinetic (PK) Study
The single dose rat pharmacokinetic study was conducted by Vasyl Sava and Shijie Song
at the James A. Haley VA hospital in Tampa. Samples 1-6 and pure meloxicam were
tested. The plasma concentrations as a function of time are shown in Figure 4.16. 7 was
not studied because the cocrystal lattice collapsed after 1 month of exposure to 40 ºC in
uncontrolled humidity. The maximum plasma concentration achieved at the end of the 4
hour study was 60.9 μg/ml by form 4. The concentrations for 3 and 6 were similar to the
maximum obtained for meloxicam; however, all three crystal forms showed similarly low
plasma levels averaging ca. 38 μg/ml. The plasma concentration for 2, however, led to a
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very intriguing profile. During the first hour of the study 2 had a profile similar to the
meloxicam profile. But, during the last 3 hours the concentration increased at a faster
rate than pure meloxicam resulting in a 4 hour plasma concentration that was 15 μg/ml
greater than pure meloxicam. An examination of the areas under the curve (AUC) for the
cocrystals presented in this study shows that 4 has the highest AUC, followed by 1. The
AUC’s for 3 and 6 are similar and greater than pure meloxicam, however, they exhibit
the lowest for all cocrystals in this study. 5 exhibits a similar profile to 1, but 5
experiences a much higher plasma concentration after 15 minutes. Since the goal of the
study was to generate cocrystals with an earlier onset of efficacy, the desired crystal form
must show a plasma concentration at the earliest time point that is equivalent to the
maximum obtained by pure meloxicam. This criterion eliminates 1 and 4 even though
they show the greatest AUCs because they take over an hour to reach their maximum
concentrations. 5 is therefore the cocrystal to take further into additional studies.
Interestingly, 5 obtains the highest plasma concentration after 15 minutes and is
also the most soluble cocrystal after a 10 minute slurry in pH 8 solution at 37°C. The
solubility of cocrystals 1-4 after 10 minutes and their plasma concentrations after 15
minutes were examined further to determine if a general correlation existed between the
solubility and plasma concentration. Figure 4.17. highlights the linear trend ( R2 =
0.8651) that can be drawn illustrating that the more soluble the cocrystal at 10 minutes
the greater the improvement in plasma concentration at early time points. These results
show that to quicken the onset of a drug that is well absorbed but has low solubility; a
more soluble cocrystal will increase the early plasma concentrations such that the drug
could reach therapeutic concentrations at a faster rate.
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Rat Plasma Concentrations of Meloxicam Crystal Forms
70
Concentration (microg/ml)

Meloxicam:L-Malic acid (3)

60
Meloxicam:Aspirin (4)

50
Meloxicam:1-Hydroxy-2naphthoic acid (1)

40

Meloxicam:Salicylic acid form I
(6)

30

Meloxicam:Salicylic acid form III
(5)

20

Meloxicam:Glutaric acid (2)
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Pure Meloxicam

0
0

50

100
150
Time (min)
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Figure 4.16. Rat plasma concentrations after single dose administration of
meloxicam and six cocrystals
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Figure 4.17. Cocrystal and meloxicam solubility versus rat plasma concentration
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4.3. Conclusions
The ability to modify the physical properties of an API but still maintain its
therapeutic attributes by altering the crystal form is an important area of research and
discovery. In this contribution seven novel crystal forms of meloxicam are presented and
analyzed based upon their supramolecular synthons, melting points, solubility, and PK
profiles. A prominent aspect of cocrystals 1-4 is the presence of the meloxicam dimer.
The meloxicam molecules in 5, however, are juxtaposed such that the dimer cannot form.
A salient feature in 1-5 is the 2-point recognition carboxylic acid-azole/NH
supramolecular heterosynthon. An analysis of the melting points of 1-7 and the
respective cocrystal formers illustrated that the melting points of the cocrystals were
typically in between the melting points of meloxicam and the cocrystal former. The
highest melting cocrystal, 1, was also the only cocrystal to remain intact throughout the
solubility/dissolution study.
The solubility and dissolution profiles for 1-5 showed that after 4 hours 1 was the
most soluble and 2 was the least soluble cocrystal. The solubility of the cocrystal was not
related to the solubility of the cocrystal former. Due to the purpose of the study, i.e.
decrease the time taken for meloxicam to reach therapeutic concentrations, the greater
solubility of the cocrystal at the early time points was of greater importance than the
solubility at 4 hours thus narrowing the desirable cocrystal list down to 3 and 5. To select
one both solubility/dissolution and PK data was considered.
The AUCs from the rat PK data were the lowest for 2, 3, and 6. 1 and 4 showed a
plasma concentration that gradually increased over the 4 hour period resulting in
therapeutic concentrations after approximately 30 minutes to 1 hour. 5, however, reached
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the therapeutic concentration after 15 minutes thus 5 would be the desired crystal form
for future product development as it experienced the solubility and pharmacokinetic
profile that is most likely to reduce the time needed to obtain the therapeutic
concentration and patient efficacy. Unfortunately, there are known complications when
aspirin, which hydrolyzes to salicylic acid, is administered concomitantly with
meloxicam. The acid causes an increase in the AUC by 10% and the maximum
concentration increases by 24%. There is no explanation in the literature for this
conundrum but results presented in this study indicate that the effect is most likely due to
cocrystal formation.
The cocrystals of meloxicam presented herein provide further evidence that
cocrystals can change the physical and pharmacokinetic properties of an API. The
greatest improvements in solubility and PK profile were shown with meloxicam salicylic
acid form III (5), however, due to the clinical warnings the meloxicam 1-hydroxy-2naphthoic acid cocrystal (1) would be taken further into clinical trials as the
pharmacokinetic profile suggests that 1 will achieve similar efficacy after 30 minutes.

4.4. Materials and Methods
4.4.1. Materials
Meloxicam was purchased from Jai Radhe Sales, India with a purity of 99.64%
and was used without further purification. All other chemicals were supplied by SigmaAldrich and used without further purification.
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4.4.2. Synthesis of Compounds 1-7
Meloxicam was reacted with five cocrystal formers shown in Scheme 4.2. They
were 1-hydroxy-2-naphthoic acid, glutaric acid, L-malic acid, aspirin, and salicylic acid.
The cocrystallization attempts resulted in seven crystal forms. All of the crystal forms
can be made from solvent-drop grinding and slurrying, however, only five crystal forms
can be made from solution crystallization.
Synthesis of meloxicam 1-hydroxy-2-naphthoic acid cocrystal (1) – (a)
solvent-drop grinding – 0.176 g (0.501 mmol) meloxicam was ground together with
0.0957 g (0.508 mmol) of 1-hydroxy-2-naphthoic acid and 40 μl of tetrahydrofuran
(THF) for 30 minutes in a ball-mill. 1 was generated in ca. 100% yield. (b) slurry –
0.700 g (1.99 mmol) meloxicam and 0.391 g (2.07 mmol)of 1-hydroxy-2-naphthoic acid
were slurried in 3ml of THF overnight sealed under ambient conditions at ca. 250 rpm.
The resulting solid was filtered and washed with THF. 1 was obtained in ca. 90% yield.
(c) solution crystallization – 0.0176 g (0.0501mmol) meloxicam and 0.0095 g (0.505
mmol) of 1-hydroxy-2-naphthoic acid dissolved in 10 ml of ethyl acetate and left to
slowly evaporate. 1 was obtained in ca. 93% yield.
Synthesis of meloxicam glutaric acid cocrystal (2) – (a) solvent-drop grinding –
0.179 g (0.511 mmol) meloxicam was ballmilled together with 0.0699 g (0.529 mmol) of
glutaric acid and 40 μl of chloroform for 30 minutes, producing 2 in ca. 100% yield. (b)
slurry – 0.892 g (2.54 mmol) meloxicam and 0.351 g (2.66 mmol) of glutaric acid were
slurried in 3 ml of ethyl acetate overnight sealed under ambient conditions at ca. 250 rpm.
The resulting solid was filtered and washed with ethyl acetate. 2 was made in ca. 96%
yield. (c) solution crystallization – 0.0194 g (0.0552 mmol) meloxicam and 0.159 g (1.20
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mmol) of glutaric acid dissolved in 2 ml of ethyl acetate and left to slowly evaporate. 2
was isolated in ca. 89% yield.
Synthesis of meloxicam L-malic acid cocrystal of a salt (3) – (a) solvent-drop
grinding – 0.176 g (0.501mmol) meloxicam was ground together with 0.0361 g (0.269
mmol) of L-malic acid and 40 μl of THF for 30 minutes in a mechanical ball-mill. 3 was
generated in ca. 100% yield. (b) slurry – 0.897 g (2.55 mmol) meloxicam and 0.182 g
(1.36 mmol) of L-malic acid were slurried in 3ml of THF overnight sealed under ambient
conditions at ca. 250 rpm. The solid was filtered and washed with THF resulting in ca.
92% yield of 3. (c) solution crystallization – 0.0214 g (0.0609 mmol) meloxicam and
0.0416 g (0.301 mmol) of L-malic acid dissolved in 2 ml of a 1:1 mix of dioxane and
ethyl acetate and left to slowly evaporate. The resulting single crystals of 3 were isolated
in ca. 82% yield.
Synthesis of meloxicam aspirin cocrystal (4) – (a) solvent-drop grinding – 0.182
g (0.517 mmol) meloxicam was ball-milled together with 0.0966 g (0.536 mmol) of
aspirin and 40 μl of chloroform for 30 minutes to obtain 4 in ca. 100% yield. (b) slurry –
0.905 g (2.56 mmol) meloxicam and 0.452 g (2.51 mmol) of aspirin were slurried in 3ml
of THF overnight sealed under ambient conditions at ca. 250 rpm. The resulting solid was
filtered and washed with THF. 4 was isolated in 96% yield. (c) solution crystallization 0.0232 g (0.0660 mmol) meloxicam and 0.110 g (0.611 mmol) of aspirin dissolved in 8
ml of ethyl acetate and left to slowly evaporate, generating single crystals of 4 (ca. 35%
yield) concomitantly with meloxicam form I and aspirin.
Synthesis of meloxicam salicylic acid form III (5) – (a) solvent-drop grinding –
0.174 g (0.495 mmol) meloxicam was ball-milled together with 0.0724 g (0.524 mmol)
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of salicylic acid and 40 μl of ethyl acetate for 30 minutes. 5 was synthesized in ca. 100%
yield. (b) slurry – 0.876 g (2.49 mmol) meloxicam and 0.350 g (2.53 mmol) of salicylic
acid were slurried in 2 ml of THF overnight sealed under ambient conditions at ca. 250
rpm. The resulting solid was filtered and washed with THF. 5 was isolated in ca. 84%
yield. (c) solution crystallization – 0.0226 g (0.0643 mmol) meloxicam and 0.0787 g
(0.570 mmol) of salicylic acid was dissolved in 8 ml of a 6:2 mixture of ethyl acetate and
dioxane, respectively, and left to slowly evaporate. Single crystals of 5 (ca. 33% yield)
grew concomitantly with meloxicam form I and salicylic acid.
Synthesis of meloxicam salicylic acid form I (6) – (a) solvent-drop grinding –
0.177 g (0.504 mmol) meloxicam was ball-milled together with 0.0675 g (0.489 mmol)
of salicylic acid and 40 μl of THF for 30 minutes. 6 was made in ca. 100% yield. (b)
slurry – 0.871 g (2.47 mmol) meloxicam and 0.352 g (2.55 mmol) of salicylic acid were
slurried in 2 ml of methanol overnight sealed under ambient conditions at ca. 250 rpm.
The resulting solid was filtered and washed with methanol. 6 was obtained in ca. 91%
yield.
Synthesis of meloxicam salicylic acid form II (7) – (a) solvent-drop grinding –
0.175 g (0.498 mmol) meloxicam was ball-milled together with 0.0705 g (0.510 mmol)
of salicylic acid and 40 μl of chloroform for 30 minutes, generating 7 in ca. 100% yield.
(b) slurry – 0.869 g (2.47 mmol) meloxicam and 0.356 g (2.58 mmol) of salicylic acid
were slurried in 2 ml of chloroform overnight sealed under ambient conditions at ca. 250
rpm. The resulting solid was filtered and washed with chloroform. 7 was isolated in ca.
89% yield.
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4.4.3. Crystal Form Characterization
Single-Crystal X-ray Diffraction: Single crystals were obtained for five
compounds. Attempts to crystallize 6 and 7 did not afford crystals suitable for single
crystal X-ray crystallographic analysis. Single crystal analysis for 1-3 was performed on
a Bruker-AXS SMART APEX CCD diffractometer with monochromatized Mo Kα
radiation (λ = 0.71073 Å) connected to a KRYO-FLEX low-temperature device while
4and 5 was collected using a Cu Kα radiation (λ = 1.54178 Å). Data for 1, 2 was
collected at 100 K. Data for 3- 5 was collected at 293 K. Lattice parameters were
determined from least-squares analysis, and reflection data were integrated using
SAINT.69 Structures were solved by direct methods and refined by full matrix least
squares based on F2 using the SHELXTL package.70 All non-hydrogen atoms were
refined with anisotropic displacement parameters. All hydrogen atoms bonded to carbon,
nitrogen, and oxygen atoms were placed geometrically and refined with an isotropic
displacement parameter fixed at 1.2 times Uq of the atoms to which they were attached.
Hydrogen atoms bonded to methyl groups were placed geometrically and refined with an
isotropic displacement parameter fixed at 1.5 times Uq of the carbon atoms.
Powder X-Ray Diffraction (PXRD): 1-7 were characterized by a D-8 Bruker Xray Powder Diffractometer using a Cu Kα radiation (λ = 1.54178 Å), 40kV, 40mA. Data
was collected over an angular range of 3° to 40° 2θ value in continuous scan mode using
a step size of 0.05° 2θ value and a scan speed of 1.0 º/min.
Calculated PXRD: Calculated PXRD diffractograms were generated from the
single crystal structures using Mercury 1.5 (Cambridge Crystallographic Data Centre,
UK) for the following complexes: 1-5 for comparison to the bulk sample.
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Differential Scanning Calorimetry (DSC): Differential Scanning Calorimetry
was performed on a Perkin Elmer Diamond DSC with a typical scan range of 25 ºC – 280
ºC, scan rate of 10 ºC/min, and nitrogen purge of ca. 30 psi.
Fourier Transform Infrared Spectroscopy (FT-IR): FT-IR analysis was
performed on a Perkin Elmer Spectrum 100 FT-IR spectrometer equipped with a solidstate ATR accessory.
Ultraviolet-Visible Spectroscopy (UV/Vis): UV/Vis analysis was performed on
a Perkin Elmer Lambda 25 UV/Vis spectrophotometer.
High Performance Liquid Chromatography (HPLC): Analysis was performed
on an HPLC system (Perkin Elmer Instruments LLC) comprising the following units: a
series 200 Gradient Pump; a 785A UV/VIS Detector; a series 200 Autosampler; an NCI
900 Network Chromatography Interface and a 600 Series Link. The system was operated
by a Total Chrome Workstation. The sample holder temperature was kept at 4 ºC with a
flow rate of 1 mL/min. The column was a Microsorb-MV 300-5 C-18 (250 x 4.6 mm x
1/4”). The mobile phase consisted of a mixture of phosphate buffer (pH 3.0) with
methanol (1/1, v/v). The phosphate buffer was prepared from 50 mmol/L Na2HPO3 water
solution with pH-controlled HCl titration.

4.4.4. Solubility and Dissolution Study
Dissolution profiles and thermodynamic solubility were obtained for five crystal
forms (1-5) in pH 8 phosphate buffer at 37 ºC. The study was conducted using excess
free flowing solid, stirring with a magnetic stir bar at a rate of ca. 250-300 rpm. The
solids were sieved to achieve a particle size between 53-75μm. Aliquots were taken out
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after 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, and 240 minutes and filtered
with 0.45 μm filters. The resulting solution was processed and the concentration of
meloxicam was measured using a UV/Vis spectrophotometer. The experiment was
repeated twice to allow for statistical analysis.

4.4.5. Animal Pharmacokinetic (PK) Study
Six crystal forms (1-6) were submitted for pharmacokinetic analysis via a single
dose oral gavage administration to Sprague-Dawley rats (225-250 g). The rats were preimplanted with jugular vein catheters for withdrawing of blood samples. The animals
were allowed water ad libitum and fasted overnight before drug administration. The
crystal forms were administered a dosage of 10 mg/kg of meloxicam or meloxicam
cocrystal, in the suspension vehicle of a 5% PEG and 95% methyl cellulose aqueous
solution. After dosing, 2 ml of blood was withdrawn at 0, 15, 30, 45, 60, 120, and 240
minutes. The blood samples were processed and analyzed by HPLC according to the
literature procedure.71

Table 4.6. Hydrogen bond distances and parameters
Compound

1

Hydrogen Bond

d(H...A)/ Å

d(D...A)/ Å

θ/ º

N-HO

2.09

2.935(6)

161.7

O-HN

1.76

2.596(6)

170.9

O-HO

2.59

3.075(5)

118.3

O-HO

1.85

2.585(5)

O-HO

1.87

2.603(5)

210

145.8
145.1

2

3

4

5

O-HO

2.45

2.917(2)

115.9

O-HN

1.84

2.675(2)

174.2

N-HO

1.99

2.849(2)

165.1

O-HO

1.81

2.646(2)

176.0

O-HO

1.89

2.6226(18)

144.4

N-HO

2.08

2.90(3)

159.9

N-HO

2.05

2.89(3)

168.5

N-HO

1.85

2.70(3)

169.0

O-HN

1.92

2.73(3)

172.3

O-HO

2.42

2.90(3)

117.8

N-HN

2.23

2.67(3)

112.1

O-HO

1.86

2.59(3)

148.4

O-HO

2.49

2.92(2)

114.1

O-HO

1.98

2.67(3)

141.4

O-HO

2.32

2.81(2)

119.5

O-HO

2.51

3.04(3)

123.8

O-HO

1.85

2.568(2)

145.7

N-HO

2.01

2.856(3)

165.6

O-HN

1.85

2.665(3)

173.4

N-HO

2.14

2.975(5)

164.0

O-HN

1.84

2.627(5)

161.7

O-HO

1.84

2.556(4)

145.7

O-HO

1.97

2.678(5)

143.9
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Chapter 5 – Summary and Future Directions

5.1. Summary
The field of supramolecular chemistry has grown dramatically since the early
works of Jean-Marie Lehn, Donald Cram and others both in complexity and in scope.
The subtopic crystal engineering has also grown alongside it from a [2+2]
photodimerization topochemical reaction to pharmaceutical cocrystals with improved
physicochemical properties. The research presented in this dissertation is a contribution
to the current knowledge base of the crystal engineering of cocrystals with a particular
focus upon two separate applications: cocrystal controlled solid-state synthesis and
pharmaceutical cocrystallization. Cocrystal controlled solid-state synthesis targets the
cocrystal as the key intermediate stage that brings the two reactive components in close
proximity such that the reaction can take place. Once the cocrystal is formed then the
reaction can occur faster and with greater yield than traditional solution methods. The
cocrystal controlled solid-state synthesis of imides was targeted due to the potential for
supramolecular heterosynthon formation with the primary amine and carboxylic acid
anhydride starting materials. Three cocrystals: 1, 2-methyl-4-nitroaniline 1,4,5,8naphthalenetetracarboxylic dianhydride, (2:1), 2, 3-aminobenzoic acid 1,4,5,8naphthalenetetracarboxylic dianhydride, (2:1)), 3 (2-methyl-4-nitroaniline pyromellitic
anhydride, (2:1))) were isolated and characterized by single crystal analysis, DSC, FTIR,
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1

HNMR, and PXRD. Their transformations in the solid-state to their corresponding

imides were closely monitored and the imides were also characterized. Interestingly, the
envisioned supramolecular synthon (amine-anhydride hydrogen bonding) did not occur,
the cocrystals were instead sustained by π system interactions of the aromatic rings that,
in some cases, was determined to be charge-transfer interaction. The project concluded
in an approximate 50% success rate of imide formation.
Cocrystals were also studied in relevance to pharmaceuticals. Lamotrigine and
meloxicam were the targeted pharmaceuticals due to their inherently low solubility but
high bioavailability. The goal for both drugs was to improve the solubility by
cocrystallizing with a pharmaceutically acceptable cocrystal former. Additionally since
meloxicam is a drug used for indications of acute pain, the goal was to reduce the time
taken to reach the maximum concentration by at least half.
Ten crystal forms were isolated for lamotrigine: lamotrigine methylparaben
cocrystal form I (1:1) (1), lamotrigine methylparaben cocrystal form II (1:1) (2),
lamotrigine nicotinamide cocrystal (1:1) (3), lamotrigine nicotinamide cocrystal
monohydrate (1:1:1) (4), lamotrigine saccharin salt (1:1) (5), lamotrigine adipate salt
(2:1) (6), lamotrigine malate salt (2:1) (7), lamotrigine nicotinate dimethanol solvate
(1:1:2) (8), lamotrigine dimethanol solvate (1:2) (9), and lamotrigine ethanol
monohydrate (1:1:1) (10). An underlying theme for the lamotrigine cocrystals, salts, and
solvates was the supramolecular synthon motifs. All of the crystal forms either hydrogen
bonded to the exterior of the lamotrigine dimer or they broke the lamotrigine dimer.
Crystal forms 1, 5, 6, and 8 break the lamotrigine dimer while 2, 4, 7, 9, and 10 hydrogen
bond to the exterior of the dimer.
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Solubility and dissolution measurements were conducted on crystal forms 1-5 and
pure lamotrigine in water and pH 1 HCl solution. 5 was the most soluble crystal form in
water, however, it was the least soluble in the pH 1 HCl solution. Instead, 2 exhibited the
highest concentration in the acidified solution. The average concentration for 2 and 4 in
aqueous solution were similar to that of lamotrigine while 3 was similar to the maximum
of lamotrigine. In the acidic media the concentrations for 2, 3, 4, and 5 all surpassed that
of pure lamotrigine. The solubility of the cocrystal former did not correlate to the
solubility of the corresponding cocrystal.
The animal pharmacokinetic data was gathered via a single dose rat study. The
area under the curve for the serum concentrations after administration of 5 was increased
by 66% compared to lamotrigine. The other crystal forms, 3 and 4, however, resulted in
a decrease in serum concentration by 37% and 26%, respectively.
Analyzing the solubility and pharmacokinetic data in light of the original goal
shows that the crystal forms of lamotrigine show great potential for an improved drug in
clinical studies. 5 exhibits the greatest improvements in solubility and serum
concentration thus 5 is the best candidate for further clinical studies.
Pharmaceutical cocrystallizations of meloxicam afforded seven novel cocrystals:
meloxicam 1-hydroxy-2-naphthoic acid cocrystal (1:1) (1), meloxicam glutaric acid
cocrystal (1:1) (2), meloxicam L-malic acid cocrystal of a salt (1:1:1) (3), meloxicam
aspirin cocrystal (1:1) (4), meloxicam salicylic acid cocrystal form III (1:1) (5),
meloxicam salicylic acid cocrystal form II (1:1) (6), and meloxicam salicylic acid
cocrystal form I (1:1) (7). Five of the seven resulting crystal forms were analyzed in
terms of their crystal packing, solubility, dissolution rate, and pharmacokinetic properties.
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Crystal structures of cocrystals 1-5 were obtained from single crystal X-ray
diffraction analysis of high quality single crystals grown from slow evaporation of a
solution. Examination of the crystal packing revealed the common motif of the
meloxicam dimer and the two-point recognition carboxylic acid-azole/NH
supramolecular synthon. The meloxicam dimer was only prevalent in crystal forms 1-4
while the carboxylic acid-azole/NH supramolecular synthon sustained forms 1-5. The
lack of the meloxicam dimer in 5 is unique and possibly contributes to the unique
solubility and pharmacokinetic properties of 5.
The dissolution profiles, conducted in pH 8 buffer, predicated the improved
solubility of many of the cocrystals. 1 was the most soluble cocrystal while 2 was the
least soluble cocrystal at the end of the 4 hour trial. However, due to the desire to
improve the concentration in solution at the fastest rate to decrease the onset of efficacy,
the concentration after the first 15 minutes was the most crucial point. Examining of the
concentrations at the early time points illustrated that 3 and 5 were the most soluble after
5 minutes but 3 quickly decreased in concentration while 5 maintained an elevated level.
The solubility of the cocrystal former did not correlate to the of the corresponding
cocrystal.
The single dose rat pharmacokinetic study administered forms 1-5, 7, and
meloxicam. The area under the curves for the plasma concentrations of 2, 3, and 6 were
lower than pure meloxicam. Two hours into the 4-hour study 1 and 4 had achieved
concentrations similar to meloxicam, 5 however, reaches therapeutic concentrations 15
minutes after administration.
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A consideration of the solubility and pharmacokinetic data for the meloxicam
cocrystals led to the selection of 5 as the product that should be taken further into clinical
trials. Unfortunately, there remains a problem with marketing 5 as it is well known that
meloxicam should not be taken with other NSAID pain killers. With this in mind the
next best crystal form, 1, would be selected for clinical trial testing.

5.2. Future Directions
The future for the field of crystal engineering is glowing bright. The interest in
developing solids as functional materials is progressing rapidly as scientists are learning
how to utilize the principles of crystal engineering and expand upon the existing synthetic
methods for the design of novel materials. The advent of novel synthetic techniques such
as cocrystal controlled solid-state synthesis, have been instrumental in the development
of new molecules. Furthermore, with the facile generation of new molecules one can
synthesize functional materials such as metal-organic frameworks that are currently being
explored for applications such as hydrogen storage.
Crystal engineering has within the last decade also had a major impact upon the
pharmaceutical industry with a particular emphasis upon crystal form and pharmaceutical
cocrystals. Currently the physical properties of pharmaceutical cocrystals that result from
the screening process are unpredictable. Perhaps with the knowledge gained from the
studies presented herein coupled with future studies will allow for the generation of a
library that will facilitate the estimation or possibly predict the solubility or maybe even
the bioavailability of pharmaceutical cocrystals.
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The scientific literature surrounding pharmaceutical cocrystals has also grown
exponentially over the past decade containing many articles from major pharmaceutical
companies as well as academic scientists. Furthermore, there are now more
collaborations than ever between industry and academia resulting in fascinating science
and influential papers. The conglomeration of industry and academia appears to be the
wave of the future and cocrystals will continue to play a major role in crystal form
development. The ability to control the properties of a crystal form still remains for
futuristic development but as the future draws near Feynman’s dreams of possessing the
ability to arrange the molecules exactly as we want them are growing one step closer to
becoming the reality.
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Appendix 1. Experimental data for PA1+AA1 (2-methyl-4-nitroaniline+NTCDA)
IR and Powder X-ray diffractogram of heated and ground material and 1HNMR of imide
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Appendix 2. Experimental data for PA1+AA2 (2-methyl-4-nitroaniline+pyromellitic
anhydride) IR and Powder X-ray diffractogram of heated and ground material and
1
HNMR of imide
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Appendix 3. Experimental data for PA1+AA3 (2-methyl-4-nitroaniline+maleic
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and
1
HNMR of imide
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Appendix 4. Experimental data for PA1+AA4 (2-methyl-4-nitroaniline+phthalic
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and
1
HNMR of imide
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Appendix 5. Experimental data for PA1+AA5 (2-methyl-4-nitroaniline+3, 3’, 4, 4’biphenyltetracarboxylic dianhydride) IR, Powder X-ray diffractogram, and DSC of
heated and ground material and 1HNMR of imide
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Appendix 6. Experimental data for PA2+AA1 (3-aminobenzoic acid+NTCDA) IR
and Powder X-ray diffractogram of heated and ground material and 1HNMR of imide
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Appendix 7. Experimental data for PA2+AA2 (3-aminobenzoic acid+pyromellitic
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and
1
HNMR of imide
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1

HNMR could not be obtained due to low solubility
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Appendix 8. Experimental data for PA2+AA3 (3-aminobenzoic acid+maleic
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and
1
HNMR of imide
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Appendix 9. Experimental data for PA2+AA4 (3-aminobenzoic acid+phthalic
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and
1
HNMR of imide
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Appendix 10. Experimental data for PA2+AA5 (3-aminobenzoic acid+3, 3’, 4, 4’biphenyltetracarboxylic dianhydride) IR, Powder X-ray diffractogram, and DSC of
heated and ground material and 1HNMR of imide
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1

HNMR could not be obtained due to low solubility
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Appendix 11. Experimental data for PA2+AA6 (3-aminobenzoic acid+1,8naphthalic anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground
material and 1HNMR of imide

253

254

1

HNMR could not be obtained due to low solubility
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Appendix 12. Experimental data for PA3+AA2 (melamine+pyromellitic anhydride)
IR, Powder X-ray diffractogram, and DSC of heated and ground material and 1HNMR of
imide

256

XPDS of heated material are not provided because the material was amorphous.
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Appendix 13. Experimental data for PA3+AA3 (melamine+maleic anhydride)
IR, Powder X-ray diffractogram, and DSC of heated and ground material and 1HNMR of
imide
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Appendix 14. Experimental data for PA3+AA4 (melamine+phthalic anhydride) IR,
Powder X-ray diffractogram, and DSC of heated and ground material and 1HNMR of
imide
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Appendix 15. Experimental data for PA4+AA1 (1,4-phenylenediamine+NTCDA) IR,
Powder X-ray diffractogram, and DSC of heated and ground material and 1HNMR of
imide
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1

HNMR could not be obtained due to low solubility
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Appendix 16. Experimental data for PA4+AA2 (1,4-phenylenediamine+pyromellitic
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and
1
HNMR of imide
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Appendix 17. Experimental data for PA4+AA3 (1,4-phenylenediamine+maleic
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and
1
HNMR of imide
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Appendix 18. Experimental data for PA4+AA4 (1,4-phenylenediamine+phthalic
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and
1
HNMR of imide
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1

HNMR could not be obtained due to low solubility
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Appendix 19. Experimental data for PA4+AA5 (1,4-phenylenediamine+3, 3’, 4, 4’biphenyltetracarboxylic dianhydride) IR, Powder X-ray diffractogram, and DSC of
heated and ground material and 1HNMR of imide
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Appendix 20. Experimental data for PA4+AA6 (1,4-phenylenediamine+1,8naphthalic anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground
material and 1HNMR of imide
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Appendix 21. Experimental data for PA5+AA1 (1,5-naphthalenediamine+NTCDA)
IR, Powder X-ray diffractogram, and DSC of heated and ground material and 1HNMR of
imide

283

XPD of heated material not included because the compound is amorphous.

284

285

Appendix 22. Experimental data for PA5+AA2 (1,5-naphthalenediamine+
pyromellitic anhydride) IR, Powder X-ray diffractogram, and DSC of heated and
ground material and 1HNMR of imide

286

XPD of heated material not included because the compound is amorphous.
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Appendix 23. Experimental data for PA5+AA3 (1,5-naphthalenediamine+maleic
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and
1
HNMR of imide
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Appendix 24. Experimental data for PA5+AA4 (1,5-naphthalenediamine+phthalic
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and
1
HNMR of imide
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Appendix 25. Experimental data for PA5+AA5 (1,5-naphthalenediamine+3, 3’, 4, 4’biphenyltetracarboxylic dianhydride) IR, Powder X-ray diffractogram, and DSC of
heated and ground material and 1HNMR of imide
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XPD of heated material not included because the compound is amorphous.
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Appendix 26. Experimental data for PA5+AA6 (1,5-naphthalenediamine+1,8naphthalic anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground
material and 1HNMR of imide
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XPD of heated material not included because the compound is amorphous.
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Appendix 27. Experimental data for PA6+AA3 (1-adamantylamine+maleic
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and
1
HNMR of imide
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Appendix 28. Experimental data for PA6+AA4 (1-adamantylamine+phthalic
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and
1
HNMR of imide
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Appendix 29. Experimental data for PA7+AA2 (triphenylmethylamine+pyromellitic
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and
1
HNMR of imide
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Appendix 30. Experimental data for PA7+AA3 (triphenylmethylamine+maleic
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and
1
HNMR of imide
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Appendix 31. Experimental data for PA7+AA4 (triphenylmethylamine+phthalic
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and
1
HNMR of imide
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Appendix 32. Experimental data for PA7+AA5 (triphenylmethylamine+3, 3’, 4, 4’biphenyltetracarboxylic dianhydride) IR, Powder X-ray diffractogram, and DSC of
heated and ground material and 1HNMR of imide
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Appendix 33. Histograms for specified contacts between aminopyridine to
carboxylic acid and aminopyridine to alcohol moieties (comprised of entries in the
CSD)
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Appendix 34. Experimental data for lamotrigine methylparaben form I
Powder X-ray diffractogram comparison of cocrystal to starting material
400
350
300
Calculated Lamotrigine methylparaben cocrystal
form I

250
200
150
100

Methylparaben

50
Lamotrigine

0
4

6

8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40

2Theta (deg)

An experimental PXRD is not shown because the crystallization results in multiple
products in the same vial.
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Appendix 35. Experimental data for lamotrigine methylparaben form II
Powder X-ray diffractogram, DSC, and IR for lamotrigine methylparaben form II
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Appendix 36. Experimental data for lamotrigine nicotinamide cocrystal
Powder X-ray diffractogram, DSC, and IR for lamotrigine nicotinamide cocrystal
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Appendix 37. Experimental data for lamotrigine nicotinamide monohydrate
Powder X-ray diffractogram, DSC, IR, and TGA for lamotrigine nicotinamide
monohydrate
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Experimental Lamotrigine nicotinamide cocrystal hydrate
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Calculated Lamotrigine nicotinamide cocrystal hydrate

200
100
4

6

8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40

2Theta (deg)

325

326

Appendix 38. Experimental data for lamotrigine saccharinate salt
Powder X-ray diffractogram, DSC, and IR for lamotrigine saccharinate salt
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Appendix 39. Experimental data for lamotrigine adipate salt
Powder X-ray diffractogram, DSC, and IR for lamotrigine adipate salt
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Appendix 40. Experimental data for lamotrigine malate salt
Powder X-ray diffractogram, DSC, and IR for lamotrigine malate salt
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Appendix 41. Experimental data for lamotrigine nicotinate dimethanol solvate
Powder X-ray diffractogram, DSC, IR, and TGA for lamotrigine nicotinate dimethanol
solvate
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Appendix 42. Experimental data for lamotrigine dimethanol solvate
Powder X-ray diffractogram, DSC, IR, and TGA for lamotrigine dimethanol solvate
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Appendix 43. Experimental data for lamotrigine ethanol hydrate
Powder X-ray diffractogram, DSC, IR, and TGA for lamotrigine ethanol hydrate
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Appendix 44. Histograms for specified contacts between carboxylic acid-azole,
alcohol-azole, and primary amide-azole compiled from entries in the CSD

(b)

(a)
Acid homosynthon in the presence of azole

Acid-azole supramolecular heterosynthon

(c)
Alcohol homosynthon in the presence of azole

(d)
Alcohol-azole supramolecular heterosynthon

(e)
Amide homosynthon in the presence of azole

(f)
Amide-azole supramolecular heterosynthon
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Appendix 45. Experimental data for meloxicam 1-hydroxy-2-naphthoic acid
cocrystal Powder X-ray diffractogram, DSC, IR, and for meloxicam 1-hydroxy-2naphthoic acid cocrystal
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Experimental Meloxicam 1-Hydroxy-2-naphthoic acid cocrystal
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Calculated Meloxicam 1-Hydroxy-2-naphthoic acid cocrystal
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Appendix 46. Experimental data for meloxicam glutaric acid cocrystal
Powder X-ray diffractogram, DSC, IR, and for meloxicam glutaric acid cocrystal
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Appendix 47. Experimental data for meloxicam L-malic acid cocrystal of a salt
Powder X-ray diffractogram, DSC, IR, and for meloxicam L-malic acid cocrystal of a salt
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Appendix 48. Experimental data for meloxicam aspirin cocrystal
Powder X-ray diffractogram, DSC, IR, and for meloxicam aspirin cocrystal
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Appendix 49. Experimental data for meloxicam salicylic acid cocrystal form III
Powder X-ray diffractogram, DSC, IR, and for meloxicam salicylic acid cocrystal form
III
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Appendix 50. Experimental data for meloxicam salicylic acid cocrystal form I
Powder X-ray diffractogram, DSC, IR, and for meloxicam salicylic acid cocrystal form I
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Appendix 51. Experimental data for meloxicam salicylic acid cocrystal form II
Powder X-ray diffractogram, DSC, IR, and for meloxicam salicylic acid cocrystal form II
2200
2000
1800

Meloxicam:Salicylic acid form II
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